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Abstract  
 
Peptides are attracting increasing attention from pharmaceutical companies as promising 
drug leads. Peptides have high specificity and high-affinity potency towards molecular targets as 
well as low toxicity, making them viable alternatives to small molecules. However, their lack of 
membrane permeability, bioavailability and in vivo stability hinders most peptides from becoming 
actual drugs. Although peptides are generally thought to be poor drugs, disulfide-rich cyclic 
peptides show great potential as pharmaceutical scaffolds in peptide-based drug design because of 
their exceptional stability.  
Naturally occurring disulfide-rich cyclic peptides have been found in plants and animals. 
Cyclotides are among the largest naturally occurring disulfide-rich cyclic peptides discovered so far 
and have been identified in species of Violaceae, Rubiaceae, Cucurbitaceae, Fabaceae and 
Solanaceae plant families. Cyclotides are distinguished by the cyclic cystine knot (CCK) motif, 
which comprises a macrocyclic backbone and three conserved disulfide bonds. The CCK motif 
provides cyclotides with exceptional stability, making them promising scaffolds for peptide drugs. 
Cyclotides were initially classified into two main subfamilies, Mӧbius (e.g, kalata B1 and kalata 
B2) and bracelet (e.g, cycloviolacin O2), based on the presence/absence of a cis-Pro peptide bond. 
A third subfamily, the trypsin inhibitor subfamily, was later introduced following the discovery of 
two peptides (MCoTI-I and MCoTI-II) obtained from Momordica cochinchinensis seeds. Other 
trypsin inhibitors in this family have now been identified. This subfamily is homologous to acyclic 
squash inhibitors and share little sequence similarity to cyclotides from the other two subfamilies. 
Recently, cyclotides kalata B1 and MCoTI-II have been shown to internalise into cells and were 
therefore named cyclic cell-penetrating peptides (CCPPs). Another CCPP is SFTI-1, a sunflower 
trypsin inhibitor that comprises a single disulfide-bond and has been used as a scaffold in drug 
design.  
The aim of my Ph.D. thesis was to understand the mechanism of action and unravel the cell-
penetrating properties of disulfide-rich cyclic peptides. Chapter 1 provides an introduction on 
disulfide-rich cyclic peptides with an emphasis on their structural features and their biological 
activities, including membrane-binding and cell-penetrating properties, as well as their potential as 
drug design scaffolds in various therapeutic applications.  
Chapter 2 describes the materials and methods used to carry out the experiments in this 
thesis, which include methods to synthesise peptides that were studied, and biological assays used 
to evaluate them. In addition biophysical methodologies to evaluate structural features, peptide 
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internalisation and peptide-membrane interactions are also detailed.  
Chapter 3 is a research article published in the European Journal of Medicinal Chemistry 
(2014) that focuses on the structural characteristics affecting the cell-penetrating properties of 
disulfide-rich cyclic peptides, MCoTI-II and SFTI-1. Sets of MCoTI-II and SFTI-1 analogues were 
synthesised to investigate the relevance of positively charged, hydrophobic residues and other 
structural modifications in the cell-penetrating ability of these CCPP scaffolds. This study showed 
that MCoTI-II cellular uptake can be improved by increasing the overall positive charge of the 
native sequence. On the other hand, structural mutations to SFTI-1 did not significantly influence 
its cellular uptake. This study provides information for the development of these disulfide-rich 
cyclic scaffolds into potential drug candidates towards intracellular therapeutic targets.  
In Chapter 4, MCoTI-II is used as a scaffold to target an intracellular protein. In this study, 
COG1410, an ApoE-derived linear peptide, was engineered onto MCoTI-II with the aim of 
inhibiting the SET protein, which modulates the NF-κB pathway. The grafted peptides showed high 
stability in human serum and cytotoxicity towards a cancer cell line. One of the grafted peptides 
was able to suppress NF-κB dependent gene promoter activity in lipopolysaccharide-stimulated 
macrophages. This study shows the application of disulfide-rich cyclic peptides as a scaffold for the 
development of stable antagonists towards an intracellular target.  
Chapter 5 discusses the self-association of the cyclotides kalata B1 and kalata B2 in a 
membrane environment and the significance of its oligomerisation properties to its mechanism of 
action. Based on the proposed model of cyclotides self-associating in membranes, different mutants 
of kalata B1 and kalata B2 were synthesised and chemical cross-linking experiments were carried 
out in presence of liposomes. In this study, a kalata B2 mutant showed oligomer formation in the 
presence of lipid membranes. This study broadens the knowledge on self-association of cyclotides 
in membranes, which will help in our understanding on how cyclotides deliver their activities.  
In summary, this thesis provides new information on the development of disulfide-rich 
cyclic peptides as templates in drug design. Cellular uptake studies on disulfide-rich cyclic peptides 
highlighted the importance of positive charge to the internalisation process. In addition, grafted 
cyclotides can be directed towards an intracellular therapeutic target to modulate a cellular pathway. 
Finally, cyclotides can self-associate in a membrane environment, expanding our knowledge on 
their mechanism of action and membrane binding properties. The findings in this thesis will assist 
in the development of disulfide-rich cyclic peptides into drugs, further broadening their applications 
in peptide-based therapeutics. 
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Chapter 1 Introduction 
 
 
 
3
1.0 Introduction 
 Peptides are promising drug leads because they have a range of beneficial properties 
compared to traditional small organic molecules (1,2). Peptides can bind to a protein target with 
high specificity and high potency. They are metabolised in the body producing non-toxic 
degradation products and thus potentially have few adverse effects. Compared to protein biologics, 
another major drug design modality, peptides are smaller in size and cheaper to produce using 
modern chemical strategies. Some examples of peptide drugs that are currently in the market 
include insulin, cyclosporine and oxytocin (2). However, there are several issues involved in 
peptide-based drug design, such as lack of membrane permeability, low bioavailability and low 
metabolic stability (3). 
 There have been efforts made to overcome these hurdles to develop successful peptide 
pharmaceuticals. One strategy for improving the therapeutic potential of peptides involves the use 
of highly constrained disulfide-rich cyclic peptides, which are found in plants and animals. 
Disulfide-rich cyclic peptides are attractive in drug design due to their extremely high stability and 
unique structural features (4). Among the naturally occurring disulfide-rich cyclic peptides are 
cyclotides (5), which are found in the Rubiaceae (coffee), Violaceae (violet), Curcurbitaceace 
(curcubit), Solanaceae (nightshade) and Fabaceae (legume) plant families. Another plant-derived 
cyclic peptide is sunflower trypsin inhibitor-1 (SFTI-1), which is obtained from sunflower seeds. 
Cyclic disulfide-rich peptides obtained from animals include θ-defensins, which have anti-microbial 
activity (6).  
 The aim of this thesis is to study some examples of disulfide-rich cyclic peptides derived 
from plants, to understand their mechanism of action and explore their cell-penetrating properties, 
which can be useful in the design of disulfide-rich cyclic peptides as lead drugs for various 
therapeutic applications. 
 
1.1 Disulfide-rich cyclic peptides  
1.1.1 Cyclotides  
Cyclotides are the largest family of disulfide-rich cyclic peptides obtained from plants (7). The 
prototypic cyclotide kalata B1 (Figure 1-1A) was first discovered in 1970 by a Norwegian physician, 
Lorents Gran, in a medicinal tea prepared from the African herb, Oldenlandia affinis (8) belonging to 
the Rubiaceae family. This traditional tea was used by African women in Congo to accelerate 
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childbirth. Studies showed that the active agent exerting the uterotonic effect was the 29 amino acid 
residue peptide kalata B1 (9). Following this discovery, other cyclotides were discovered in plants 
from the Rubiaceae (10,11) family as well as the Violaceae family (12). Cyclotides have also been 
found in other plant families such as Curcurbitaceae and Fabaceae, suggesting that cyclotides are 
widespread among the plant kingdom and there are still more yet to be discovered (13,14). A number 
of reviews have been published on cyclotides discovery (15-17). 
 
Figure 1-1: Structure and surface representation of A) kalata B1 and B) MCoTI-II. Disulfide 
bonds between the cysteine residues (numbered in Roman numerals) are shown in yellow. The 
cystine knot is defined by the CysI–CysIV, CysII–CysV and CysIII–CysVI connectivity. The loops 
are numbered 1-6 and refer to the backbone segments between consecutive cysteine residues. A 
surface representation of kalata (PDB code 1NB1) shows the bioactive patch (in red) required for 
binding to phosphatidylethanolamine (PE) head groups and the hydrophobic patch (in yellow) 
thought to be for membrane insertion. The surface representation of MCoTI-II (PDB code 1IB9) 
shows positively charged residues (in blue), important for its cell-penetration properties, and 
negatively charged residues (in red).  
 
 Cyclotides are characterised by a cyclic backbone combined with three conserved disulfide 
bonds forming the cyclic cystine knot (CCK) motif. The cystine knot is formed by the penetration 
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of the CysIII-CysVI bond through a ring formed by the CysI-CysIV and CysII-CysV disulfide 
bonds and their inter-Cys backbone segments (18,19) as shown in Figure 1-1. Cyclotides have about 
30 amino acids in their sequence and fold into a three-dimensional structure containing a small β-
sheet motif as well as a series of turns. This compact topology provides cyclotides with exceptional 
stability against chemical, thermal and enzymatic degradation (20). A highly conserved glutamic 
acid residue in loop 1 is involved in stabilising the cyclotide fold (21,22).  
 Cyclotides were initially divided into two subfamilies, Möbius and bracelet, based on the 
presence and absence of a cis-X-proline peptide bond in loop 5, which, when present, introduces a 
conceptual “twist” in the cyclic peptide backbone (5). Later, a third subfamily, the trypsin inhibitor 
subfamily was defined to classify Momordica cochinchinensis trypsin inhibitors, e.g. MCoTI-I and 
MCoTI-II (23). MCoTI-II comprises 34 amino acids and differs from MCoTI-I by two amino acid 
residues. Other trypsin inhibitors belonging to this subfamily have been isolated and characterised 
(24,25). Some examples of cyclotides from each subfamily are shown in Figure 1-2 and a complete 
list of sequences is available in Cybase (26). 
 
 
 
Figure 1-2: Representative sequences of selected cyclotides from the three subfamilies- 
Möbius, Bracelet and Trypsin inhibitor. The six conserved Cys residues are numbered I-VI and 
highlighted in yellow boxes. The loops are numbered 1-6 and the disulfide bond connectivity is 
shown in red at the bottom of the sequences.  
 
 In addition to their uterotonic activity, cyclotides possess a wide range of biological 
activities (27). The native function of cyclotides is thought to be in plant defense against pests and 
this has been shown by their ability to inhibit the growth and development of insect larvae (28,29). 
Cyclotides also possess nematocidal activity (30) as they can inhibit the development and motility 
of adult worms of two species Hemonchus contortus and Trichostrongylus colubriformis. The 
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mollusicidal activity of cyclotides has also been investigated, and cyclotides such as cycloviolacin 
O1, kalata B1 and kalata B2 were found to be toxic to Pomacea canaliculata, a major pest of rice in 
South-East Asia (31). Several cyclotides belonging to the bracelet or Möbius subfamilies have been 
shown to exhibit anti-HIV activity (10,32-35). Hemolytic activity of cyclotides was first reported 
for violapeptide-I (12) and then was observed for most other cyclotides tested. This activity is not 
observed for linear analogues of cyclotides, suggesting that the cyclic backbone is important in 
maintaining the hemolytic activity (36). Some cyclotides have been shown to be cytotoxic towards 
human cancer cell lines (37-39). Interestingly, cyclotides from the trypsin inhibitor subfamily show 
no toxic effects in all the bioassays tested so far (40,41) and also do not bind to membranes (42). 
This absence of membrane binding is in contrast to what has been observed for cyclotides from the 
Möbius and bracelet subfamilies. However, MCoTI-II has been shown to inhibit the enzyme 
matriptase a type II transmembrane serine protease which has been involved in the progression of 
epithelium derived tumors (43). 
 
1.1.2 SFTI-1 
SFTI-1 is the most potent Bowman-Birk trypsin inhibitor (44) and can also inhibit the 
enzyme matriptase (45,46). It is a 14-amino acid residue disulfide-rich cyclic peptide (Figure 1-3) 
containing a single disulfide bond and two short anti-parallel β-strands, which are connected by two 
loops (47,48). One of these loops, which contains the Lys5-Ser6 residues, is involved in direct 
binding to the active site of trypsin and the other loop forms a β-hairpin turn. The presence of 
Asp14 in this loop is thought to be important in maintaining the rigid structure and is involved in 
the cyclisation process during biosynthesis.  
 
Figure 1-3: Structure and sequence representation of SFTI-1. Cysteine residues in the sequence 
are highlighted in bold and numbered with roman numerals. Loop 1 and 2 are labeled and the β-
strands present in the structure are indicated by broad arrows. Disulfide bond connectivity is shown 
in yellow. 
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The disulfide bond and cyclic backbone are crucial in maintaining the activity and stability 
of SFTI-1. Studies have shown that removal of the disulfide bond (49) or opening of the cyclic 
backbone (50) between Asp14-Gly1 results in the reduction of trypsin inhibitory activity. In 
addition the disulfide-deficient analogues were susceptible to proteolytic degradation, 
demonstrating the importance of the disulfide bond in maintaining the stability of SFTI-1. Alanine 
scan studies have also shown that SFTI-1 can maintain the overall native structure when single 
point mutations are introduced (51). Overall, SFTI-1 is an attractive scaffold in drug design (52) 
due to its compact structure and high stability. 
1.2 Properties of disulfide-rich cyclic peptides 
1.2.1 Membrane-acting properties  
 It has been proposed that cyclotides belonging to the Möbius and bracelet subfamilies act 
through a common mechanism, which involves binding to biological membranes by specifically 
targeting phosphatidylethanolamine (PE)-phospholipids followed by insertion into the lipid bilayer 
and subsequent membrane disruption (53). This mechanism might explain their hemolytic 
properties (12), which has been observed for most cyclotides, and their ability to disrupt the 
epithelial cells in the midgut of Lepidopteran larvae, which has been observed by transmission 
electron microscopy (54). 
 The mirror image peptide D-kalata B1 showed similar activity to L-kalata B1 in a range of 
bioassays tested (e.g. hemolytic, insecticidal and anti-HIV activity) and selectivity for PE-
containing membranes, which suggests that for those activities the tested cyclotides act by 
interacting with membranes and not through interaction with a protein receptor (55). 
Electrophysiological experiments (56) conducted with patch clamping have shown that kalata B1 
induces large pores in bilayers containing PE-phospholipids, suggesting disruption by a pore 
formation mechanism as proposed in Figure 1-4. Several biophysical experiments have been used to 
understand how cyclotides bind to membranes but it is not clear if cyclotides oligomerise to form a 
pore and if the putative pore formation can explain all the reported activities. Analytical 
centrifugation studies (57) showed that kalata B2 form tetramers and octamers in solution, 
suggesting that oligomer formation may have a role in the pore formation mechanism. Recent 
nuclear magnetic resonance (NMR) spectroscopy studies (58) on kalata B2 in solution revealed that 
the hydrophobic residues are involved in oligomer formation. Furthermore, diffusion coefficient 
measurements on kalata B2 (59) showed that this formation of oligomers is concentration 
dependent. 
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 Exposed hydrophobic residues present on the surface of cyclotides have been shown to be 
important for membrane binding. NMR experiments showed that surface-exposed hydrophobic 
residues of kalata B1 interact with dodecylphosphocholine (DPC) micelles (60). Additional NMR 
studies on other cyclotides showed that the orientation of cyclotides in DPC micelles differs and 
depends on the location of hydrophobic residues on their surface (61,62). Interestingly, an alanine 
mutagenesis study identified a patch of residues on the surface of kalata B1 that is distinct from the 
hydrophobic residues but important for the activity (63). As this so-called bioactive patch was not 
involved in binding to DPC micelles, it was initially thought that it was involved in oligomer 
formation, which is possibly a prerequisite for pore formation. A lysine scan of kalata B1 confirmed 
that both hydrophobic and bioactive patches are essential for anthelminthic and hemolytic activities 
of kalata B1 (64) and a direct correlation between ability to bind to lipid membranes containing PE-
phospholipids and the tested activities was found (65).  
 Biophysical studies have demonstrated that cyclotides bind directly to model membranes 
and specifically to phospholipids containing PE headgroup (65-68). NMR experiments revealed that 
the bioactive patch is in fact important for PE targeting (65). Recently, kalata B1 and conservative 
analogues together with kalata B2 and cycloviolacin O2, were evaluated for their membrane 
binding affinity and selectivity towards cancer cells (69). These studies demonstrated that affinity 
for PE phospholipids correlated with the toxicity of cyclotides against cancer cells. A mechanism of 
cyclotide-membrane interaction has been recently proposed based on the membrane binding studies 
(68,70) shown in Figure 1-4. This mechanism suggests that cyclotides target the membrane surface 
through specific interactions with PE-containing phospholipids via their bioactive patch, which 
involves electrostatic interactions, whereas the hydrophobic surface inserts into the hydrophobic 
core of the membrane. This induces membrane permeabilisation that can result from the formation 
of either barrel-stave or toroidal pores. Once a threshold concentration is reached, cyclotides disrupt 
the membrane leading to membrane solubilisation.  
 In addition to membrane activity, cyclotides have also shown to interact with GCPR and 
oxytocin receptors which can explain their observed biological activities (71).  
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Figure 1-4: Proposed pore mechanism of cyclotides in biological membranes. 1) monomeric or 
oligomeric form of cyclotides in solution, 2) cyclotides contact the membrane surface through 
specific interactions with PE headgroups and then insert into the membrane via their hydrophobic 
patch, 3) formation of oligomers in the membrane, and 4) pore formation which can be either 
barrel-stave or toroidal 5) membrane solubilisation occurs at higher cyclotide concentrations. 
  
1.2.2 Cell-penetrating properties  
 In addition to membrane binding properties, some disulfide-rich cyclic peptides also possess 
cell-penetrating properties. For example, MCoTI-II from the trypsin inhibitor subfamily was 
reported to internalise into macrophages and human breast cancer cells (41) without displaying 
cytotoxicity. MCoTI-II seems to internalise into cells through endocytic pathways, and cell 
treatment with a macropinocytosis inhibitor suggested that internalisation is at least partially 
dependent on macropinocytosis (41,42). MCoTI-I, which differs from MCoTI-II by only two amino 
acid residues, was also shown to internalise into cells through endocytic pathways (72). Studies 
have shown that replacement of lysine with alanine residues in the MCoTI-II sequence results in a 
significant decrease in cellular uptake. This highlighted the importance of positively charged 
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residues (Figure 1-1B) in the cellular uptake mechanism (42). Although unable to bind to tested 
model membranes, MCoTI-II could bind directly to negatively charged phosphoinositide-phosphate 
and it was proposed that binding to the cell surface might be triggering the endocytic mechanism. 
Studies involving live cell imaging and flow cytometry showed that kalata B1 is also able to 
internalise inside cells but uses a mechanism different to that used by MCoTI-II (42). The 
internalisation of kalata B1 seems to be dependent on interaction with the phospholipid membrane 
(42). Interestingly, SFTI-1 also penetrates cells but did not interact with any phospholipids tested 
and the mechanism of internalisation is not clear (42). Overall, the results suggest that MCoTI-II, 
kalata B1 and SFTI-1 are taken up readily by cells and therefore they have been designated as 
cyclic cell-penetrating peptides (CCPPs) (42). 
1.3 Cell-penetrating peptides (CPPs) 
 The application of MCoTI-II and SFTI-1 as drug scaffolds to deliver bioactive peptide 
sequences would benefit from knowledge on the peptide features required to internalise inside cells. 
Therefore, one of the aims in this thesis is to study the structural features that could facilitate and 
improve the internalisation of these two distinct disulfide-rich cyclic peptides. Thus it is important 
to discuss the cell-penetrating peptides features that are believed to play an important role in their 
cellular uptake process. CPPs (73) are peptides known to deliver macromolecules from the 
extracellular space through the cell membrane into cells. They are usually short in length and 
composed either of basic and hydrophobic amino acids (74). They often have rapid and highly 
efficient internalisation and also low toxicity (75). These peptides have been used to deliver 
different cargoes including liposomes, proteins, peptides and nucleic acids into cells. The most 
studied CPPs are cationic peptides such as Tat derived from the HIV-1 tat protein, penetratin from 
Drosophila Antennapedia protein (pAntp) and the synthetic octarginine peptide (R8). CPPs have 
been classified based on their source of origin or on their chemical properties (76) as shown in 
Table 1-1.  
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Table 1-1: Amino acid sequences and original source of selected cell-penetrating peptides  
 
Name Source of origin Sequence Ref Class 
Tat 
 
Penetratin 
 
Oligoarginines 
HIV-transactivator (tat) 
 
Antennapedia Drosophila 
 
Synthetic 
YGRKKRRQRRR 
 
RQIKIWFQNRRMKWKK 
 
RRRRRRRRR /RRRRRRRRRRRR 
(77) 
 
(78) 
 
(79) 
 
Cationic 
peptides 
Transportan 
 
Pep-1 
 
pVEC 
 
MAP 
Chimeric galanin/mastoparan 
 
Chimeric Try rich + SV40 NLS 
 
Vascular endothelial cadherin 
 
Synthetic 
GWTLNSAGYLLGKINLKALAALAKKIL 
 
KETWWETWWTEWWTEWSQPKKKRKV 
 
LLILRRRIRKQAHAHSK 
 
KLALKLALKALKAALKLA 
(80) 
 
(81) 
 
(82) 
 
(83) 
 
 
Amphipathic 
peptides 
MTS Membrane translocating 
sequence 
AAVALLPAVLLALLP 
 
(84) 
 
Hydrophobic 
peptides 
 
1.3.1 Structural characteristics and mechanism of cell-penetrating peptides  
 Numerous studies have been done to understand the structural features responsible for the 
cellular uptake of CPPs (85). The overall charge on the peptide has been shown to be important for 
the internalisation of most CPPs. However, other features such as amphipathicity, hydrophobicity 
and secondary structure content are crucial for cell penetration. Studies have shown that the 
replacement of charged residues with alanine residues in the Tat peptide sequence causes a decrease 
in the rate of cellular uptake (86). The chemical nature of the positively charged residues also 
influences cellular uptake. It has been reported that arginine residues contribute more to the 
internalisation of CPPs than lysine residues. This is because the guanidium group of arginine 
residues, unlike the amino group of lysine residues, can form additional interactions with phosphate, 
sulphate and carboxylate groups that are typically exposed on the surface of cells, leading to 
improved cellular uptake (87). In addition to charged residues, hydrophobic residues such as 
tryptophan can also improve cellular uptake because of their contribution to membrane binding and 
translocation (88).  
Several mechanisms of internalisation have been reported for CPPs (89). The internalisation 
mechanism varies depending on the specific CPP and the experimental conditions used, including 
peptide concentration, cell type, incubation time and other physiochemical parameters. CPPs can be 
taken up into cells via multiple pathways that include either endocytosis or direct penetration 
through the plasma membrane (Figure 1-5). Direct penetration is an ATP-independent pathway and 
peptides internalised through this mechanism enter directly into the cytoplasm. Endocytosis is an 
energy-dependent process, which involves engulfing molecules and this process is further 
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categorised into two pathways, i.e. phagocytosis and pinocytosis. Phagocytosis is carried out by 
specialised cells, such as macrophages, and is used for the uptake of large objects such as viruses, 
cells and bacteria. Pinocytosis occurs in most cell types and involves uptake of solute and is divided 
into two pathways, i.e. macropinocytosis and micropinocytosis. Macropinocytosis (90) is non-
selective and actin-dependent and is characterised by the formation of membrane ruffles that 
collapse and fuse with the plasma membrane to form large vesicles. On the other hand, 
micropinocytosis involves interactions with specific receptors that stimulate the vesicle formation 
process (91). 
 
 
 
Figure 1-5: Different internalisation mechanisms of cell-penetrating peptides (CPPs). 
Endocytosis and direct translocation are two mechanism of cell internalisation used by CPPs. 
Several endocytotic pathways are present in particular pinocytosis includes macropinocytosis, 
clarithrin-mediated, caveolin-mediated and clarithrin or caveolin independent endocytosis. 
 
 Studies have shown that CPP uptake can involve one or more endocytosis pathways that 
occur simultaneously which depends on the nature of the CPP and also on the type of cargo 
attached (92). Once peptides enter the cell through endocytosis they can reach various destinations. 
Some peptides can be trapped in the endosomal compartments and after this stage, these molecules 
can be sent back to the plasma membrane (exocytosis) or processed in late endosomes and 
lysosomes. 
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 1.4 Disulfide-rich cyclic peptides as templates in peptide based drug design  
 Disulfide-rich cyclic peptides are excellent scaffolds in peptide drug design due to their 
extraordinary stability. The chemical approach involving the substitution of one or more loops of 
cyclotides with a pharmaceutically relevant bioactive sequence is known as “grafting” as shown in 
Figure 1-6. This bioactive sequence can be either a segment of a larger protein or identified from 
peptide combinatorial libraries. The grafting approach increases the stability of the bioactive 
sequences, preventing their proteolytic degradation and increasing their bioavailability.  
 
 
Figure 1-6: Schematic illustration of grafting approach on a cyclotide framework. Bioactive 
epitopes derived from a large protein or a peptide sequence can be grafted onto the stable 
framework leading to a grafted cyclotide. 
 
1.4.1 Cyclotide grafting 
 Cyclotides have been used as scaffolds in several molecular grafting studies (93). Kalata B1 
was the first cyclotide that was engineered to produce an antiangiogenic agent in cancer therapy 
(94). Different loops of kalata B1 were grafted with an antiangiogenic sequence (RRKRRR) that 
possessed inhibitory activity against VEGFR2. One of the grafted peptides, cpr3, was found to be 
active and inhibited BAF3-VEGFR2 proliferation, suggesting that the cyclotide scaffold can be 
used to design peptides for cancer therapy. Potent angiogenic peptides have been produced on 
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grafting small peptide sequences derived from extracellular matrix proteins onto cyclotides MCoTI-
II and SFTI-1 (40). The grafted peptides showed activity in the nanomolar range in biological 
assays and their stability was increased in the presence of human serum. The potential use of 
cyclotides as orally active drugs was recently shown in a study where an antagonist of bradykinin 
(BK) B1 receptor was grafted onto loop 6 of kalata B1 (95). The grafted cyclotides were active and 
blocked the B1 receptor in cell-based assays. In addition, these peptides showed a significant 
inhibition of pain response in an animal model. The potential of cyclotides as a stable vaccine to 
treat immunomodulatory diseases was shown by grafting myelin oligodendrocyte glycoprotein 
(MOG) peptide fragments onto the kalata B1 framework (96). 
 MCoTI-II has been used for the development of inhibitors against the serine proteases β-
tryptase and human leukocyte elastase (HLE) (97). Grafted MCoTI-II showed activity against HLE 
on a low nanomolar range. Furthermore, in this study the deletion of SDGG segment in loop 6 of 
MCoTI-II resulted in a potent β-tryptase inhibitor for allergic and inflammatory disorders. Some 
modifications on MCoTI-II resulted in inhibitors for foot and mouth disease virus (FMDV) 3C 
protease (98). MCoTI-I cyclotides have also been used to produce potent grafted cyclotides that 
target extracellular cytokine receptor CXCR4 (99). In the above examples, the grafted cyclotides 
interacted with a protein on the cell surface but recently MCoTI-I was engineered to target an 
intracellular protein (100). Camarero and co-workers (100) grafted the α-helical peptide PMI onto 
loop 6 of MCoTI-II. The resulting cyclotide was able to disrupt the protein-protein interaction 
between the transcription factor p53 and Hdm2 or HdmX. In addition, the grafted cyclotide showed 
high stability in serum and suppressed tumor growth in a mouse model.  
 
1.4.2 SFTI-1 grafting 
 SFTI-1 has been used as a scaffold to design inhibitors against human kallikrein-related 
peptidase 4 (KLK4), which is a trypsin-like serine protease (101,102) and is a target in prostate 
cancer therapy. In that study, SFTI-1 scaffold was engineered with the sequence FCQR, producing 
a potent and selective inhibitor against KLK4. SFTI-1 has been also used for the design of potent 
pro-angiogenesis peptides (40). In that study, three linear epitopes reported to promote angiogenic 
activity were grafted onto the SFTI-1 framework. The grafted peptides were stable in human serum 
and showed increased activity compared to the linear epitopes. These examples show that SFTI-1 is 
a promising framework for grafting and can produce novel peptides with improved bioactivity.  
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1.5 Aims and significance of this thesis 
 Disulfide-rich cyclic peptides are promising candidates in drug design due to their well-
defined three-dimensional structure, which provides them with exceptional stability (4). Different 
bioactive linear epitopes have been accommodated on disulfide-rich cyclic frameworks to increase 
the stability and bioactivity of the linear peptides. In addition to this, disulfide-rich cyclic peptides 
have also shown the ability to interact with biological membranes and penetrate into cells, which 
are very important features and can be considered valuable in drug design applications. Therefore 
the overall goal of my PhD is to understand the mechanism of action and unravel the cell-
penetrating properties of disulfide-rich cyclic peptides. Both of these aspects will broaden our 
knowledge on the mechanism of action of cyclotides and facilitate development of cyclotides as a 
scaffold for delivering biologically active epitopes further broadening their application as peptide 
therapeutics. The overall goal of the thesis is addressed via three specific aims: 
 
Aim 1. To understand the structural features affecting the cellular uptake of disulfide-rich 
cyclic cell-penetrating peptides: MCoTI-II and SFTI-1. 
 MCoTI-II and SFTI-1 possess cell-penetrating properties (42). MCoTI-II internalises 
mammalian cells through macropinocytosis, an energy dependent process (41,42). Mutation studies 
highlighted that positively charged residues present on the surface of MCoTI-II are very important 
for its cellular uptake mechanism (42). SFTI-1 was also shown to penetrate into cells with an 
unknown mechanism. The aim of this chapter is to further characterise the structural elements that 
are responsible for the cellular uptake of MCoTI-II and SFTI-1. Mutants of MCoTI-II and SFTI-1 
were designed with distinct modifications in the native sequence and their internalisation 
efficiencies was assessed in mammalian cells using flow cytometry. The cellular uptake of the 
mutants was also compared with a positive control, Tat peptide, and a negative control, Tat-G, 
which has the same length as Tat but all the positively-charged residues replaced with glycine 
except for one (i.e Lys5) to enable the conjugation of fluorescent dye. This study expands our 
knowledge on the structural features of MCoTI-II and SFTI-1 that could facilitate their optimisation 
and development as vectors to deliver and stabilise peptide sequences able to inhibit specific 
protein-protein interactions important in diseases conditions.  
 
Aim 2. To design a stable cyclic peptide antagonist targeting SET protein overexpressed in 
human cancer using MCoTI-II scaffold. 
 MCoTI-II is a stable cyclic cell-penetrating peptide (42) and can be used to develop novel 
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peptide drugs to target intracellular protein-protein interactions. This chapter focuses on designing a 
stable cyclic peptide antagonist using the MCoTI-II scaffold to inhibit the intracellular SET protein, 
a promising molecular target in human cancer (103). MCoTI-II was engineered with an anti-cancer 
epitope COG1410 to produce novel cyclic peptides that bind to protein SET. Characterisation of the 
grafted peptides was done using biophysical techniques. Grafted peptides were assessed for their 
stability and biological activity using cell-based assays. This study shows the application of 
MCoTI-II for the development of stable peptide-based drugs towards intracellular targets that are 
difficult to access by current therapeutics. 
 
Aim 3. To study the self-association of cyclotides in membrane environment 
Cyclotides such as kalata B1 and kalata B2 have previously shown to form oligomers in 
aqueous solution (57). NMR studies on kalata B2 showed that hydrophobic residues are involved in 
the self-association of peptides in solution (58). Based on these observations and on the membrane 
binding ability of cyclotides, it was proposed that self-association of cyclotides might have an 
important role in their mechanism of action and membrane binding. But whether self-association 
occurs only in an aqueous environment or also in membranes is still unknown. To address this 
problem, possible models of cyclotides self-associating in the membranes were designed based on 
previous NMR studies (58). Different mutants of kalata B1 and kalata B2 were synthesised 
containing lysine residues present at specific positions in the native sequence. Mutants were 
chemically cross-linked in the presence of liposomes to provide information on the possible 
membrane-bound oligomeric structure of cyclotides. Understanding the self-association of 
cyclotides in membranes will broaden our knowledge on how cyclotides deliver their activities and 
further their application as frameworks in future grafting studies. 
 
 Figure 1-7 shows how these three aims relate to one another and how they fit in with the 
overall structure of the thesis. Overall the thesis comprises six chapters that follow this introduction 
(Chapter 1). Chapter 2 describes the materials and methods used in this thesis. Chapter 3 describes 
the structural parameters modulating the cell uptake of cyclic cell-penetrating peptides: MCoTI-II 
and SFTI-1. Chapter 4 describes using a cyclotide scaffold to design a stable cyclic peptide 
antagonist of SET, a protein overexpressed in cancer. Chapter 5 describes self-association of 
cyclotides in membranes. Finally in Chapter 6 I sum up the findings and identify directions for 
future work. 
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Figure 1-7: An overview of the thesis project.  
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2.0 Overview  
This chapter gives an overview of the materials and methods used to perform the experiments 
in this thesis. This includes peptide synthesis techniques, biological assays to assess cytotoxicity 
and activity of peptides and biophysical techniques used to study the structural characteristics of 
peptides, peptide internalisation and peptide-membrane interactions which are described in detail in 
this section. 
2.1 Peptide synthesis  
2.1.1 Theory  
Solid phase synthesis (SPPS) is a powerful method for synthesising peptides or proteins in 
the laboratory (1,2). Peptides are made of building blocks of amino acids and the peptide chain is 
usually built from C to N-terminus on a solid support comprising of insoluble polymer beads 
(resin). During the peptide synthesis, a short organic linker is usually interposed between the amino 
acid and the resin, which overcomes the aggregate formation. The amide bond is formed between 
the carbonyl group of the next amino acid in the sequence with the preceding unprotected amino 
group. In order to form the peptide bond, the free carboxyl terminus is converted into an active 
electrophilic species using coupling agents. After each amino acid coupling, the N-terminal 
protecting group is removed to produce a free amine, which is available for the next coupling 
reaction. These alternating steps of deprotection, activation and coupling are repeated until the 
desired peptide chain is obtained. Finally, the resin is treated with an acid to remove the peptide 
from the solid support and then the peptide is available for further purification.  
The purpose of the protecting groups is to avoid unwanted side reaction and modification to 
the N-terminus as a result of coupling reaction. The protective groups are selected on the basis of 
the conditions (acidic or basic) used during the peptide synthesis. There are two major protecting 
groups commonly used in SPPS i.e. Boc (tert-butyloxycarbonyl) and Fmoc (9-
fluorenylmethoxycarbonyl) where Boc protecting group can be removed by treating with acid and 
Fmoc protecting groups deprotection requires basic conditions (3). Usually benzyl groups are used 
as protecting groups for the side chains of Boc amino acids and the deprotection requires strong 
acids such as hydrogen fluoride (HF). Side-chain protecting groups used in Fmoc synthesis include 
t-butyl groups, which are unstable towards trifluoroacetic acid (TFA).  
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2.1.2 Boc solid-phase peptide synthesis 
The cyclic peptides studied in this thesis were synthesised either manually or on a CS bio 
automated peptide synthesizer with Boc chemistry (4). Peptides were assembled on a 0.5 mM scale 
with Boc-Gly-phenylacetamidomethyl resin (Boc-Gly-PAM resin) (Chem-Impex International) and 
S-tritylmercaptopropionic acid (Peptides International) as a linker. The peptides were synthesised 
from the C to N-terminus to produce an N-terminal cysteine residue that allowed cyclisation by 
native chemical ligation (5). Boc protected amino acids were double coupled and activated with 2-
(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) or 2-(6-chloro-
1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) with 
diisopropylethylamine (DIPEA) in dimethylformamide (DMF). The coupled amino acid was 
deprotected with TFA and then washed with DMF before the addition of next amino acid.  
 
2.1.3 Fmoc solid-phase peptide synthesis  
The cyclic peptides (MCoTI-M5, MCoTI-M6, SFTI-M6, SFTI-M7, D-SFTI-1) and the 
linear peptides used in this thesis were synthesised using Fmoc chemistry on a Symphony Peptide 
synthesizer (Protein Technologies Inc., Tuscon, AZ) using standard protocols. Peptides were 
constructed on 2-chlorotrityl chloride resin (Chem-Impex International) on either 0.25 or 0.5 mM 
scale and amino acids were coupled using the method previously described (6). 
 
2.1.4 Cleavage of Boc or Fmoc synthesised peptides  
Peptides synthesised by Boc chemistry were cleaved using HF using p-cresol as scavengers 
at -5 to 0°C. The HF was removed by rotary evaporation and the mixture was dissolved in solvent 
A (aqueous 0.05% (v/v) TFA in water) and lyophilised. Peptides synthesised by Fmoc chemistry 
were cleaved by stirring in 95%TFA/triisopropylsilane/water (95:2.5:2.5) for 3 h. The mixture was 
subjected to rotary evaporation to remove TFA and then partitioned in solvent A and solvent B 
(90% (v/v) acetonitrile in 0.045% TFA) (50:50) and cold diethyl ether. The aqueous layer obtained 
from the above step was lyophilised. Crude peptides were purified on RP-HPLC using a C18 
column (Phenomenex) with 1%/min gradient of 0%-80% solvent B and solvent A and the 
absorbance were detected at 215 and 280 nm. The masses of peptides were confirmed by 
electrospray ionisation mass spectrometry (ESI-MS). 
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2.1.5 Cyclisation and oxidation of peptides  
Native MCoTI-II and its mutants synthesised by Boc chemistry were cyclised and oxidised 
in a single-step process. The linear reduced peptides were stirred in the presence of 0.1 M 
ammonium bicarbonate (pH 8.5) for 24 h. Native SFTI-1 and its mutants were cyclised and 
oxidised in a two-step procedure as mentioned previously (7). The reduced peptides were cyclised 
in the presence of 0.1 M tris(2-carboxyethyl)phosphine for 24 h followed by purification. The 
oxidisation of these cyclic reduced peptides was carried out in 0.1 M ammonium bicarbonate (pH 
8.0) for 24 h. Cyclic peptides synthesised by Fmoc chemistry, were cyclised in three-step as 
mentioned previously (6). Briefly, the peptides were cleaved using 1 % (v/v) TFA in DCM which 
removes the resin and leaves the side-chain protecting groups deprotected. TFA and DCM was 
removed using rotatory evaporator and then lyophilised. The cyclisation was achieved in the 
presence of 2-(7-Aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HATU) and DIPEA in DMF for 3 h. After cyclisation step, the side-chain protecting groups were 
deprotected using similar steps used for linear peptides. Cyclic reduced peptides were oxidised 
using 0.1 M ammonium bicarbonate (pH 8.5) for 24 h. Kalata B1 mutants synthesised by Boc 
chemistry were folded using 0.1 M ammonium bicarbonate (pH 8.5), 2 mM reduced glutathione and 
0.4 mM oxidised glutathione with varying concentrations of isopropanol stirred at 48 h at room 
temperature. Similar folding conditions were used for kalata B2 mutants but were performed 
without the addition of isopropanol. The cyclic peptides were purified by RP-HPLC. Both linear 
and cyclic peptides were purified to >95% purity as assessed by analytical RP-HPLC and the 
masses of purified peptides were determined by ESI-MS.  
2.2 NMR spectroscopy  
NMR is a versatile and robust method that can be used to provide structural information on 
peptides and their molecular interactions (8). In the NMR technique, the sample is placed in an 
external magnetic field and the spin axes of certain nuclei (such as 1H or 13C) align with the 
direction of the magnetic field. The nuclei flip to a higher energy level when it is excited with the 
pulse of radio-frequency electromagnetic radiation. The resonating nuclei return to a low energy 
state on relaxation, where the signal detected is Fourier transformed. The resonance frequency of a 
given nucleus with a magnetic moment reflects the chemical environment around the nuclei. The 
resonance frequency relative to a standard is known as the “chemical shift”. The αH secondary shift 
is the difference in the chemical shift of αH for a particular amino acid of a given peptide and the 
chemical shift for αH of the same amino acid in a random coil peptide. Secondary structure of 
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peptides can be predicted based on secondary shifts values, whereby negative secondary shifts are 
an indication of α-helix structure and positive secondary values correlate with β-strand structure. 
To determine the solution conformation and three-dimensional (3D) structure of peptides 
homonuclear one-dimensional (1D) or two-dimensional (2D) NMR experiments are used. 2D NMR 
experiments include Total Correlation Spectroscopy (TOCSY), and Nuclear Overhauser Effect 
Spectroscopy (NOESY), which are used for homonuclear studies, and Heteronuclear Single 
Quantum Coherence spectroscopy (HSQC) for heteronuclear studies. The 1D NMR is the first step 
in the analysis of peptides and used to confirm the purity of peptides or to see if the peptide is 
structured or unstructured and even to observe aggregation formation. A structured peptide has a 
well-dispersed amide chemical shift in the range 7.5-8.5 ppm whereas peptides that are unfolded or 
unstructured have narrow distribution in this region. Different conditions such as pH, buffer, co-
solvent or peptide concentrations affect the 1D spectra of peptides and can be further adjusted to 
improve spectral quality.  
The 2D spectra can help to determine the secondary structure of the peptides which is based 
on chemical shifts, coupling constants and (Nuclear Overhauser effects) NOEs. This information 
can then help to get a full 3D structure of a peptide or protein. The nature, duration and combination 
of the radiofrequency pulses are varied in 2D NMR, to probe the molecule for different nuclear 
interactions. The NOESY (9) spectra provide information about protons that are 5Å or less apart in 
space. The cross-peaks observed in NOESY are due to dipolar coupling resulting from the 
interactions of the spins via space and hence depend on the distance but not the number of the 
intervening bonds (NOE ∝ 1/r6). The intensities of the cross peaks from which distance are derived 
can be useful for structure calculations in solutions and sequential resonance assignment process. In 
case of TOSCY (scalar coupling information) between all the members of spin system can be 
obtained which is through bond and not through space. The cross peaks in a TOCSY (10) 
experiment are due to protons of the same spin systems which can be used to identify individual 
amino acids. It is possible to clearly assign all cross-peaks in a 2D NMR spectrum with the help of 
primary sequence of a peptide or protein.  
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Figure 2-1: Bruker Avance 500 and 600 MHz NMR spectrometers. 
 
For NMR experiments, peptides were dissolved in 90% (v/v) H2O and 10% (v/v) D2O 
(Cambridge Isotope Laboratories) at a concentration of 1 mM (pH 3.5). 1H 1D and TOCSY and 
NOESY 2D NMR spectra of the synthesised peptides were recorded on Bruker Avance-500 or 600 
MHz spectrometer (Figure 2-1) at 25°C. TOCSY experiments were recorded using a 80 ms mixing 
time and for NOESY 100-200 ms was used. The spectra obtained for the peptides were processed 
using TopSpin 2.1 (Bruker) and assigned using CCPNMR Version 2.1.5 (11). 
2.3 Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy is an excellent technique to examine the overall 
secondary structure of proteins or peptides and in particular to determine the presence of α-helices 
(12). It is based on the differential absorption of left and right circular polarized light and occurs 
when the molecule under study contains chiral chomophores (light-absorbing group). The α-helical 
protein shows negative bands at 222 nm and 208 nm and a positive band at 193 nm. Proteins 
containing well-defined antiparallel β-sheets have negative bands at 218 nm and positive bands at 
195 nm. Circular dichroism (CD) measurements were performed using a Jasco model J-810 
spectropolarimeter (Figure 2-2) between wavelength of 190-300 nm. Peptides were dissolved in 
Dulbecco’s phosphate-buffered saline (PBS) containing 2.7 mM potassium chloride, 1.5 mM 
potassium phosphate monobasic, 138 mM sodium chloride, 8 mM sodium phosphate dibasic, 
(calcium/magnesium free, Invitrogen) with pH 7.4 at 100 µM at 25°C. Spectra were recorded using a 
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0.1 cm path length quartz cuvette. Each spectrum represents the average of three scans at 100 
nm/min. The CD signal obtained for each of the peptides were corrected by subtracting with the 
blank and the molar ellipticity was determined using the formula  
 
Where [θ] is expressed in degrees.cm2.decimole-1, θ is ellipticity in millidegrees, c is concentration in 
molar units and l is the optical path length in centimeters. The percentage helicity of peptides were 
calculated from molar residue ellipticity at 222 nm using the following equation (13) 
    
 
Where [θ]222 ([θ]222 = 1/n. [θ]obs /( c x l x 10) is the observed residue ellipticity of peptide at 222 nm, 
[θ]max ([θ]max = [θ]∞ (n-x)/n) is the maximum theoretical mean residue ellipticity for a helix of n 
residues, [θ]∞ is the mean residue ellipticity of an helix and x is an empirical constant (x=3),          
[θ]∞ = (-44000 +250T) (T is temperature of the sample solution in °C), [θ]0 ([θ]0 = 2220 – 53T) (is the 
mean residue ellipticity of the peptide in random coil conformation.  
   
Figure 2-2: Jasco model J-810 spectropolarimeter used for CD experiments. 
2.4 Labeling peptides with Alexa Flour 488  
The internalisation of the labeled peptides (in Chapter 3) was studied using flow cytometry. 
Peptides were labeled with Alexa Fluor 488 sulfodichlorophenol ester (Life Technologies) by 
f  
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covalently attaching it to the lysine side chain of the peptide forming an amide bond. The peptides 
were incubated with 2 moles equivalent of Alexa Fluor 488 (1 mg in DMSO) in 0.1 M sodium 
bicarbonate buffer (pH 8.0) at room temperature for 3 h with gentle shaking. The labeled peptides 
were purified using semi-preparative column on RP-HPLC. Fractions from RP-HPLC containing 
peptides conjugated to one label were identified based on their masses by ESI-MS and selected for 
internalisation experiments. To identify which Lys residue was labeled in the sequence, labeled 
peptides were reduced and digested with trypsin (14) and the peptide fragments obtained were 
subjected to MS/MS using a MALDI-TOF-TOF (Applied Biosystems). 
2.5 Surface plasmon resonance (SPR)  
 Surface plasmon resonance (SPR) is an important biochemical technique for studying 
molecular interactions using lipid membranes or proteins (15). It measures bimolecular interactions 
in real time without any need to label the molecules. Small amounts of sample in nanomolar 
concentrations are required due to the high sensitivity of the technique. Sensor chips that are glass 
slides coated with thin layer of gold are used to study the macromolecular interactions, which 
measures the reflective index near the vicinity of the metal surface (15). For example if one 
molecule (analyte) binds to another molecule (ligand) there is an increase in the refractive index 
that is measured in real time in this technique.  
 
2.5.1 Preparation of lipid vesicles 
To study peptide-membrane binding interactions, the synthetic lipids 1-palmitoyl-2- 
oleoylphosphatidyl choline (POPC), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), 1-
palmitoyl-2-oleoylphosphatidylglycerol (POPG) and 1-palmitoyl-2-oleoylphosphatidylserine 
(POPS) were purchased from Avanti polar lipids to prepare model membranes. Small unilamellar 
vesicles (SUVs) with a diameter of 50 nM were prepared as described previously (16). All the 
peptide solutions and liposomes were freshly prepared in 10 mM HEPES buffer containing 150 mM 
NaCl, pH 7.4 filtered through 0.22 µm filter pore. Briefly, synthetic lipids were dissolved in 
chloroform and the solvent was evaporated with a stream of nitrogen to form a thin layer of film 
and left in vacuum overnight. Next day, buffer was added to obtain a suspension, which was 
vortexed and freeze-thawed for eight times. To obtain SUVs, the suspension was extruded 21 times 
through a polycarbonate membrane with a 50 nm pore size diameter using mini-extruder as shown 
in Figure 2-3. 
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Figure 2-3: Mini-extruder used to preparation of liposomes. 
 
2.5.2 Peptide binding studies using SPR 
 SPR measurements were conducted with a Biacore 3000 instrument (Figure 2-4) using an L1 
sensor chip for peptide-membrane binding studies (in Chapter 3) following protocols previously 
optimised (17). The experiments were performed in 10 mM HEPES with 150 mM NaCl (pH 7.4) 
buffer. The prepared lipids were deposited onto the L1 sensor chip surface (2 µL/min, 2400 s 
contact time). Peptide solutions at selected concentrations were prepared in buffer. Peptides were 
injected over the lipid surface (5 µL/min, 180 s) and dissociation followed for 600 s per injection 
cycle. The affinity of each peptide for the membrane was compared based on the peptide-to-lipid 
ratio determined as described previously (16). The experiments were performed in triplicate at 
25°C. The binding signal was monitored and the sensorgrams were processed using BIAevaluation 
software 4.0 version.  
 
 
Figure 2-4: Biacore 3000 used for peptide binding studies.  
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2.6 Cell based assays 
2.6.1 Cell culture conditions  
Cells used for this thesis for the biological assays are shown in Figure 2-5. Cervical 
cancer cells (HeLa) were cultured in Dulbecco’s Modified Eagle’s medium (DMEM; 
Invitrogen) supplemented with 50 U/mL of penicillin (Invitrogen) and 50 µg/mL streptomycin 
(Invitrogen) and 10% (v/v) of heat inactivated fetal bovine serum (FBS, Invitrogen). Human 
chronic myelogenous leukemia cell line (K562) and murine macrophage-like cell line 
(RAW264) stably transfected with the human ELAM (E-selectin) promoter (i.e. endothelial 
cell-leukocyte adhesion molecule cells (ELAM) were grown in Roswell Park Memorial 
Institute medium (RPMI 1640; Invitrogen) supplemented with 5% (v/v) (for K562 cells) or 
10% (v/v) FBS (for ELAM cells), L-glutamine (Invitrogen) (for K562 cells) or Glutamax-I 
(Invitrogen) (for ELAM cells), 50 U/mL penicillin and 50 µg/mL streptomycin. All the cells 
were incubated at 37°C with 5% CO2.  
 
Figure 2-5: Cell lines used for the biological assays. HeLa (Cervical cancer cell line), K562 
(Chronic myeloid leukemia cell line) and ELAM (Macrophage-like cell line). 
 
2.6.2 Resazurin dye assay 
Resazurin dye assay is a simple, rapid and sensitive measurement for the viability of 
mammalian cells and bacteria (18). Resazurin is a redox dye, which shows both colorimetric, and 
fluorometric change relating to the metabolic activity of the cells. This assay involves the 
conversion of the non-fluorescent dye resazurin (blue color) to fluorescent dye resorufin (pink 
color) by viable, metabolically active cells (Figure 2-6). The oxidised form of the resazurin is 
converted to the reduced form by the enzymes in mitochondria and therefore also making it useful 
to assess mitochondrial metabolic activity. 
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Figure 2-6: Conversion of resazurin (blue) to resorufin (pink). The diagram shows the oxidised 
form of resazurin (blue) is converted to the reduced form resorufin (pink) by the enzymes in the 
mitochondria of living cells. The absorbance signal of this solution is measured at 540 and 620 nm 
by a spectrophotometer. 
 
The resazurin dye assay was done on three cell lines K562, HeLa and ELAM cells as 
reported previously (19). The desired numbers of HeLa (5×103 cells/well) or ELAM cells (adherent 
cells) (2.5×106 cells/well) were plated in a 96-well plates and incubated for 24 h at 37°C and then 
treated with 2-fold concentrations of each peptide (0.25 to 64 µM) in serum-free media for 2 h. 
After 2 h of incubation the media was removed and 100 µL fresh media containing serum and 10 
µL resazurin dye (0.02% (w/v) was added and absorbance signal was measured at 540 and 620 nm 
after 18 h incubation at 37°C. The percentage of cell death was calculated as described previously 
(20). The suspension K562 cells were plated and treated with the peptide on the same day in serum-
free media. After 2 h of peptide incubation, 10µL resazurin dye was added and absorbance signal 
was read after 18 h. All the experiments were done in triplicate. 
 
2.6.3 Internalisation assays 
The internalisation of the peptides in HeLa cells was examined using flow cytometry (BD 
FACSCanto II) (Figure 2-7) as described previously (19). The quantification of Alexa Fluor 488-
labeled peptides was done measuring the absorbance at 495 nm considering ε495 as 71,000 cm-1 M-
1
. Different concentrations of the peptides (1, 2, 4, 8 and 16 µM) were incubated with the cells 
containing fresh medium without serum. After incubating the peptides for 1 h at 37 °C the cells 
were washed with phosphate-buffered saline (PBS) and harvested with trypsin. The cells were then 
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centrifuged (500g) and resuspended in PBS. The population of healthy cells was selected based on 
side and forward scatter dot plot. Cells were excited with 488 nm laser and fluorescence emission 
signal detected at 530 nm (30 nm bandpass). The fluorescence signal of the membrane-bound 
peptide was quenched using trypan blue (160 µg/ml or 164 µM). Each experiment was done in 
triplicate and 10,000 cells were screened per sample. 
 
 
Figure 2-7: BD FACSCantoII flow cytometer used for internalisation experiments.  
 
2.6.4 Serum stability assay of peptides  
  Human serum from male AB plasma (Sigma-Aldrich) was used for the stability assays as 
described previously (4). The serum was centrifuged at 17,000g for 10 minutes to remove the lipid 
component. Peptides were dissolved in PBS and incubated with human serum at 37°C for different 
time points (0, 1, 4, 8, 24 h). Proteins present in the serum/peptide sample were precipitated on 
addition of 20% trichloroacetic acid (10 minutes, 4°C) and were centrifuged at 17,000g for 10 
minutes. The resultant pellet obtained was solubilised in 8 M guanidine hydrochloride solution 
(21). The supernatant obtained was analysed on RP-HPLC using 0.4 mL/min Phenomenex column 
1%/min gradient of 0-80% solvent B and solvent A. As a control, peptides were dissolved in PBS 
and incubated at 37°C in parallel at different time points. The amount of the peptide at each time 
points was analysed by calculating the peak area at absorbance of 215 nm obtained on RP-HPLC. 
All the experiments were performed in triplicate. 
 
2.6.5 ELAM assay  
ELAM cells were grown in 24-well plate (2.5×106 cells/well) and incubated overnight. Next 
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day media was removed and incubated with peptides at different concentrations for 1 h in fresh 
serum-free media. After 1 h, cells were washed with PBS and stimulated with lipopolysaccharide 
(LPS) from Salmonella Minnesota L2137 (Sigma-Aldrich, USA) (10 ng/mL) for 4 h. Cells were 
then harvested with LIFT solution (1 mM EDTA and 0.1% sodium azide in PBS) and the 
fluorescence emission of expressed green fluorescent protein (GFP) was followed by flow 
cytometry (BD FACSCanto II) (Figure 2-7) (22). The cells were excited at 488 nm and emission 
detected at 530 nm (with 30 nm band pass). The population of cells was gated based on 
forward/side scattering and 10,000 cells analysed per sample. Data represents the mean of three 
independent experiments. 
 
2.7 Crosslinking experiments  
 Peptides were incubated with liposomes composed of POPC/POPE (4:1), POPE/POPG (1:1) 
and POPC in 10 mM sodium phosphate buffer, pH 7.5 at 25°C for 1 h. The suspension was 
subsequently centrifuged at 13,000g for 30 minutes. The supernatant was removed and the pellet 
was washed twice prior to resuspension in the same buffer. Cross-linker disuccinimidyl glutarate 
(DSG) was added at 5 mM concentration and the lipid suspension was allowed to react at room 
temperature for 1 h at 25°C. The reaction was stopped with 200 mM Tris (pH 8.8) buffer and 
allowed to react for 10-15 minutes at room temperature. The sample was mixed with a tricine 
sample buffer and incubated at 95°C for 5 minutes. The samples were loaded on 16% tricine 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels to separate the cross-
linked peptides. Gels were further stained using Silver Quest silver staining kit (Invitrogen) to 
identify the peptide bands.  
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3.0 Overview  
As described in introductory Chapter 1, disulfide-rich cyclic peptides have an ultra-stable 
structure that has attracted attention in drug design applications (1). Owing to their cell-penetrating 
properties, disufide-rich cyclic peptides can be explored as stable vectors to inhibit important 
therapeutic targets intracellularly. MCoTI-II and SFTI-1 are disulfide-rich cyclic peptides belonging 
to the recently discovered CCPP family (2). MCoTI-II has shown the ability to internalise 
mammalian cells through macropinocytosis (2,3). Further mutation studies showed that the 
positively charged residues present on MCoTI-II are very important for its internalisation 
mechanism (2). On the other hand, SFTI-1, which is structurally different to MCoTI-II, enters into 
cells via an unknown mechanism.  
Cell-penetrating peptides are short peptide sequences able to cross the cell membrane and 
deliver bioactive cargoes inside cells (4). Structural properties such as charge and hydrophobicity 
seem to be relevant in their cellular uptake process. Positively charged residues (e.g. lysine and 
arginine) have been shown to increase their cellular uptake, probably due to interaction with the 
negatively charged cellular components present on the cell surface such as sulfate, phosphate and 
carboxylate groups (5). Hydrophobic residues (e.g. tryptophan and tyrosine) increase the overall 
affinity of the peptide for the lipid bilayer of the cell membrane (6,7). 
In this Chapter, the structural characteristics affecting the cellular uptake of MCoTI-II and 
SFTI-1 were investigated. The information gathered with this study will provide valuable 
information to rationally improve their cell-penetrating properties and enable their future 
application as delivery vectors. A series of mutants was designed by replacing single or multiple 
residues within MCoTI-II and SFTI-1 sequence with charged (e.g. arginine and lysine) and 
hydrophobic (e.g. tryptophan) amino acid residues with the aim to improve their cell-penetrating 
properties. In addition to this, other structural modifications included disconnecting the cyclic 
backbone and removing the disulfide bond. The D-entianomer form of SFTI-1 was synthesised to 
evaluate whether its internalisation mechanism is dependent on a chiral receptor. The structure of 
the synthesised peptides was characterised using NMR spectroscopy. Synthesised peptides were 
fluorescently-labeled and internalisation of the peptides was monitored in HeLa cells using flow 
cytometry. The efficiency of the analogues was compared with a positive and a negative control. 
Our observations suggested that increasing the overall positive charge improves the cellular uptake 
of MCoTI-II. SFTI-1 and its mutants showed similar cellular uptake but with a low efficiency 
which was comparable to Tat-G (control used to estimate non-stimulated uptake) suggesting a non-
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specific internalisation mechanism. D-SFTI-1 and SFTI-1 showed similar uptake suggesting a non-
receptor mediated pathway. The uptake rate of SFTI-1 and its mutants was lower compared to that 
of the native MCoTI-II. 
Overall this chapter identified structural features that are important during the internalisation 
of MCoTI-II and SFTI-1. These molecules have been used in drug design therefore the data 
presented here can be useful in their future application as vectors and as a guide for developing 
novel peptide based drug candidates.  
 
The chapter is presented in the form of a paper that has been published in European Journal of 
Medicinal Chemistry (2014). 
 
Charlotte D’Souza, Sónia Troeira Henriques, Conan K. Wang and David J. Craik, Structural 
parameters modulating the cellular uptake of disulfide-rich cyclic cell-penetrating peptides: 
MCoTI-II and SFTI-1, European Journal of Medicinal Chemistry 88 (2014) 10-18. 
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Peptides are emerging as a new class of therapeutics due to their high potency and specificity for a range
of targets, including the inhibition of proteineprotein interactions. Disulfide-rich cyclic peptides, in
particular, have attracted much attention in drug design due to their ultra-stable structure. Moreover,
some of them have been shown to internalize into cells, which makes them potential scaffolds to deliver
pharmaceutically bioactive sequences to intracellular targets. Here we examined the effects of structural
modifications on the cell-penetrating properties of two disulfide-rich cyclic cell-penetrating peptides,
Momordica cochinchinensis trypsin inhibitor II (MCoTI-II) and sunflower trypsin inhibitor-1 (SFTI-1). We
found that the cellular uptake of MCoTI-II can be improved by increasing the overall positive charge of
the native sequence. On the other hand, mutations to SFTI-1 did not significantly influence its cellular
uptake, suggesting a non-specific endocytosis-dependent mechanism of cellular uptake. This study
provides an understanding of the structural features affecting the internalization of MCoTI-II and SFTI-1,
and hence provides a guide for the development of these disulfide-rich cyclic scaffolds into potential
drug leads.
© 2014 Elsevier Masson SAS. All rights reserved.1. Introduction
Peptides have re-captured the attention of pharmaceutical
companies as promising drug leads because they generally display
low toxicity, high potency and the ability to address previously
‘undruggable’ targets. For example, they can specifically modulate
proteineprotein interactions, which typically do not involve deep
involutions that enable selective and potent targeting by small
organic molecules [1,2]. However, the delivery of peptide thera-
peutics to target proteineprotein interactions within cells has been
challenging because the cell membrane is an efficient barrier that
prevents entry of extracellular macromolecules. Nevertheless, over
the past decade, there has been growing recognition that some
peptides can be internalized into cells, a feature that is largely
dependent on their amino acid composition and sequence [3].
Cell-penetrating peptides (CPPs) usually contain a high content
of positively-charged residues (e.g. arginine and lysine) and also, cell-penetrating peptides;
fluorenyl)methyloxycarbonyl;
tor II; POPC, 1-palmitoyl-2-
oylphosphatidylserine; SPR,
inhibitor-1.
b.uq.edu.au (D.J. Craik).
served.hydrophobic residues like tryptophan [4]. Some notable examples
of CPPs include HIV-Tat, penetratin, transportan and octaarginine,
which enter cells via various mechanisms [5], including endocy-
tosis, membrane permeation, or by a combination of pathways.
From a drug design perspective, CPPs are important because they
can be used as vectors to deliver therapeutic peptides that have
been conjugated to the CPP [3]. This strategy has led to the devel-
opment of awide range of peptides that bind to intracellular targets
in disease conditions like cancer [6], neurological disorders [7] and
inflammation [8].
Recently we characterized a novel family of CPPs referred to as
cyclic cell-penetrating peptides (CCPPs) that are topologically
distinct from other CPPs [9]. Members of this family include
Momordica cochinchinensis trypsin inhibitor II (MCoTI-II) [10,11],
kalata B1 (kB1) [12] and sunflower trypsin inhibitor 1 (SFTI-1) [13].
These peptides display well-defined tertiary structures that are
characterized by the presence of head-to-tail backbone cyclization
and one or more disulfide bonds. MCoTI-II and kB1 contain three
disulfide bonds, whereas SFTI-1 contains one. The combination of a
macrocyclic backbone and internal disulfide bonds is thought to
underpin the remarkable stability of these peptides against enzy-
matic proteolysis [14,15], rendering them more stable than linear
peptides [16], including conventional linear CPPs. Other cyclic
peptides that can internalize into cells have also been reported [17].
C. D’Souza et al. / European Journal of Medicinal Chemistry 88 (2014) 10e18 11The internalizationmechanism of currently known CCPPs seems
to be dependent on the peptide. Both MCoTI-I, which has high
sequence similarity toMCoTI-II, and MCoTI-II are internalized by an
energy-dependent process (e.g. endocytosis) and are unable to
cross the cell by direct membrane permeation [9,18,19]. Specifically,
internalization of MCoTI-II into MCF-7 (breast cancer) cells was
found to occur through macropinocytosis (~40%) and other endo-
cytic pathways. Mutational studies indicated that the positive patch
at the surface of MCoTI-II is important for its internalization. Direct
binding of MCoTI-II with phosphoinositide-phosphates in vitrowas
observed and it was hypothesized that the interaction of basic
residues in MCoTI-II with negatively-charged phosphoinositides on
the cell membrane might play a role in activating endocytic pro-
cesses [9]. Kalata B1 uses a different mechanism of cell entry
compared to MCoTI-I and MCoTI-II; internalization of kB1 into cells
seems to be dependent on its ability to bind to lipid components
and to insert its hydrophobic patch into the cell membrane [9]. The
mechanism of internalization of SFTI-1 has yet to be elucidated.
The remarkable stability of disulfide-rich cyclic peptides makes
them ideal scaffolds for drug design [20]. In one approach for
example, these highly stable frameworks have been substituted
(‘grafted’) with bioactive peptide epitopes to increase the stability
and biopharmaceutical properties of the epitope. This grafting
approach has led to the development of lead molecules against
HIV-1 viral replication [21], angiogenesis [22], tryptase and human
leukocyte elastase activity [23], cancer [24] and multiple sclerosis
[25], as well as a range of other applications [26,27]. Most of these
applications have focused on extracellular targets but recently,
Camarero and co-workers demonstrated the application of a
disulfide-rich cyclic peptide framework towards an intracellular
target. In this work, MCoTI-I was engineered to harbor a p53 helical
peptide fragment, which inhibited the interaction between p53 and
Hdm2/HdmX, suppressing tumor growth in a mouse xenograft
model [28]. This example suggests that CCPPs can be used as vec-
tors to deliver engineered peptides to intracellular targets, thus
even further broadening their applications in drug design.
Wewere interested in determining the structural characteristics
influencing cellular uptake of two CCPPs of differing size and di-
sulfide content, MCoTI-II and SFTI-1, to enable the further optimi-
zation and development of CCPPs as vectors to address important
disease conditions. Analogues of MCoTI-II and SFTI-1 involving in-
dividual residue substitutions were synthesized and their inter-
nalization efficiencies were determined.2. Results and discussion
2.1. Peptide design and characterization
To investigate the relationship between structure and cellular
uptake, two series of MCoTI-II and SFTI-1 analogues were synthe-
sized and their internalization was assessed by flow cytometry.
Lysine residues were substituted with arginine to examine the ef-
fect of the guanidine moiety, which has an extra hydrogen bond
donor when compared to the amine moiety in lysine residues and
can form additional interactions with phosphate, sulfate, and
carboxylate groups present on the cell surface, leading to improved
cellular uptake in some cases [29]. Additionally, hydrophobic resi-
dues, such as tryptophan, which can improve the uptake of CPPs by
increasing their affinity for lipids within the cell membrane [30],
were incorporated into the parent peptides. Other modifications
included disconnecting the cyclic backbone, removing the disulfide
bonds and modifying the chirality of certain residues to elucidate
the importance of these features to the internalization process. The
various analogues synthesized are summarized in Fig. 1.The synthesized peptides were fluorescently-labeled with Alexa
Fluor 488 through amide-bond ligation to the side chain of a Lys.
The fluorescence of Alexa Fluor 488 was used to follow the inter-
nalization of peptides using flow cytometry. We also synthesized
and labeled Tat (YGRKKRRQRRRPPQG-amide), a gold standard CPP
[31], to use as a positive control to compare the uptake efficiency of
MCoTI-II and SFTI-1. As internalization of Tat is known to be
dependent on its positively-charged residues [32], we designed an
analogue of Tat, referred to as Tat-G (YGGGKGGQGGGPPQG-amide),
inwhich all but one of the basic residues was replaced with Gly; the
exception was Lys-5 to enable conjugation of the dye. Tat-G was
included in the studies as a negative control to evaluate non-
specific solute internalization.
The structures of the novel analogues were characterized using
solution-state NMR spectroscopy. 1D and 2D NMR spectra were
recorded for the peptides in aqueous solution at 298 K and assigned
using previously reported methods [11,33,34]. Fig. 2A shows a
comparison of the Ha chemical shifts for native MCoTI-II and its
analogues. All analogues have essentially identical Ha chemical
shifts to native MCoTI-II, suggesting that they have similar overall
three-dimensional structures. Small differences are present only in
those residues that are mutated, as expected due to local steric or
electronic effects. The chemical shift data for SFTI-1 analogues
(Fig. 2B) also suggest identical folds to the native peptide. Previous
studies of native SFTI-1 [34] have shown that Pro-8 and Pro-9 exist
in cis and trans conformations, respectively, for the X-Pro bonds,
and Pro-13 occurs in the trans conformation. Most of the SFTI-1
analogues displayed this trend, except for SFTI-M2 (Fig. 2C) and
SFTI-M4 (Fig. 2D), where two conformers co-existed due to Pro-13
occurring in both cis and trans conformations. There was also a
difference in the chemical shifts observed for SFTI-M6 at the Cys-3
and Cys-11 positions, which were replaced with a-aminobutyric
acid (Abu), an amino acid that does not form disulfide bonds but
possesses isosteric properties similar to cysteine.
2.2. Cytotoxicity of synthesized peptides on HeLa cells
Before assessing internalization the cytotoxicity of the ana-
logues was evaluated at concentrations ranging from 0.5 to 64 mM
on HeLa cells. Kalata B1, extracted from the leaves of Oldenlandia
affinis, was used as a positive control [35]. All MCoTI-II and SFTI-1
analogues were non-cytotoxic in the concentration range tested
(Fig. 3). The absence of cytotoxicity for these synthesized peptides
on mammalian cells provides support for the potential application
of these frameworks in peptide-based drug design.
2.3. Structural mutations improving cellular uptake of MCoTI-II
Fluorescently-labeledMCoTI-II and its analogueswere compared
on their ability to internalize into HeLa cells bymeasuring themean
fluorescence emission of Alexa Flour 488 by flow cytometry
following protocols previously optimized [36]. Varying concentra-
tions of each peptidewere incubated with HeLa cells at 37 C for 1 h
and non-internalized peptide was washed; trypan blue, a hydro-
philic fluorescence quencher unable to enter viable cells and able to
quench non-internalized and membrane-bound fluorophore
[37,38], was subsequently added to quench the fluorescence of any
membrane-bound peptide and/or the fluorescence of cells with the
membrane integrity compromised. Interestingly, the fluorescence
emission signal did not change significantly after addition of trypan
blue, suggesting that neither MCoTI-II nor its analogues were
membrane-bound. Moreover there was also no difference observed
in the percentage offluorescent cells (Fig. S1 in supplementary data)
obtained before and after addition of trypan blue, confirming
that the membrane integrity in not compromised during the
Fig. 1. Amino acid sequences of MCoTI-II and SFTI-1 analogues used in this study. Cysteine residues are shaded in gray and loops between them are labeled. The mutated residues
are highlighted in bold. D-amino acids are represented in lower case. X represents a-aminobutyric acid (Abu). Lys residues derivatized with Alexa Fluor 488 are underlined and the
overall net charge on the peptides after labeling is shown.
C. D’Souza et al. / European Journal of Medicinal Chemistry 88 (2014) 10e1812internalizationprocess. At 4 mMvirtually all the cells are fluorescent,
indicating that at this concentration all the cells can be targeted and
have MCoTI-II internalized.
A previous study [9] suggested the importance of a positively-
charged patch on the surface of MCoTI-II to its cellular uptake
(Fig. 4). Therefore, we synthesized three analogues, MCoTI-M1,
MCoTI-M2 and MCoTI-M3, replacing Tyr-28 with Trp, or both Lys-
9 and Lys-10 with Arg residues, or incorporating both sets of mu-
tations. These analogues were designed to assess whether it is
possible to improve the cellular internalization of MCoTI-II.
These analogues internalized into HeLa cells (Fig. 5) but no
improvement in internalization efficiency was achieved compared
to native MCoTI-II. Thus, substitution of Lys residues with Arg, and
Tyr with Trp, does not alter the uptake characteristics of MCoTI-II.
This finding suggests that MCoTI-II behaves differently to other
CPPs, such as penetratin and octaarginine, for which Trp and/or Arg
mutations increase cellular uptake [29,30].
It was previously shown for other CPPs that the net charge and
charge distribution within the sequence might influence internal-
ization efficiency [39]. Therefore, to examine whether increasing
the net charge of MCoTI-II could improve its uptake we replaced
Asp-34, Lys-9 and Lys-10 with Arg residues (MCoTI-M4). Interest-
ingly, this analogue showed a significant improvement in uptake
compared to MCoTI-II. As the positively-charged patch on the sur-
face of the MCoTI-II (Fig. 4) is believed to be important for its
internalization [9] and studies with other CPPs have shown that the
presence of hydrophobic label can interfere with cell entry [38], we
designed the mutant, MCoTI-M5, which has the same net charge asMCoTI-M4 but has the label positioned away from the positive
patch region (Lys-34; see sequence in Fig. 1 and structure in Fig. 4).
MCoTI-M5 internalizes with comparable efficiency to MCoTI-M4
(Fig. 5), suggesting that the position of the label does not inter-
fere with the internalization efficiency. Our results suggest that
increasing the overall net charge improves the cellular uptake of
MCoTI-II. Since bothMCoTI-M4 andMCoTI-M5 aremore positively-
charged thanMCoTI-II there is potentially an improved electrostatic
attraction with negatively-charged components at the cell surface,
which serves to increase the concentration of peptide at the cell
vicinity and consequently its uptake by endocytic routes.
We also examined the importance of the cyclic backbone by
evaluating the internalization of an acyclic MCoTI-II mutant opened
in loop 6 between the Gly-1 and Asp-34 residues (MCoTI-M6).
Interestingly, this acyclic mutant internalizedwith higher efficiency
than MCoTI-II (Fig. 5), suggesting that the cyclic backbone is not a
requirement for internalization. The increase in cellular uptake
could be due to the exposed NH2 and COOH termini, which is the
main structural difference between MCoTI-M6 and MCoTI-II.
2.4. Internalization of MCoTI-II analogues does not involve
membrane-binding
Lipid binding is an important mechanistic feature of several
CPPs [40]. Although MCoTI-II apparently does not have affinity for
lipid membranes during the internalization process, as suggested
bymicroscopy studies with cells and by surface plasmon resonance
(SPR) with lipid model membranes [9,18], we were interested to
Fig. 2. Structural analysis of native and synthesized peptides. A) Ha chemical shifts of
MCoTI-II mutants compared with native MCoTI-II. B) Ha chemical shifts of SFTI-1
mutants compared with native SFTI-1. Chemical shifts of cis and trans isomers of
SFTI-M2 (C) and SFTI-M4 (D) in comparison with native SFTI-1.
Fig. 3. Cytotoxicity study of MCoTI-II (A) and SFTI-1 (B) analogues on HeLa cells. The
peptides were incubated with cells for 2 h at concentrations ranging from 0.5 mM to
64 mM. Cell death was evaluated by a resazurin dye assay. Data are represented as
mean ± SD of three replicates.
C. D’Souza et al. / European Journal of Medicinal Chemistry 88 (2014) 10e18 13determine whether the improved cellular uptake of MCoTI-M4,
MCoTI-M5 and MCoTI-M6 was due to an altered membrane-
binding profile. Due to the overall positive-charge of MCoTI-II and
its analogues, we compared the affinity of MCoTI-II and its ana-
logues for neutral (1-palmitoyl-2-oleoylphosphatidylcholine
(POPC)), and negatively-charged membranes (POPC/1-palmitoyl-
2-oleoylphosphatidylserine (POPS) 80:20 M ratio) using SPR. POPC
is a zwitterionic phospholipid that forms fluid membranes at 25 C
and was used to mimic the neutral fluid phase in mammalian cell
membranes [41], whereas POPS is the most common negatively-
charged phospholipid in mammalian cells. For the sake of com-
parison we also included MCoTI-M1, which contains a Trp insteadof Tyr-28 and was shown to be internalized with comparable effi-
ciency as MCoTI-II. Kalata B1, a disulfide rich-cyclic peptide known
to have weak affinity for both POPC and POPC/POPS membranes
[42] and Tat, a CPP assumed to interact with membranes, were also
included as controls.
Fig. 6 shows thatMCoTI-II and its mutants haveminimal binding
affinity to both POPC and POPC/POPS (80:20) model membranes at
concentrations as high as 50 mM, suggesting that the improvement
in the internalization efficiency does not correlate with stronger
affinity for the phospholipid bilayer. Conversely, Tat binds to both
lipid systems, but with higher affinity for the negatively-charged
POPC/POPS mixture. Kalata B1 showed weak affinity towards
both lipid systems tested, which is in agreement with previous
reports showing that kB1 binds specifically to phosphatidyletha-
nolamine lipids head groups [42].
Fluorescent labels, such as Alexa Fluor, are hydrophobic and
have been shown to change the surface properties, efficiency and
membrane-binding affinity of other CPPs by changing their inter-
nalizationmechanism [43]; therefore, to examine if Alexa Fluor 488
improves the membrane-binding properties of MCoTI-II, labeled
and unlabeled MCoTI-II were compared on their affinity to bind to
POPC membranes. Our SPR results (data not shown) did not show
any difference between the binding affinity of the labeled and
unlabeled MCoTI-II at 10 mM with POPC membranes, confirming
that the fluorescent label does not promote binding to neutral
membranes, though interactionwith other cell surface components
cannot be excluded.2.5. SFTI-1 internalizes by non-specific endocytosis and a receptor
independent mechanism
Earlier studies suggested that SFTI-1 enters mammalian cells
but notmuch is known about its internalizationmechanism [9]. We
Fig. 4. Structure and surface representation of MCoTI-II (PDB code 1IB9). (A) The disulfide bonds are indicated with dark gray sticks and the loops between them are labeled (loops
1e6). The cysteines residues are highlighted using Roman numerals (IeVI). (B) Surface representations are shown in two views. Basic residues are shaded in black and labeled in
white; acidic residues are labeled in black.
C. D’Souza et al. / European Journal of Medicinal Chemistry 88 (2014) 10e1814were specifically interested in identifying structural elements that
might be responsible for its penetration properties. Therefore, we
designed a series of analogues with distinct modifications in the
native sequence (Fig. 1) and compared their cellular uptake into
HeLa cells. An increase in the fluorescence emission signal at
different concentration of peptides after quenching of non-
internalized peptides with trypan blue was observed suggesting
that peptides are internalized into HeLa cells. Furthermore, the
similarity in the fluorescence signal or percentage of fluorescent
cells (Fig. S1 in supplementary data) obtained before and after the
addition of trypan blue confirmed that peptides are not bound to
cell membranes and that cell membrane is not permeabilized. The
importance of the charged residues was examined by comparing
SFTI-1 with SFTI-M1 and SFTI-M2, which have Arg-2 and Asp-14,
respectively, replaced with an Ala residue. SFTI-M3 and SFTI-M4
were included to evaluate the effect of having a Trp residue; both
peptides have Phe-12 replaced with a Trp but SFTI-M4 has a more
positive overall charge (Fig. 1) due to replacement of Asp-14 with
Lys. The location of the fluorescent label within the molecule
contributing towards the cellular uptake was evaluated by replac-
ing Lys-5 with Arg and Ile-10 with Lys (SFTI-M5).
The importance of the disulfide bond and the cyclic backbone
were assessed by SFTI-M6 (no disulfide bond) and SFTI-M7 (noFig. 5. Internalization of fluorescently-labeled MCoTI-II analogues into HeLa cells measured
for 1 h at 37 C and the mean fluorescence emission intensity was measured using excitatio
were used as controls. Data was normalized to the fluorescence emission intensity obtained
8 mM is compared. Data are represented as mean ± SD; *p < 0.05, ***p < 0.001, ****p <
fluorescently-labeled peptides are indicated with *.disulfide bond and acyclic). The cysteine residues in these ana-
logues were replaced with Abu. No significant differences were
observed in the internalization of these SFTI-1 analogues into HeLa
cells, as shown in Fig. 7A and B.
We were also interested to determine whether a receptor is
involved in cellular uptake and to evaluate this we synthesized the
D-enantiomer of SFTI-1. We found that D-SFTI-1 internalizes with
the same efficiency as SFTI-1. This indicates that internalization of
SFTI-1 is independent of a chiral receptor suggesting a non-receptor
mediated internalization process. Furthermore, as we observed
similar cellular uptake for all SFTI-1 mutants we evaluated the
possibility of the fluorescent label interfering with the internali-
zation process. For this purpose, the binding affinity of labeled and
unlabeled SFTI-1 to POPC membranes was studied. No binding af-
finity towards POPC lipids were observed for labeled and unlabeled
SFTI-1 at 10 mM (Fig. 7C), suggesting that the cellular uptake is not
affected by any potential effect of the fluorescent label increasing
the lipid binding affinity of the peptide. This does not exclude the
possibility that the label might contribute to improved affinity to
other components on the cell surface.
Despite the sequence modifications, the cellular uptake of the
tested SFTI-1 analogues was comparable with the internalization of
the native form. Physicochemical properties such as positiveby flow cytometry. Alexa Fluor 488-MCoTI-II analogues were incubated with HeLa cells
n with laser at 488 nm and detection at 530 nm with bandpass of 30 nm. Tat and Tat-G
with 8 mM of MCoTI-II (A) Dose-response curves and (B) mean fluorescence intensity at
0.0001 (ANOVA, Bonferroni's Multiple Comparison Test). For the sake of simplicity,
Fig. 6. Binding of peptides to model membranes studied by SPR. Sensorgrams ob-
tained with 50 mMMCoTI-II, MCoTI-M1, MCoTI-M4, MCoTI-M5, MCoTI-M6, kB1 and Tat
towards A) POPC and B) POPC/POPS (4:1) lipid bilayers deposited on the chip surface.
The response signal was normalized and is given as peptide-to-lipid ratio (P/L, mol/
mol).
Fig. 7. Internalization of fluorescently-labeled SFTI-1 analogues into HeLa cells
measured by flow cytometry. Alexa Fluor 488-SFTI-1 analogues were incubated with
HeLa cells for 1 h at 37 C and mean fluorescence intensity was measured. (A) Dose
response curves and (B) cellular uptake at 16 mM are compared for all SFTI-1 analogues.
Data are represented as mean ± SD. No significant difference was observed amongst
the analogues. Tat and Tat-G are used as controls. Data was normalized to the mean
fluorescence emission intensity obtained with 16 mM of SFTI-1. (C) SPR sensorgrams
obtained with SFTI-1 and Alexa Fluor 488-SFTI-1 (SFTI-1*) obtained upon injection of
10 mM over POPC bilayers. The response signal was normalized and is given as P/L
(mol/mol).
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tant in the uptake of CPPs. Although having common properties, a
single internalization mechanism does not explain the uptake of all
CPPs, but cell entry routes used can be broadly divided into energy-
driven (e.g. endocytic) mechanisms and direct membrane pene-
tration (also referred to as transduction). Endocytosis [29,44] ap-
pears to be the major cell entry pathway, but some CPPs are mainly
internalized by a translocation mechanism involving direct inter-
action with the lipid membrane [45] and others use both pathways
[46,47]. Internalization of CPPs through endocytic pathways can
result through specific (receptor) or non-specific (adsorptive, fluid
phase) binding of CPPs to cell surface components. Fluid phase
endocytosis [44] is a non-specific and low efficiency process that
involves bulk uptake of solutes, and is not influenced by any specific
physicochemical features of the peptide. The similarity in uptake
for all the tested SFTI-1 analogues suggests that SFTI-1 internalizes
by a non-specific pathway. Furthermore, the low efficiency of
internalization observed for SFTI-1, which is similar to Tat-G
(negative control) further supports a non-specific internalization
mechanism. Unlike specific endocytosis, this mechanism does not
involve a specific receptor, as shown by comparing D-SFTI-1 with
SFTI-1. Overall, our studies suggest that SFTI-1 internalization oc-
curs by a non-receptor and non-specific endocytic pathway.
3. Conclusions
The results presented here indicate that MCoTI-II internalization
can be improved by increasing the overall positive charge based onthe observation that MCoTI-M4 and MCoTI-M5 showed significant
increases in cellular uptake. Interestingly, an acyclic analogue of
MCoTI-II also demonstrated improved cellular uptake compared to
the cyclic form. Similar to what was previously shown for native
MCoTI-II [9], internalization of these analogues was independent of
the ability to insert into the lipid membrane. Interactionwith other
cellular components might contribute to an increase of peptide
concentration in the cell vicinity and therefore improve cellular
C. D’Souza et al. / European Journal of Medicinal Chemistry 88 (2014) 10e1816uptake. Nevertheless, a similar internalization mechanism depen-
dent on endocytic routes is likely to be operative for the novel
MCoTI-II analogues. On the other hand, structural mutations to
SFTI-1 did not significantly affect its cellular uptake efficiency,
which was in any case significantly weaker than MCoTI-II. These
observations suggest that SFTI-1 internalizes through a non-
receptor and non-specific endocytosis dependent mechanism.
Overall, these studies have helped in elucidating the structural
requirements that might be important during the internalization of
MCoTI-II and SFTI-1. This information obtained could be useful in
the design of disulfide-rich cyclic peptides as drug leads to address
intracellular targets associated with various diseases conditions.
4. Experimental section
4.1. Peptide synthesis and purification
The peptide sequences tested in this study are shown in Fig. 1.
The cyclic peptides were synthesized on a 0.5 mmol scale using
solid phase peptide synthesis with tert-butyloxycarbonyl (Boc)
chemistry as previously described [22]. Peptides were assembled
on Boc-Gly-phenylacetamidomethyl resin (Boc-Gly-PAM resin)
(Chem-Impex International) with S-tritylmercaptopropionic acid
(Peptides International) as a linker using 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) or 2-(6-
chloro-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-
fluorophosphate (HCTU) with diisopropylethylamine (DIPEA) in
dimethylformamide (DMF) to activate Boc-protected amino acids.
The peptides were cleaved from the resin in presence of hydrogen
fluoride (HF) with p-cresol as a scavenger at 0 C for 2 h. Residual HF
present was removed by rotatory evaporation and the mixture was
solubilized in 90% (v/v) acetonitrile/0.045% (v/v) trifluoroacetic acid
(TFA) in water and lyophilized. Peptides (MCoTI-M5, MCoTI-M6,
SFTI-M6, D-SFTI-1, SFTI-M7, Tat, Tat-G) were synthesized using N-
(9-fluorenyl)methyloxycarbonyl (Fmoc) chemistry on a Symphony
Peptide synthesizer (Protein Technologies Inc., Tuscon, AZ). Pep-
tides were constructed on 2-chlorotrityl-chloride resin (Chem-
Impex International) and cleaved using a mixture of 95% TFA/trii-
sopropylsilane/water (95:2.5:2.5) for 3 h. After removal of TFA by
rotatory evaporation, the crude mixture was diluted with 50% (v/v)
acetonitrile/water mixture containing 0.1% (v/v) TFA and cold
diethyl ether. The aqueous layer obtained from the above step was
lyophilized. Crude peptides were purified on RP-HPLC using a C18
column (Phenomenex) with 1%/min gradient of 90% (v/v) acetoni-
trile/0.045% (v/v) aqueous TFA in water and the absorbance was
detected at 215 and 280 nm andmasses of peptides were confirmed
by electrospray ionization mass spectrometry (ESI-MS).
4.2. Cyclization and oxidation conditions
Native MCoTI-II and its mutants were cyclized and oxidized in a
single-step process in 0.1 M ammonium bicarbonate (pH 8.5) for
24 h. In the case of MCoTI-M5, which was synthesized by Fmoc
chemistry [48], the cyclization was carried out in presence of 2-(7-
Aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-
fluorophosphate and DIPEA in DMF for 3 h and further purified by
RP-HPLC. The oxidation step was achieved using 0.1 M ammonium
bicarbonate (pH 8.5) for 24 h. Cyclization and oxidation of native
SFTI-1 and its mutants were achieved in a two-step procedure as
mentioned previously [34]. The peptides were cyclized in the
presence of 0.1 M tris(2-carboxyethyl)phosphine for 24 h followed
by purification. The oxidization of these cyclic reduced peptides
was carried out in 0.1 M ammonium bicarbonate (pH 8.0) for 24 h.
SFTI-M6 and D-SFTI-1 was cyclized in same manner as MCoTI-M5
and oxidization was achieved in 0.1 M ammonium bicarbonate(pH 8.0) for 24 h. The peptides were purified by RP-HPLC on C18
(Phenomenex) columns using 0.5%/min gradient of 90% (v/v)
acetonitrile in 0.05% (v/v) aqueous TFA. The purity of the peptides
was determined by analytical RP-HPLC (Agilent Technologies, USA)
and masses determined by ESI-MS.
4.3. NMR characterization
Peptides were dissolved in 90% (v/v) H2O and 10% (v/v) D2O
(Cambridge Isotope Laboratories) at a concentration of 1 mM at pH
~3.5 for NMR studies. 1H one-dimensional and TOCSY and NOESY
two-dimensional NMR spectra of the synthesized peptides were
recorded on a Bruker Avance-600 MHz spectrometer at 298 K.
Spectra were processed with TopSpin 2.1 (Bruker) and CCPNMR
Version 2.1.5 [49] was used for assignment of spectra using con-
ventional methods [33].
4.4. Alexa Fluor 488 labeling of peptides
To examine the internalization of the peptides using flow
cytometry all the peptides were labeled with Alexa Fluor 488
through amide bond ligation. Each peptide was incubated with
2 mol equivalent of Alexa Fluor 488 sulfodichlorophenol ester (Life
Technologies) in 0.1 M sodium bicarbonate buffer (pH 8.0) for 3 h at
room temperature. The labeled peptides were purified by RP-HPLC,
and their mass confirmed by ESI-MS. Peptides conjugated to one
label only were selected for internalization experiments.
4.5. Identification of Lys residues labeled with Alexa Fluor 488
To determinewhich Lys residuewas labeled in the sequence, the
peptides were reduced and digested with trypsin as described
previously [50]. The peptide fragments obtained from the digestion
were subjected to MS/MS using a MALDI-TOF-TOF (Applied
Biosystems).
4.6. Cell culture conditions
Unless otherwise stated, cervical cancer cells (HeLa) were
cultured in Dulbecco's Modified Eagle's medium (DMEM) (Invi-
trogen) supplemented with 10% heat inactivated fetal calf serum
(FCS) (Invitrogen) and 50 U/ml of penicillin (Invitrogen) and 50 mg/
ml streptomycin (Invitrogen) incubated at 37 C with 5% CO2.
4.7. Cytotoxicity studies
The cytotoxicity of the synthesized peptides was evaluated in
HeLa cells using resazurin dye assay, whichmeasures the metabolic
activity of viable cells, as described previously [36].
4.8. Flow cytometry
Internalization of the peptides in HeLa cells was examined using
flow cytometry as reported previously [36]. The concentration of
Alexa Fluor 488-labeled peptides was quantified by absorbance at
495 nm considering ε495 as 71,000 cm1 M1. Cells were incubated
with labeled peptides at different concentrations (1, 2, 4, 8 and
16 mM) for 1 h at 37 C in fresh medium without serum. The pop-
ulation of cells that were evaluated was selected based on side and
forward scatter dot plot. Cells were excited with 488 nm laser and
fluorescence emission signal detected at 530 nm (30 nm bandpass)
to detect Alexa Fluor 488-labeled peptide. The fluorescence signal
was read before and after the addition of trypan blue (160 mg/ml or
164 mM), which was used to quench the fluorescence signal of
C. D’Souza et al. / European Journal of Medicinal Chemistry 88 (2014) 10e18 17membrane-bound peptide. 10,000 cells were screened per sample.
Each experiment was performed in triplicate.
4.9. Peptide-lipid interaction studies by surface plasmon resonance
Synthetic lipids 1-palmitoyl-2-oleoylphosphatidylcholine
(POPC) and 1-palmitoyl-2-oleoylphosphatidylserine (POPS) used
to prepare model membranes were purchased from Avanti polar
lipids. POPC and POPC/POPS (4:1) small unilamellar vesicles
(1 mM) were prepared using the previously described method [51].
Peptide solutions were prepared in 10 mMHEPES buffer containing
150 mM NaCl (pH 7.4) at selected concentrations. SPR measure-
ments were conducted with a Biacore 3000 instrument using an L1
sensor chip following protocols previously optimized [52]. The af-
finity of each peptide for the membrane was compared based on
the peptide-to-lipid ratio determined as described previously [51].
Acknowledgments
This work was funded by the Australian Research Council
(LP110200213). D.J.C. is an NHMRC Professorial Fellow (grant ID
APP1026501). S.T.H is supported by a Discovery Early Career
Research Award (grant ID DE120103152) from the Australian
Research Council. C.K.W was supported by an NHMRC Early Career
Fellowship (grant ID 536578). C.D.S is supported by a University of
Queensland International Scholarship. We thank Phillip Walsh,
Philip Sunderland and Olivier Cheneval for assistance in peptide
synthesis.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.ejmech.2014.06.047.
References
[1] D.J. Craik, D.P. Fairlie, S. Liras, D. Price, The future of peptide-based drugs,
Chem. Biol. Drug. Des. 81 (2013) 136e147.
[2] P. Vlieghe, V. Lisowski, J. Martinez, M. Khrestchatisky, Synthetic therapeutic
peptides: science and market, Drug. Discov. Today 15 (2010) 40e56.
[3] P. Jarver, U. Langel, Cell-penetrating peptides-a brief introduction, Biochim.
Biophys. Acta 1758 (2006) 260e263.
[4] S.T. Henriques, M.N. Melo, M.A.R.B. Castanho, Cell-penetrating peptides and
antimicrobial peptides: how different are they? Biochem. J. 399 (2006) 1e7.
[5] F. Madani, S. Lindberg, U. Langel, S. Futaki, A. Graslund, Mechanisms of cellular
uptake of cell-penetrating peptides, J. Biophys. 2011 (2011) 414729.
[6] G.L. Bidwell 3rd, D. Raucher, Therapeutic peptides for cancer therapy. Part I -
peptide inhibitors of signal transduction cascades, Expert Opin. Drug. Deliv. 6
(2009) 1033e1047.
[7] A. Lalatsa, A.G. Schatzlein, I.F. Uchegbu, Strategies to deliver peptide drugs to
the brain, Mol. Pharm. 11 (2014) 1081e1093.
[8] J.S. Orange, M.J. May, Cell penetrating peptide inhibitors of nuclear factor-
kappa B, Cell. Mol. Life Sci. CMLS 65 (2008) 3564e3591.
[9] L. Cascales, S.T. Henriques, M.C. Kerr, Y.H. Huang, M.J. Sweet, N.L. Daly,
D.J. Craik, Identification and characterization of a new family of cell-
penetrating peptides: cyclic cell-penetrating peptides, J. Biol. Chem. 286
(2011) 36932e36943.
[10] J.F. Hernandez, J. Gagnon, L. Chiche, T.M. Nguyen, J.P. Andrieu, A. Heitz,
T. Trinh Hong, T.T. Pham, D. Le Nguyen, Squash trypsin inhibitors from
Momordica cochinchinensis exhibit an atypical macrocyclic structure,
Biochemistry 39 (2000) 5722e5730.
[11] M.E. Felizmenio-Quimio, N.L. Daly, D.J. Craik, Circular proteins in plants: so-
lution structure of a novel macrocyclic trypsin inhibitor from Momordica
cochinchinensis, J. Biol. Chem. 276 (2001) 22875e22882.
[12] O. Saether, D.J. Craik, I.D. Campbell, K. Sletten, J. Juul, D.G. Norman, Elucidation
of the primary and three-dimensional structure of the uterotonic polypeptide
kalata B1, Biochemistry 34 (1995) 4147e4158.
[13] S. Luckett, R.S. Garcia, J.J. Barker, A.V. Konarev, P.R. Shewry, A.R. Clarke,
R.L. Brady, High-resolution structure of a potent, cyclic proteinase inhibitor
from sunflower seeds, J. Mol. Biol. 290 (1999) 525e533.
[14] M.L. Colgrave, D.J. Craik, Thermal, chemical, and enzymatic stability of the
cyclotide kalata B1: the importance of the cyclic cystine knot, Biochemistry 43
(2004) 5965e5975.[15] M.L. Colgrave, M.J.L. Korsinczky, R.J. Clark, F. Foley, D.J. Craik, Sunflower
trypsin inhibitor-1, proteolytic studies on a trypsin inhibitor peptide and its
analogs, Biopolymers 94 (2010) 665e672.
[16] D.G. Barry, N.L. Daly, R.J. Clark, L. Sando, D.J. Craik, Linearization of a naturally
occurring circular protein maintains structure but eliminates hemolytic ac-
tivity, Biochemistry 42 (2003) 6688e6695.
[17] D. Mandal, A.N. Shirazi, K. Parang, Cell-Penetrating homochiral cyclic peptides
as nuclear-targeting molecular transporters, Angew. Chem. Int. Ed. 50 (2011)
9633e9637.
[18] K.P. Greenwood, N.L. Daly, D.L. Brown, J.L. Stow, D.J. Craik, The cyclic cystine
knot miniprotein MCoTI-II is internalized into cells by macropinocytosis, Int. J.
Biochem. Cell. Biol. 39 (2007) 2252e2264.
[19] J. Contreras, A.Y. Elnagar, S.F. Hamm-Alvarez, J.A. Camarero, Cellular uptake of
cyclotide MCoTI-I follows multiple endocytic pathways, J. Control Release 155
(2011) 134e143.
[20] S.E. Northfield, C.K. Wang, C.I. Schroeder, T. Durek, M. Kan, J.E. Swedberg,
D.J. Craik, Disulfide-rich macrocyclic peptides as templates in drug design,
Eur. J. Med. Chem. 77 (2014) 248e257.
[21] T.L. Aboye, H. Ha, S. Majumder, F. Christ, Z. Debyser, A. Shekhtman,
N. Neamati, J.A. Camarero, Design of a novel cyclotide-based CXCR4 antago-
nist with anti-human immunodeficiency virus (HIV)-1 activity, J. Med. Chem.
55 (2012) 10729e10734.
[22] L.Y. Chan, S. Gunasekera, S.T. Henriques, N.F. Worth, S.J. Le, R.J. Clark,
J.H. Campbell, D.J. Craik, N.L. Daly, Engineering pro-angiogenic peptides using
stable, disulfide-rich cyclic scaffolds, Blood 118 (2011) 6709e6717.
[23] P. Thongyoo, C. Bonomelli, R.J. Leatherbarrow, E.W. Tate, Potent inhibitors of
beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold,
J. Med. Chem. 52 (2009) 6197e6200.
[24] S. Gunasekera, F.M. Foley, R.J. Clark, L. Sando, L.J. Fabri, D.J. Craik, N.L. Daly,
Engineering stabilized vascular endothelial growth factor-A antagonists:
synthesis, structural characterization, and bioactivity of grafted analogues of
cyclotides, J. Med. Chem. 51 (2008) 7697e7704.
[25] C.K. Wang, C.W. Gruber, M. Cemazar, C. Siatskas, P. Tagore, N. Payne, G. Sun,
S. Wang, C.C. Bernard, D.J. Craik, Molecular grafting onto a stable framework
yields novel cyclic peptides for the treatment of multiple sclerosis, ACS Chem.
Biol. 9 (2014) 156e163.
[26] A.G. Poth, L.Y. Chan, D.J. Craik, Cyclotides as grafting frameworks for protein
engineering and drug design applications, Biopolymers 100 (2013) 480e491.
[27] J.A. Camarero, Optimizing the future for biotechnology therapies, the key role
of protein engineering, Adv. Drug. Deliv. Rev. 61 (2009) 897e898.
[28] Y. Ji, S. Majumder, M. Millard, R. Borra, T. Bi, A.Y. Elnagar, N. Neamati,
A. Shekhtman, J.A. Camarero, In vivo activation of the p53 tumor suppressor
pathway by an engineered cyclotide, J. Am. Chem. Soc. 135 (2013)
11623e11633.
[29] H.L. Amand, K. Fant, B. Norden, E.K. Esbjorner, Stimulated endocytosis in
penetratin uptake: effect of arginine and lysine, Biochem. Biophys. Res.
Commun. 371 (2008) 621e625.
[30] H.A. Rydberg, M. Matson, H.L. Amand, E.K. Esbjorner, B. Norden, Effects of
tryptophan content and backbone spacing on the uptake efficiency of cell-
penetrating peptides, Biochemistry 51 (2012) 5531e5539.
[31] H. Brooks, B. Lebleu, E. Vives, Tat peptide-mediated cellular delivery: back to
basics, Adv. Drug. Deliv. Rev. 57 (2005) 559e577.
[32] P.A. Wender, D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman,
J.B. Rothbard, The design, synthesis, and evaluation of molecules that enable
or enhance cellular uptake: peptoid molecular transporters, Proc. Natl. Acad.
Sci. USA 97 (2000) 13003e13008.
[33] K. Wüthrich, NMR of Proteins and Nucleic Acids, Wiley Interscience, New
York, 1986.
[34] N.L. Daly, Y.K. Chen, F.M. Foley, P.S. Bansal, R. Bharathi, R.J. Clark,
C.P. Sommerhoff, D.J. Craik, The absolute structural requirement for a proline
in the P3'-position of Bowman-Birk protease inhibitors is surmounted in the
minimized SFTI-1 scaffold, J. Biol. Chem. 281 (2006) 23668e23675.
[35] M.R. Plan, U. Goransson, R.J. Clark, N.L. Daly, M.L. Colgrave, D.J. Craik, The
cyclotide fingerprint in Oldenlandia affinis: elucidation of chemically modified,
linear and novel macrocyclic peptides, Chembiochem 8 (2007) 1001e1011.
[36] I.M. Torcato, Y.H. Huang, H.G. Franquelim, D.D. Gaspar, D.J. Craik,
M.A.R.B. Castanho, S.T. Henriques, The antimicrobial activity of Sub3 is
dependent on membrane binding and cell-penetrating ability, Chembiochem
14 (2013) 2013e2022.
[37] M. Benincasa, S. Pacor, R. Gennaro, M. Scocchi, Rapid and reliable detection of
antimicrobial peptide penetration into gram-negative bacteria based on fluo-
rescence quenching, Antimicrob. Agents Chemother. 53 (2009) 3501e3504.
[38] S.T. Henriques, J. Costa, M.A.R.B. Castanho, Re-evaluating the role of strongly
charged sequences in amphipathic cell-penetrating peptides e a fluorescence
study using Pep-1, FEBS Lett. 579 (2005) 4498e4502.
[39] L. Fei, L. Ren, J.L. Zaro, W.C. Shen, The influence of net charge and charge
distribution on cellular uptake and cytosolic localization of arginine-rich
peptides, J. Drug Target 19 (2011) 675e680.
[40] A. Ziegler, Thermodynamic studies and binding mechanisms of cell-
penetrating peptides with lipids and glycosaminoglycans, Adv. Drug. Deliv.
Rev. 60 (2008) 580e597.
[41] D.L. Daleke, Regulation of phospholipid asymmetry in the erythrocyte mem-
brane, Curr. Opin. Hematol. 15 (2008) 191e195.
[42] S.T. Henriques, Y.H. Huang, K.J. Rosengren, H.G. Franquelim, F.A. Carvalho,
A. Johnson, S. Sonza, G. Tachedjian, M.A.R.B. Castanho, N.L. Daly, D.J. Craik,
C. D’Souza et al. / European Journal of Medicinal Chemistry 88 (2014) 10e1818Decoding the membrane activity of the cyclotide kalata B1: the importance of
phosphatidylethanolamine phospholipids and lipid organization on hemolytic
and anti-HIV activities, J. Biol. Chem. 286 (2011) 24231e24241.
[43] H.H. Szeto, P.W. Schiller, K.S. Zhao, G.X. Luo, Fluorescent dyes alter intracel-
lular targeting and function of cell-penetrating tetrapeptides, FASEB J. 19
(2004) 118e120.
[44] S.D. Conner, S.L. Schmid, Regulated portals of entry into the cell, Nature 422
(2003) 37e44.
[45] S.T. Henriques, J. Costa, M.A.R.B. Castanho, Translocation of beta-galactosidase
mediated by the cell-penetrating peptide pep-1 into lipid vesicles and human
HeLa cells is driven by membrane electrostatic potential, Biochemistry 44
(2005) 10189e10198.
[46] S. Boisseau, K. Mabrouk, N. Ram, N. Garmy, V. Collin, A. Tadmouri, M. Mikati,
J.-M. Sabatier, M. Ronjat, J. Fantini, M. DeWaard, Cell penetration properties of
maurocalcine, a natural venom peptide active on the intracellular ryanodine
receptor, Biochim. Biophys. Acta 1758 (2006) 308e319.
[47] M. Mano, A. Henriques, A. Paiva, M. Prieto, F. Gavilanes, S. Simoes,
M.C. Pedroso de Lima, Cellular uptake of S413-PV peptide occurs uponconformational changes induced by peptide-membrane interactions, Biochim.
Biophys. Acta 1758 (2006) 336e346.
[48] O. Cheneval, C.I. Schroeder, T. Durek, P. Walsh, Y.H. Huang, S. Liras, D.A. Price,
D.J. Craik, Fmoc-based synthesis of disulfide-rich cyclic peptides, J. Org. Chem.
79 (2014) 5538e5544.
[49] W.F. Vranken, W. Boucher, T.J. Stevens, R.H. Fogh, A. Pajon, M. Llinas,
E.L. Ulrich, J.L. Markley, J. Ionides, E.D. Laue, The CCPN data model for NMR
spectroscopy: development of a software pipeline, Proteins 59 (2005)
687e696.
[50] B. Chen, M.L. Colgrave, C. Wang, D.J. Craik, Cycloviolacin H4, a hydrophobic
cyclotide from Viola hederaceae, J. Nat. Prod. 69 (2006) 23e28.
[51] S.T. Henriques, Y.H. Huang, M.A.R.B. Castanho, L.A. Bagatolli, S. Sonza,
G. Tachedjian, N.L. Daly, D.J. Craik, Phosphatidylethanolamine binding is a
conserved feature of cyclotide-membrane interactions, J. Biol. Chem. 287
(2012) 33629e33643.
[52] S.T. Henriques, L.K. Pattenden, M.I. Aguilar, M.A.R.B. Castanho, PrP(106-126)
does not interact with membranes under physiological conditions, Biophys. J.
95 (2008) 1877e1889.
  
Supplementary Data 
 
Figure S1 
 
 
 
 
 
Figure S1. Percentage of fluorescent HeLa cells after 1 h incubation at 37ºC with A) Alexa Fluor 
488-MCoTI-II and its analogues or with B) Alexa Fluor 488-SFTI-1 and its analogues. Fluorescent 
cells were recorded before and after addition of trypan blue (TB). No differences were observed in 
the percentage of fluorescent cells before and after addition of TB, confirming that the cells are not 
permeabilized. 
 
  
Figure S2 
 
 
 
 
Figure S2. Internalization of fluorescently-labeled (A) Alexa Fluor 488-MCoTI-II and its 
analogues and (B) Alexa Fluor 488-SFTI-1 and its analogues into HeLa cells after 1 h incubation at 
37 ºC. Data was normalized to mean fluorescence emission intensity obtained with the control Tat 
at 8 µM in (A) and 16 µM in (B). 
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4.0 Overview 
 Several bioactive linear sequences targeting extracellular receptors and proteins have been 
grafted on different loops of MCoTI-II which have resulted in potent molecules with increased 
affinity and stability (1). MCoTI-II possess cell-penetrating properties (2,3), which can be further 
improved as described in Chapter 3. The advantage of the stable structure and ability to internalise 
inside cells makes it a potential vector in delivering bioactive epitopes which lack in vivo stability 
and have low cell penetration. Recently MCoTI-I which differs to MCoTI-II by two residues was 
successfully used to introduce bioactive epitope sequences inside the cell and modulate intracellular 
protein-protein interactions (4). Therefore in this chapter a proof-of-concept study is carried out to 
see whether MCoTI-II grafted with a bioactive sequence can enter cells and interact with a 
therapeutic target. The therapeutic target selected in this study is a protein known as SET, which is 
overexpressed in various cancers and is a promising drug target in cancer therapy.  
 SET is a potent physiologic inhibitor of protein phosphatase 2A (PP2A) and is also referred 
to as IPP2A. PP2A interacts and dephosphorylates a number of important signalling proteins that 
are associated with cancer progression, as shown in Figure 4-1A. Therefore SET is an attractive 
molecular target for developing novel cancer drugs (5). Peptide antagonists of SET derived from 
amino acids (133-149) of the receptor-binding region of apolipoprotein E (apoE) have been 
reported and are referred to as COG peptides. Studies showed that COG and other apoE mimetic 
peptides bind to SET, leading to an increase in PP2A activity, as shown in Figure 4-1B (6). In 
addition, these peptides induce apoptosis in leukemia cancer cell lines (7). COG and apoE mimetic 
peptides can block the phosphorylation of IκB and inactivation of nuclear factor kappa B (NF-κB) 
in the inflammatory pathway (8). COG peptides were conjugated to cell-penetrating peptides to 
improve their cell uptake, which in turn enhanced their biological activity (9). Structure-active 
relationship studies on COG peptides led to the development of COG1410, a truncated peptide 
showing more potency and binding affinity (10).  
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Figure 4-1: An overview scheme of targeting SET oncoprotein function with multiple effects 
on human cancer cell lines. A) SET inhibits the function of phosphatase 2A (PP2A) and prevents 
it deactivating the pathways involved in cell growth and activating apoptosis which allows cancer 
cell to divide and form tumors. B) COG peptides inhibit SET protein and unable the formation of 
complex with PP2A restoring the ability of cancer cells to reproduce and die.  
 
 COG peptides are drug leads in cancer treatment, but their in vivo metabolic instability and 
poor tumor cell penetration have resulted in decreased therapeutic efficacy. These limitations can be 
overcome by the use of cyclotides, a class of cyclic peptides, which are known to have unique 
constrained topology and possess cell-penetrating properties. In this chapter, the cyclotide MCoTI-
II was used to improve the stability and enhance the delivery of COG1410 towards the target SET 
protein. COG1410, an α-helical peptide was grafted onto loop 6 of MCoTI-II using several adapter 
sequences to optimise the conformation. The grafted peptides were synthesised using SPPS with 
Boc chemistry. Characterisation of grafted peptides was done using NMR and CD spectroscopy, 
which showed that the peptides retain the native structure and displayed the correct biological 
conformation of COG1410. Grafted peptides were tested for their stability in human serum and 
cytotoxicity in cancer cells using biological assays. The grafted peptides showed high stability in 
human serum and conferred the cytotoxic properties of the linear epitope towards CML cell line. In 
addition to this, the ability of the grafted peptide to modulate the NF-κB dependent gene promoter 
activity inside the LPS-stimulated macrophages was also demonstrated using a cell-based reporter 
assay (Figure 4-2).  
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Figure 4-2: Cell-based reported assay used to measure the inhibition of NF-κB activity. ELAM 
cells were treated with LPS in the presence and absence of peptides used in this study, which 
showed expression of GFP. Decrease in the mean fluorescence intensity was observed for ELAM 
cells with NF-κB inhibitor (either COG or grafted peptides) compared to ELAM cells without NF-
κB inhibitor. ELAM cells treated without LPS were used as a negative control, which did not show 
any GFP expression. Detection of GFP expression was done using flow cytometry and mean 
fluorescence intensity was measured. 
 
Overall, this chapter shows that MCoTI-II can be used as a stable cyclic framework to 
deliver an α-helical peptide towards a therapeutic target inside the cell. The stability and cell-
penetration of MCoTI-II are two important features that make it a promising template for the 
development of novel peptide-based therapeutics targeting intracellular protein-protein interactions.  
 
This chapter forms the basis of a manuscript, which will be submitted to Biochemistry. 
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protein overexpressed in cancer, (Manuscript in Preparation).  
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4.1 Introduction  
SET is a protein that is overexpressed in various human cancers, including chronic myeloid 
leukemia (CML), acute myeloid leukemia and B-cell non-Hodgkin's lymphoma (1). SET inhibits the 
tumor suppressor function of protein phosphatase 2A (PP2A), which regulates multiple pathways 
associated with cancer progression. Therefore, SET is a potential molecular target for the treatment of 
human cancer (2). Small peptides derived from the receptor-binding region of apolipoprotein E 
(apoE), also referred to as COG peptides, are potent antagonists of SET and can induce apoptosis in 
leukemia cancer cell lines (1). COG peptides can bind to SET (3) and enhance PP2A activity, which 
subsequently leads to the inactivation of NF-κB, a protein complex involved in the inflammatory 
signaling process (4,5). To facilitate cell penetration, COG peptides have been conjugated to cell-
penetrating peptides, which also enhanced their biological activity (6). In a previous study, analogues 
of COG peptides were designed and optimised leading to the development of COG1410 (7). This 
peptide contains amino-isobutyric acid (Aib) residues that stabilise the peptide’s α-helical 
conformation that is necessary for its biological activity (8). 
Although COG peptides are promising anti-cancer drug leads, their poor in vivo stability and 
poor cell penetration limit their therapeutic efficacy. A class of peptides named cyclotides, which 
possess high stability and cell-penetrating properties can in principle be used to improve the 
therapeutic properties of COG peptides. Cyclotides (9) are plant-derived peptides comprising a head-
to-tail cyclic backbone and a cystine knot that together form the cyclic cystine knot (CCK) motif. The 
cystine knot is formed by the penetration of one disulfide bond through a macrocyclic ring formed by 
the other two disulfide bonds and their interconnecting backbone segments. Because of the high 
stability of the CCK structure, cyclotides are resistant towards proteolytic, chemical or thermal 
degradation (10), making them promising templates for the design of novel drugs. They have been 
used as scaffolds (11) for the design of drugs for a wide range of conditions, cancer (12), 
cardiovascular disease (13) and multiple sclerosis (14) as well as other applications (15-17). These 
examples focused on targeting cyclotides towards extracellular receptors or membrane proteins. 
Cyclotides such as kalata B1 (18) and Momordica cochinchinensis trypsin inhibitor-I and II 
(MCoTI-I/II) (19,20) have been shown to internalise into mammalian cells and have been classified 
as CCPPs. These studies suggest that the cellular uptake of MCoTI-I/II in human cells occurs by 
endocytosis (21-23) and that an overall positive charge of the peptide is important for efficient 
internalisation (22,24). The structural stability and cell-penetrating properties of MCoTI-I/II make 
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them potential frameworks in drug design for modulating intracellular protein-protein interactions. 
Recent studies by Camarero and co-workers (25), where the MCoTI-I framework was engineered to 
incorporate a 12 amino acid helical peptide sequence, confirmed that MCoTI-I can be used as an 
intracellular delivery vehicle. The resulting grafted cyclotide inhibited the interaction of p53 with 
Hdm2/HdmX, thus activating the p53 tumor suppressor pathway. 
In this chapter MCoTI-II has been explored for the first time to deliver bioactive sequence to 
modulate biological pathway intracellularly. We have re-engineered MCoTI-II by grafting COG1410 
onto this scaffold to produce stable cyclic peptides able to internalise into cells and inhibit 
intercellular SET. The linker sequence derived from apamin peptide is used to display the α-helical 
conformation of COG1410 peptide onto the MCoTI-II scaffold. The grafted peptides were shown to 
have high serum stability and induce cytotoxicity in CML cancer cells. One of the grafted peptides 
inhibited NF-κB dependent gene promoter activity in lipopolysaccharide (LPS) stimulated 
macrophages. Overall, the results demonstrate the potential of the MCoTI-II scaffold in the design of 
stable peptide drugs for cancer treatment. 
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4.2 Experimental Procedures 
4.2.1 Peptide synthesis  
The cyclic peptides examined in this study were synthesised using solid phase peptide 
synthesis with tert-butyloxycarbonyl (Boc) chemistry on a 0.5 mmol scale as previously described 
(13). Briefly, peptides were assembled on Boc-Gly-phenylacetamidomethyl resin (Chem-Impex 
International) with s-tritylmercaptopropionic acid (Peptides International) as a linker. These peptides 
were then cleaved using HF with p-cresol as a scavenger at 0°C for 2 h to generate the C-terminal 
thioester. After the removal of residual HF, the peptides were dissolved in 50% (v/v) 
acetonitrile/water mixture containing 0.05% (v/v) TFA and lyophilised. Linear peptides (Penetratin: 
(ANTP): DRQIKIWFQNRRMKWKK; COG1410: acetyl-AS(Aib)LRKL(Aib)KRLL-amide; and 
ANTP-COG1410: Acetyl-RQIKIWFQNRRMKWKKGAS(Aib)LRKL(Aib)KRLL-amide, a chimeric 
peptide formed by fusing penetratin with COG1410) were synthesised on 0.5 mmol scale using 
fluorenylmethyloxycarbonyl (Fmoc) chemistry on a Symphony Peptide synthesizer (Protein 
Technologies Inc., Tuscon, AZ) with 2-chlorotrityl chloride resin (Chem-Impex International). The 
synthesised linear peptides were cleaved and lyophilised as described previously (24). Crude peptides 
were purified on RP-HPLC using a Phenomenex C18 column with 1%/min gradient of 90% (v/v) 
acetonitrile/0.045% (v/v) aqueous TFA in water and the eluent detected at 215 and 280 nm. The 
purity of all the peptides was determined by analytical RP-HPLC and masses were confirmed by ESI-
MS. 
 
4.2.2 Cyclisation and oxidation conditions 
Cyclisation and oxidation of MCoTI-II was done in a single-step reaction with 0.1 M 
ammonium bicarbonate (pH 8.5) with overnight stirring. MCOG1 and MCOG2 were folded in 10% 
isopropanol with 0.1 M ammonium bicarbonate (pH 8.5). All peptides were purified by RP-HPLC 
using similar solvent conditions mentioned above.  
 
4.2.3 Nuclear magnetic resonance (NMR) spectroscopy 
Peptides dissolved in 90% (v/v) H2O and 10% (v/v) D2O (Cambridge Isotope Laboratories) at 
a concentration of 1 mM (pH 3.5) were used to conduct NMR experiments. 1H one-dimensional and 
TOCSY and NOESY two-dimensional NMR spectra of the synthesised peptides were recorded on a 
Bruker Avance-600 MHz spectrometer at 25°C. Spectra were processed using TopSpin 2.1 (Bruker) 
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and assigned using CCPNMR Version 2.1.5 (26) with established methods (27). 
 
4.2.4 Circular dichroism (CD) spectroscopy 
CD spectra were recorded on a CD spectro-polarimeter (Jasco J-810) between 190 to 300 nm 
using a 0.1 cm path length quartz cuvette. Peptides were prepared at 100 µM concentrations in 
Dulbecco’s phosphate-buffered saline (PBS) containing 2.7 mM potassium chloride, 1.5 mM 
potassium phosphate monobasic, 138 mM sodium chloride, 8 mM sodium phosphate dibasic, 
(calcium/magnesium free, Invitrogen) with pH 7.4. Experiments were carried out at 25°C. The 
spectra were obtained by accumulation of three scans at 100 nm/min. The CD signal was corrected by 
subtracting the blank and the molar ellipticity was determined. The percentage helicity was calculated 
using the formula previously used (28) and discussed in section 2.5.2 of this thesis.  
 
4.2.5 Cell culture conditions 
Human CML cell line (K562) and endothelial cell-leukocyte adhesion molecule (ELAM) cells 
which are murine macrophage-like cell line (RAW 264.7) with a stably integrated ELAM promoter 
driving GFP expression (29) were grown in Roswell Park Memorial Institute medium (RPMI 1640; 
Invitrogen) supplemented with 5% (for K562 cells) or 10% (for ELAM cells) of heat inactivated fetal 
bovine serum (Invitrogen), 2 mM L-glutamine (Invitrogen) (for K562 cells) or 2 mM Glutamax-I 
(Invitrogen) (for ELAM cells), 50 U/mL penicillin (Invitrogen) and 50 µg/mL streptomycin 
(Invitrogen), and incubated at 37°C with 5% CO2. ELAM cells were maintained in bacteriological 
plates (Sterilin, UK). 
 
4.2.6 Cytotoxicity against K562 and ELAM cells  
The cytotoxicity of the synthesised peptides was evaluated on K562 and ELAM cells using a 
resazurin dye assay (30). Briefly, K562 cells (5.0×103 cells/well) were plated in a 96-well plate and 
treated with 2-fold concentrations of each peptide (0.25 to 32 µM) in serum-free media for 2 h. Next, 
resazurin dye (0.02% (w/v)) was added to cells and incubated for 18 h. The absorbance signal was 
measured at 540 and 620 nm and the percentage of cell death was calculated as described previously 
(31,32). ELAM cells were plated in a 96-well plate (5.0×104 cells/well) 24 hours before exposure to 
peptides (0.25 to 16 µM) in serum-free media for 2 h. After 2 h incubation, 100 µL fresh serum 
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media and 10 µL resazurin dye were added and absorbance signal was read after 18 h. All the 
experiments were done in triplicate. Data from the experiments were fitted in GraphPad Prism 6 
software using a sigmoidal curve with Hill slope: Cell death (%) = Bmax × [peptide]H/(IC50H + 
[peptide]H) in which Bmax is the maximum cells death, [peptide] is the peptide concentration, IC50 is 
the peptide concentration required to induce death in 50% of the cells and H is the Hill slope. 
 
4.2.7 ELAM promoter assay 
ELAM cells were plated in a 24-well plate (2.5×106 cells/well) and incubated overnight. 
Various concentrations of linear peptides COG1410 and ANTP-COG1410 (0.6 µM and 1.3 µM) were 
tested and for ANTP 1.3 µM and 5.0 µM were used. MCoTI-II and grafted peptides were tested at 
concentrations from 1.3 to 5.0 µM. The assay was initiated by incubating the cells with peptides for 1 
h in fresh serum-free media and followed by washing with PBS and stimulation with LPS from 
Salmonella Minnesota L2137 (Sigma-Aldrich, USA) (10 ng/mL) for 4 h in media containing serum. 
Cells were first washed with PBS and harvested with PBS containing 1 mM EDTA and 0.1% sodium 
azide. The fluorescence emission of expressed GFP was followed by flow cytometry (29) (BD 
FACSCanto II; excitation laser at 488 nm and emission at 530 nm with 30 nm band pass). The 
population of cells was gated based on forward/side scattering and 10,000 cells analysed per sample. 
Data represents the mean of three independent experiments. 
 
4.2.8 Serum-stability assay 
The stability of the peptides was assessed using a protocol described previously (13). Briefly, 
peptides were dissolved in PBS and mixed with human serum at various time points (0, 1, 4, 8, 24 h) 
and incubated at 37°C. In order to precipitate the proteins, 40 µL of serum/peptide samples were 
treated with 20% trichloroacetic acid (10 minutes, 4°C). The mixture was centrifuged at 17,000 g for 
10 min. The pellet obtained after centrifugation was dissolved in 8 M guanidine hydrochloride (25). 
The supernatant obtained was analysed on RP-HPLC using 1%/min gradient of 90% (v/v) 
acetonitrile/0.045% (v/v) aqueous TFA on 0.4 mL/min Phenomenex C18 column. Peptides (200 µM) 
were dissolved in PBS and incubated at 37°C as control at different time points. The amount of the 
peptide remaining was analysed by integration of the absorbance at 215 nm. The experiments were 
done in triplicate.  
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4.3 Results 
4.3.1 Design of MCoTI-II grafted cyclotides 
We incorporated sequences from COG1410, an 11-amino acid peptide, into MCoTI-II to 
engineer novel cyclic peptides that bind SET. COG1410 contains helix-stabilising residues that help 
to maintain an α-helical conformation under physiological conditions (33), which has been shown to 
be important to enhance its in vivo and in vitro biological activity (7). Loop 6 of MCoTI-II was 
chosen as the site for incorporating the anticancer epitope because this loop has a high degree of 
structural plasticity and can accommodate a variety of foreign sequences, as exemplified in a number 
of previous grafting studies (11). To ensure that the grafted sequence was displayed in its α-helical 
conformation, the N-terminus of the grafted sequence was joined to the linker peptide, Ala-Ser-Lys-
Ala-Pro, which is derived from the apamin peptide, a bee-venom neurotoxin where it provides a 
‘return’ sequence adjacent to a helix. In a previous study, an apamin template was used to maintain 
the α-helical conformation of p53-derived peptides and resulted in a series of potent p53 inhibitors, 
that interact with the MDM2 and MDMX oncoproteins (34). Recently, this approach was extended to 
engineer the cyclotide MCoTI-I to display the α-helical PMI peptide by using linker sequences 
derived from the apamin peptide Ala-Ser-Lys-Ala-Pro and Ala-Ser-Arg-Ala-Pro (25). This difference 
in the linker sequences did not affect the folding or the biological activity of resulting MCo-PMI 
cyclotides.  
In the current study COG1410 fused to the linker (Ala-Ser-Lys-Ala-Pro) is referred to as 
APL-COG1410. We introduced APL-COG1410 onto MCoTI-II by replacing the Asp34 residue in 
loop 6 of MCoTI-II to produce the grafted peptide MCOG1 (Figure 4-3). We also developed another 
grafted peptide MCOG2 (Figure 4-3), in which an Arg-Asp-Ala sequence derived from the parent 
apoE protein was introduced at the C-terminus end of APL-COG1410. Based on the structure of 
apoE (PDB ID: 1GS9), we presumed that the extension of the COG1410 epitope might facilitate the 
formation of α-helical structure by providing it more conformational freedom when inserted into loop 
6.  
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Figure 4-3: Design strategy and sequences of the MCOG grafted cyclotides. The grafted region 
consisting of the COG1410 peptide is shown in red and the apamin linker introduced to maintain the 
α-helical character of COG1410 is in blue. The COG1410 peptide was grafted in loop 6 of MCoTI-II 
replacing the aspartic acid shown in purple. The sequence of native MCoTI-II is shown below with 
conserved cysteine residues and the disulfide bond connectivity shown in yellow and the loops 
between them labeled 1-6. X represents an amino isobutyric acid residue. 
 
4.3.2 Synthesis and characterisation of MCoTI-II grafted cyclotides  
 The cyclic peptides used in this study were synthesised using Boc chemistry. Oxidation and 
folding conditions were optimised for MCOG1 and MCOG2 by adding varying volumes and types of 
organic solvents to the standard folding buffer. Both MCOG1 and MCOG2 folded into one major 
(93%) and one minor isomer (7%) as seen using the analytical RP-HPLC (Figure 4-4). The isomers 
had similar masses, as detected by ESI-MS. Isolation of the major peak and analysis using analytical 
RP-HPLC again resulted in re-equilibration to produce the same two isomers. Both isomers observed 
in HPLC were also detected in NMR experiments. We observed a set of intense peaks, which 
represent the major isomer and a set of very weak peaks for the minor isomer in TOCSY (Figure 4-5 
and 4-6) and NOESY spectra. Initially, we wondered whether this isomerisation could be due to one 
or multiple proline cis-trans events (35), as the sequence comprises three proline residues. On 
assigning the peaks associated with the two isomers no such cis-trans isomerisation could be 
detected. Instead, we observed that the weak peaks mirrored the spin systems of some of the cysteine 
residues (i.e. Cys4, Cys11, Cys23 and Cys29) and their adjacent amino acids (Figure 4-7), suggesting 
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that the isomers might arise from conformational changes occurring across the disulfide bonds has 
been observed in other disulfide–rich proteins (36). The conformational change might be possibly 
due to different chirality of cysteine residues in the disulfide bonds. 
 
Figure 4-4: Analytical reverse phase HPLC trace and electrospray mass spectra for purified 
grafted A) MCOG1 and B) MCOG2 cyclotides. HPLC profile of MCOG1 showing the major 
(retention time tR= 7.9 min) and minor (tR= 8.7 min) isomer. The mass spectra of MCOG1 (Mw: 
5199.18 Da) shows the components corresponding to M4+ (calc. 1300.79 Da) and M5+ (calc. 1040.83 
Da). HPLC profile of MCOG2 showing the major (retention time tR= 7.3 min) and minor (tR= 8.3 
min) isomer. The mass spectra of MCOG2 (Mw: 5541.54 Da) shows the components corresponding 
to M4+ (calc. 1386.38 Da), M5+ (calc. 1109.30 Da) and M6+ (calc. 924.59 Da). Intensity is represented 
as count per second (cps). The peptides analysed through analytical RP-HPLC had  > 95% purity. 
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Figure 4-5: TOSCY spectrum of MCOG1 grafted peptide.  
Spectra were acquired at a concentration of 1 mM at (pH 3.5) at 298 K. The residues are labelled as 
their one letter code followed by their number in the sequence present below the α-proton of each 
amino acid spin system. 
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Figure 4-6: TOSCY spectrum of MCOG2 grafted peptide. 
Spectra were acquired at a concentration of 1 mM at (pH 3.5) at 298 K. The residues are labelled as 
their one letter code followed by their number in the sequence present below the α-proton of each 
amino acid spin system. 
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Figure 4-7: A region of TOSCY spectrum of A) MCOG1 B) MCOG2 grafted peptides. The 
spectrum shows weak peaks mirroring the spin systems of cysteine residues (i.e. Cys4, Cys11, Cys23 
and Cys29) and their neighboring amino acids. The spin systems are labelled using single letter code 
and residue number. The weak peaks are labelled in a box. 
 
NMR spectroscopy was used to confirm that the grafted peptides maintained a similar overall 
fold to the native peptide. The secondary Hα chemical shift of MCoTI-II and grafted peptides (Figure 
4-8) were calculated by subtracting from the measured Hα chemical shift of each residue their 
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respective random coil value (37). Positive secondary shifts indicate the presence of β-sheet 
conformation whereas negative secondary shifts indicate α-helical structure. MCOG1 and MCOG2 
showed a chemical shift pattern similar to that of MCoTI-II except for the grafted region in loop 6. 
Encouragingly, the observed negative secondary shifts in the grafted area indicated the presence of α-
helical structure, suggesting that the grafted COG1410 sequence is able to adopt its active 
conformation.  
 
Figure 4-8: Secondary shift analysis of MCOG grafted peptides compared with native MCoTI-
II determined from 1H NMR spectra. The Hα secondary shifts were obtained by subtracting the 
random coil shift from the experimental Hα chemical shift. The grafted region of MCOG1 and 
MCOG2 is highlighted with a black dotted line box. The negative Hα secondary shift in this region 
indicates the α-helical structure of the grafted COG1410 sequence shown by a red helix. These shifts 
were similar to chemical shift obtained for COG1410 as shown in the inset. The black asterisk 
represents the amino isobutyric acid residue, which lacks a Hα proton, and is therefore not observed 
in NMR spectra.  
 
4.3.3 CD experiments  
To examine whether the COG peptide retains its α-helical structure when grafted into the 
MCoTI-II scaffold, CD spectra of linear and grafted peptides solubilised in PBS (pH 7.4) were 
compared (Figure 4-9). The linear peptide COG1410 showed negative bands at 202 and 222 nm 
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indicative of α-helical structure which has been observed for other α-helical peptides (38). Similarly 
to previously reported data (39), MCoTI-II showed negative band at 200 nm and a positive band at 
230 nm. Strong negative ellipticity has also been observed for hepcidin, a small disulfide-rich 
peptide; in that study, the negative peak at 200 nm was attributed to the disulfide-stabilized β-sheet 
conformation (40). The positive peak at 230 nm could be due to the disulfide bonds of MCoTI-II 
which been observed for many disulfide-containing proteins and peptides (41). In comparison to 
other cyclic peptide (e.g., kalata B1), the CD spectra of MCoTI-II was different even though both 
share similar CCK knot (42). MCOG1 and MCOG2 showed similar spectra to that of MCoTI-II but 
there was a difference in the ellipticity around 222 nm, indicating that the grafted peptides, which 
hold the COG1410 sequence, have a higher α-helical content. The peak at 230 nm observed in 
MCoTI-II is not seen in MCOG1 and MCOG2 probably due to the insertion of epitope which affects 
the conformation of the disulfide bonds of the scaffold. On calculating the percentage of helicity at 
222 nm, MOG1 and MCOG2 showed an increased in helicity (4.4 % and 5.2 %) when attached to the 
linear COG1410 sequence (14.4 % helicity) compared to MCoTI-II scaffold (1.8 % helicity). This 
result is consistent with the NMR data, suggesting that the grafted peptides are capable of displaying 
COG1410 with an α-helical structure under physiological conditions.  
 
Figure 4-9: Circular dichroism spectra of COG1410, MCOTI-II and MCOG grafted peptides 
at 100 µM in DPBS (pH 7.4). The spectra were recorded at 25°C. The COG1410 spectrum shows 
the typical profile of an α-helical structure whereas the MCoTI-II spectrum showed negative band at 
200 nm and a positive band at 230 nm. The MCOG1 and MCOG2 peptides spectra were similar to 
MCoTI-II, but the ellipticity around 222 nm is more negative, suggesting the presence of α-helical 
content from the grafted COG1410. 
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4.3.4 MCOG grafted peptides are cytotoxic towards cancer cell line 
We investigated the cytotoxic effect of peptides on K562, a CML cell line that overexpresses 
SET. Previous work (1) has demonstrated the ability of COG peptides to induce cytotoxicity in 
various cancer cells where it interacts with SET. Cytotoxicity studies were performed by incubating 
K562 cells with varying concentrations of COG1410, ANTP-COG1410, ANTP, MCoTI-II, MCOG1 
or MCOG2 peptides (Figure 4-10A) and cell death was quantified by a resazurin dye assay. The 
linear COG1410 sequence showed toxicity with an IC50 1.7 ± 0.12 µM. ANTP-COG1410, containing 
penetratin in the sequence, showed higher toxicity than COG1410, with an IC50 of 0.8 ± 0.05 µM. We 
also tested ANTP in our experiments, to see if the observed cytotoxicity of ANTP-COG1410 is due 
to the presence of cell-penetrating sequence. ANTP showed toxicity towards K562 cells at IC50 9.9 ± 
0.57 µM which was 10-fold less cytotoxic than ANTP-COG1410 which has been previously 
observed in other studies (43). MCoTI-II was found to be non-toxic to K562 cells up to 32 µM, in 
agreement with previous studies (21). MCOG1 and MCOG2 were found to be toxic against K562 
cells (IC50 2.9 ± 0.14 µM and 5.0 ± 0.15 µM, respectively), suggesting that both grafted peptides 
acquired the cytotoxic properties of COG1410. 
 
Figure 4-10: Toxicity of peptides against A) K562 and B) ELAM cells. Varying concentrations of 
penetratin, COG1410, ANTP-COG1410, MCOTI-II and MCOG grafted peptides were administered 
to cells and the percentage of cell death was assessed using a resazurin dye assay. Data represent the 
mean ± SD of experiments performed in triplicate. 
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4.3.5 MCOG peptides inhibit NF-κB pathway in macrophages 
To investigate whether MCOG1 and MCOG2 modulate NF-κB activity in an inflammatory 
signaling pathway, a cell-based assay was used. The activity of each peptide was assessed in ELAM 
cells expressing GFP under the control of NF-κB dependent human ELAM (E-selectin) promoter. 
Non-cytotoxic concentrations of the peptides were used and chosen based on the cytotoxicity studies 
done on ELAM cells (Figure 4-10B); specifically, linear peptides were tested at concentrations up to 
2 µM (the concentration required to induce 50% of cell cytotoxicity (CC50) is 9.0 ± 0.07 µM for 
COG1410 and 8.9 ± 0.69 µM for ANTP-COG1410) and grafted peptides (MCOG1 CC50 23.6 ± 5.26 
µM and MCOG2 CC50 21.0 ± 5.48 µM) up to 5 µM. ANTP and MCoTI-II, which were found to be 
non-toxic to ELAM cells up to 16 µM. 
Treatment of ELAM cells followed by LPS stimulation causes activation of the NF-κB 
pathway, resulting in expression of GFP, and its fluorescence emission can be followed by flow 
cytometry. We observed a decrease in the activation of NF-κB mediated GFP expression upon 
treatment with ANTP-COG1410 but not with COG1410 in LPS-activated ELAM cells. Treatment of 
cells with MCOG1 showed inhibition of NF-κB activity in ELAM cells stimulated with LPS in a 
dose-dependent manner (Figure 4-11A). Interestingly, MCOG2 did not display the same effect as 
MCOG1. Penetratin and MCoTI-II used as controls did not show any inhibition of NF-κB activity.  
LPS contamination in peptide samples during immunological experiments can trigger other 
events affecting the observed activity. To rule out the possibility of LPS contamination in the peptide 
samples, we incubated the ELAM cells with peptides only and the fluorescence emission was 
measured. There was no expression of GFP and the fluorescence emission observed was similar to 
non-stimulated ELAM cells, i.e. negative control confirmed that the peptide samples were not 
contaminated with LPS (data not shown). Furthermore, the assay was repeated with a new batch of 
peptides to confirm that the inhibition of NF-κB activity observed is similar across different batches 
of grafted peptides (Figure 4-11B). ANTP-COG1410 showed inhibition of NF-κB activity and among 
the grafted peptides MCOG1 showed similar dose-dependent activity. COG1410 did not show any 
inhibition of NF-κB activity.   
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Figure 4-11: Inhibition of NF-κB monitored by an ELAM assay. The ELAM assay results for 
the first (A) and second (B) batch of peptides is shown. ELAM cells were pre-incubated for 1 h 
with varying concentrations of ANTP, COG1410, ANTP-COG1410, MCOTI-II and MCOG grafted 
peptides and stimulated with LPS (10 ng/ml) for 4 h. ELAM cells stimulated with LPS were used as 
a positive control and without LPS as a negative control. Fluorescence emission of GFP was 
followed by flow cytometry (excitation at 488 nm and emission at 530 nm with 30 nm bandpass). 
Data were normalised to the mean fluorescence emission intensity obtained with ELAM cells 
stimulated with LPS. Experiments were done in triplicates and values are represented as mean ± 
SD, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (ANOVA, Bonferroni's Multiple 
Comparison Test).  
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4.3.6 Stability of native, linear, and grafted peptides 
To investigate the susceptibility of the peptides to proteolytic degradation, their stability in 
human serum was followed over 24 h. MCOG1 and MCOG2 were found to be stable at 37ºC up to 24 
h (Figure 4-12), whereas the linear peptide ANTP-COG1410 was degraded within 4 h under the 
conditions studied. These results confirm that the grafted peptides maintain the remarkable stability 
of the native scaffold. 
 
Figure 4-12: Stability of ANTP-COG1410, MCoTI-II and MCOG grafted cyclotides in human 
serum. Peptides at a concentration of 200 µM were incubated with serum at 37°C. The percentage of 
peptide remaining in serum over 24 h is shown. Mean ± SD of three independent experiments is 
shown. 
4.4 Discussion  
Small peptides derived from apoE are potent antagonists of SET, which is a promising 
therapeutic target for cancer therapy. However, these linear peptides have limited access to the 
intracellular space due to their poor intrinsic stability and poor uptake by cells, thus hindering their 
therapeutic application. To produce a stable peptide antagonist of SET that can enter cells, one 
approach is to exploit the exceptional stability and cell-penetrating ability of cyclotides. In this study 
we grafted COG1410, an α-helical peptide derived from apoE, onto MCoTI-II, a stable cyclic cell-
penetrating peptide. The grafted peptides showed toxicity against K562 cells, a CML cancer cell line 
that overexpresses SET, and were able to inactivate NF-κB activity in macrophages.  
In the design of the grafted peptides we incorporated a linker sequence derived from the apamin 
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peptide into loop 6 along with the COG1410 epitope to help stabilise the α-helical conformation of 
the bioactive epitope. This strategy has been used previously to induce a desired α-helical structure in 
potent p53 inhibitors, required for their effective MDM2/MDMX binding (33). The grafted 
cyclotides designed were able to display COG1410 with an α-helical conformation while maintaining 
the native cyclotide fold, as confirmed by NMR and CD spectroscopy. This observation indicates the 
ability of the COG1410 epitope to display an α-helical structure on grafting into the MCoTI-II 
scaffold and suggests that COG1410 is able to adopt its biologically active conformation and, thus, 
the grafted peptides have the potential to antagonise SET. 
We showed that the grafted peptides are active against cells overexpressing SET and therefore 
are potential leads with applications in cancer therapy. First, we examined the activity of the linear, 
native and grafted peptides against K562 cells, which are cancer cells that overexpress SET. 
COG1410 was cytotoxic to these cells, which is expected because it has been shown to cause 
apoptosis in SET-expressing cancer cells by reactivating PP2A upon interaction with SET (3). We 
further showed that both grafted peptides were cytotoxic to K562 cells, suggesting that engineering of 
MCoTI-II with COG1410 conferred the biological activity of the epitope onto the grafted peptide. 
Although both of the grafted peptides showed cytotoxic activity due to the grafted COG1410, 
MCOG1 was more cytotoxic compared to MCOG2, suggesting that the additional residues in 
MCOG2 might hinder its activity. 
We further tested the activity of grafted peptides using a cell-based reporter assay with ELAM 
cells. In this assay, modulation of NF-κB activity is dependent on the activity of SET. We measured 
the level of expression of green fluorescent protein, which was under the control of a NF-κB 
responsive gene promoter after addition of the linear, native and grafted peptides. The linear peptide 
ANTP-COG1410 showed reduction in the activation of NF-κB dependent gene reporter in ELAM 
cells. This is similar to results observed for COG peptides, which have previously been shown to bind 
to SET and reduce NF-κB activation on inhibiting the phosphorylation of IκB in the inflammatory 
pathway (4). One of the grafted peptides MCOG1 was able to reduce the NF-κB dependent gene 
promoter activity, providing further evidence that it might be able to antagonise SET and further 
modulate the inflammatory signaling process. Consistent with our K562 cytotoxicity results, MCOG2 
was less active than MCOG1, but in this case MCOG2 did not show any significant activity at the 
concentrations tested. It is possible that MCOG2 might modulate the NF-κB pathway at higher 
concentrations but at these concentrations, MCOG2 would cause cell death, as shown above, and 
therefore obfuscate the interpretation of the results.  
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Stability is an important feature of peptide drugs. Linear peptides are susceptible to protease 
degradation and therefore have short half-lives in serum. To examine whether the grafted peptides 
were resistant to proteolysis, their stability was compared to that of the linear COG1410 in human 
serum. Both grafted peptides were more stable in human serum than the linear peptide. The 
constrained architecture of cyclotides confers them with chemical and biological stability, allowing 
them to maintain their native structure even in harsh environments (10). Grafting of linear epitopes 
used for therapeutic applications onto the cyclotide framework improves their stability (13). Our 
result further confirms that the stable cyclotide framework is a valuable template for stabilising linear 
epitopes, which is considered to be an important factor in designing novel peptide therapeutics. 
Although there are now more than a dozen studies demonstrating the use of cyclotides as a drug 
design scaffold (11), they have mainly focused on targeting extracellular receptors or membrane 
proteins. Recently, Camarero and co-workers showed that the cyclotide MCoTI-I, a cyclic cell-
penetrating peptide, can be used as a vehicle to deliver a peptide epitope into a cell (25). In the 
current study, we used another cell-penetrating cyclotide MCoTI-II as the delivery scaffold. We 
engineered an α-helical COG1410 peptide segment onto MCoTI-II to produce a grafted peptide that 
could interact with a novel cancer protein target and modulate a biological pathway intracellularly. 
Thus, our study further demonstrates that cyclotide drugs can be used to modulate a wide range of 
therapeutic targets, including intracellular proteins that are difficult to ‘drug’ by current therapeutics.  
4.5 Conclusion  
This is a proof-of-concept study where cyclotide MCoTI-II scaffold has been explored to 
stabilize an α-helical peptide fragment and deliver the epitope into cells to modulate an intracellular 
pathway involved in the progression of cancer. This strategy can be used to lock other α-helical 
peptides in their bioactive conformation using cyclotide scaffolds that can maximize helicity and 
optimize their drug-like properties. The stability and cell-penetrating ability of MCoTI-II are useful 
properties in drug development, particularly for targeting intracellular protein-protein interactions.  
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5.1 Introduction 
Cyclotides (1) are the only known class of peptides which combine a head-to-tail backbone 
and a cystine knot, to form the cyclic cystine knot (CCK) motif. Cyclotides from the Möbius and 
bracelet subfamilies exhibit a wide range of activities, hemolytic (2), anti-HIV (2,3) and 
insecticidial activities (4), which seems to correlate with their ability to interact with and disrupt 
biological membranes (2). A mechanism of action dependent on membrane binding and disruption 
is supported by electron microscopy studies, where the disruption of midgut epithelial cells of 
Helicoverpa caterpillars was observed after ingestion of cyclotides (4). Dye leakage studies further 
supported that cyclotides can disrupt phospholipid bilayers (5). Electrophysiological studies 
conducted with liposome patches suggested the existence of pores of 41-47 Å diameter (5).  
Several biophysical studies (6-9) using model membranes have demonstrated that cyclotides 
target lipid membranes by binding specifically to PE-containing phospholipids and subsequently 
cause membrane disruption. The mirror image form of kalata B1 was shown to be active in several 
bioassays tested (e.g hemolytic, anti-HIV), suggesting that cyclotides do not bind to a chiral 
receptor (10). Structure-activity relationship studies conducted with kalata B1 and its analogues 
have provided additional information about the mechanism of action of cyclotides. Hydrophobic 
residues present on the surface of kalata B1 were identified to be involved in the interaction of 
cyclotides with DPC micelles using NMR studies (11). An alanine scan of kalata B1 showed that a 
patch of residues located on its surface is important for insecticidal and hemolytic activities (12). 
This patch was named the bioactive patch and was initially thought to be involved in the formation 
of oligomers that could be potentially important in the formation of pores in the membrane. Later, 
NMR studies showed that the bioactive patch is crucial for recognition of PE headgroups during 
membrane binding (8), whereas the hydrophobic patch is important for the insertion into the 
hydrophobic core of the lipid membranes (Figure 5-1). 
Kalata B2 has a greater tendency to self-associate into oligomers in solution than kalata B1 
based on analytical ultra-centrifugation experiments (13). In that study, kalata B2 existed in 
equilibrium between monomers (30%), tetramers (42%) and octamers (25%) at 1.6 mM 
concentration. Recently, NMR studies (14) on kalata B2 at physiological conditions revealed that 
packing of hydrophobic residues to each other is involved in the formation of oligomers in solution. 
Furthermore, the formation of these oligomers was found to be concentration dependent, as seen 
through NMR translational diffusion co-efficient measurements (15). Based on the occurrence of 
oligomers in solution, it was suggested that oligomerisation might play a role in the mechanism of 
action and might also occur during membrane interaction. Oligomerisation of cyclotides is also 
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supported by a decrease in the hemolytic efficiency observed for a mixture of L/D enantiomers 
(25:75) of kalata B1 (10). This result is consistent with the idea that oligomers composed of 
monomers of identical chirality are involved in the mechanism of action of cyclotides. In addition, 
it has been proposed that kalata B1 and kalata B2 form undefined oligomers when they insert into 
the membrane and might form toroidal pores (7).  
Although several experiments have provided some understanding on the membrane binding 
of cyclotides it is not yet clear whether cyclotides form oligomers with a defined structure when 
bound to the membrane and whether this bound oligomer structure is different to that in solution. 
Therefore the aim of this chapter was to study the quaternary structure of cyclotides in a membrane 
environment. Based on previous NMR and other membranes binding studies of cyclotides, a 
computational model of cyclotide tetramer self-associating in membrane was initially proposed in 
this study. In this model the hydrophobic face of cyclotides is exposed to the membrane 
environment and the bioactive patch is buried. To test this model of oligomeric structure of 
cyclotide in membranes, kalata B1 and kalata B2 mutants containing double lysine residues were 
designed and synthesised using Boc chemistry. The synthesised peptides folded similarly to the 
native peptides, as confirmed by NMR spectroscopy. Using chemical cross-linking experiments, it 
was possible to detect the formation of oligomers when the [T13K,P17K]kB2 mutant was incubated 
with POPC/POPE liposomes, which suggested that cyclotides might form oligomers when bound to 
phospholipid membranes. Understanding how cyclotides form oligomers in a membrane 
environment will provide insights into the mechanism of action of cyclotides and their ability to 
exert their bioactivities. 
 
Figure 5-1: Various patches present on the surface of kalata B1. Hydrophobic (yellow) and 
bioactive patches (red) on the surface of kalata B1 that have been identified as important for its 
bioactivities (e.g. hemolysis, insecticidal) are indicated. 
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5.2 Methods and Materials  
5.2.1 Peptide Synthesis  
 The protocol for peptide synthesis is described in Chapter 2. Using this protocol, peptides 
were synthesised on a 0.25 or 0.5 mM scale using SPPS on a CS Bio Automated Peptide 
Synthesizer (Figure 5-2). In addition, a linear peptide, mellitin 
(GIGAVLKVLTTGLPALISWIKRKRQQ), which was used as a control in the cross-linking 
experiments, was synthesised using Fmoc chemistry. The Boc and Fmoc synthesised peptides were 
cleaved from the resin using the method described in Chapter 2. The masses of the cleaved peptides 
from the resin are shown in Table 5-1. 
 
 
Figure 5-2. Sequences of kalata B1 (kB1), kalata B2 (kB2) and synthesised mutants. The 
mutated residues are shown in red. The loops are labeled and the disulfide bond connectivity 
between the cysteine residues is also shown.  
 
Table 5-1: Calculated (average) and observed masses of the cleaved kalata B1 and kalata B2 
mutants after synthesis determined by ESI-MS 
 
Peptides               (M2+)         (M3+)                (M4+) 
       calc.      obs.     calc.      obs.        calc.      obs. 
[T13K,P17K]kB1 1574.8 1574.6 1050.2 1050.2 787.9 - 
[T13K,R28K]kB1 1545.2 1545.2 1030.5 1030.5 773.1 - 
[T13K,P17K]kB2 1606.3 1606.0 1071.7 1071.2 803.6 803.7 
[T13K,R28K]kB2 1576.8 1576.6 1051.5 1051.4 788.9 - 
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5.2.2 Oxidation and folding of synthesised peptides 
To identify suitable folding conditions for the peptides, a range of conditions as detailed in 
Table 5-2 were tested on a small-scale at 0.1 mg/ml. The conditions that gave the highest yield of 
correctly folded peptide were selected and repeated on a larger scale. Kalata B1 mutants 
([T13K,P17K]kB1 and [T13K,R28K]kB1) were cyclised and oxidised following conditions 3 and 2 
(Table 5-2), respectively. Kalata B2 mutants, [T13K,P17K]kB2 and [T13K,R28K]kB2], were 
cyclised and oxidised using folding condition 1 (Table 5-2). Peptides were dissolved in the folding 
buffer and stirred for 48 h at room temperature. The peptides were purified using C18 preparative 
RP-HPLC column with a 1%/min gradient of 0-80% solvent B against solvent A monitoring the 
UV absorbance at 215 nm. The masses of peptides were detected by ESI-MS. The purity of the 
peptides was analysed on RP-HPLC using an analytical column.  
 
Table 5-2: Different folding conditions tested for the synthesised kalata B1 and kalata B2 
mutants  
 
Folding 
condition 
Ammonium 
bicarbonate 
(pH 8.5) (M) 
Isopropanol 
(v/v) 
Reduced 
glutathione 
(mM) 
Oxidised 
glutathione 
(mM) 
1 0.1 - 2 0.4 
2 0.1 25% 2 0.4 
3 0.1 50% 2 0.4 
4 0.1 75% 2 0.4 
 
5.2.3 NMR spectroscopy  
The folded peptides were dissolved in 90% H2O/10% D2O (v/v) at concentrations of 1-2 
mM. One-dimensional 1H NMR and two-dimensional NMR spectra (TOCSY and NOESY) were 
recorded on Bruker Avance 500 MHz or 600 MHz spectrometers at 298 K. The spectra were 
analysed using Topspin 1.3 (Bruker) and assigned using CCPNMR software (16).  
 
5.2.4 Preparation of liposomes  
Synthetic lipids POPC, POPE and POPG were purchased from Avanti Polar Lipids. A 
suspension of small unilamellar vesicles (0.5 mM) was prepared for cross-linking experiments in 10 
mM sodium phosphate buffer (pH 7.5) containing 10 mM NaCl using a previously described 
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method (2). Peptide solutions were also prepared using the same buffer. A detailed preparation of 
liposomes using a mini-extruder is explained in Chapter 2 of this thesis.  
 
5.2.5 Chemical cross-linking experiments 
Small unilamellar vesicles composed of POPC/POPE (4:1 molar ratio), POPE/POPG (1:1) 
and POPC lipids were prepared for cross-linking experiments in 10 mM sodium phosphate buffer 
(pH 7.5) containing 10 mM NaCl. Peptides were also prepared in the same buffer and incubated 
with liposomes at 25°C for 1 h. The peptide-liposome mixture was then centrifuged at 13,000 g for 
30 minutes. The pellet obtained after centrifugation was washed twice prior to resuspension in the 
same buffer. The membrane permeable cross linker disuccinimidyl glutarate (DSG) was added to 
the peptide-lipid suspension at 5 mM concentration. The sample was allowed to react at room 
temperature for 1 h. The unreacted DSG was quenched using 200 mM Tris buffer, pH 8.8 and 
allowed to react for 10-15 min at room temperature. The sample was mixed with a tricine sample 
buffer, incubated at 95°C for 5 min and then subjected to 16% tricine-SDS-PAGE for analysing the 
cross-linked species. Gels were silver stained to identify peptide band using Silver Quest silver 
staining kit. 
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5.3 Results  
5.3.1 Design of kalata B1 and kalata B2 mutants  
As the structure of putative cyclotide oligomers in a membrane environment is unknown, we 
designed possible models to gain a better understanding of the structure of cyclotides self-
associating in the membrane. Recent NMR titration studies have shown that hydrophobic residues 
of kalata B2 mediate self-association in aqueous environments (14). Based on these studies, a 
model of a cyclotide tetramer in solution, as shown in Figure 5-3A, was proposed where the 
hydrophobic face of each sub-unit is buried while the hydrophilic face of each sub-unit is exposed 
to the aqueous solution. As the hydrophobic face is important for membrane binding, it suggests 
that the structure of the cyclotide tetramer bound to membranes is different. So we proposed a 
model (Figure 5-3B) where the hydrophobic patch is exposed to the membrane, and the bioactive 
patch is buried. Previous studies have shown that hydrophobic core of cyclotides is important for 
membrane binding (11). 
 
Figure 5-3: Proposed tetramer model of cyclotides in solution and when bound to membranes. 
A) Model of cyclotide tetramer in solution or B) in the presence of membranes. The hydrophobic 
patch is shown in yellow and bioactive patch is shown in red. 
 
To test this model of the oligomeric structure of cyclotides in membranes, we carried out 
chemical cross-linking of synthesised mutants in the presence of liposomes. Chemical cross-linking 
is based on the ability to covalently cross-link peptide molecules that are in close proximity to each 
other or inserted on the membrane surface. The cross-linking agent reacts with primary amine group 
(i.e., ε-amino groups of lysine residues) on the peptide that are at a distance corresponding to the 
length of the cross-linker. Therefore we designed different kalata B1 and kalata B2 mutants 
containing double lysine residues in the sequence (Figure 5-4). The residues to be mutated in kalata 
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B1 and kalata B2 were selected based on two criteria: 1) they could result in intermolecular cross-
linking according to the model and 2) they are likely to retain their activity/ability to bind to 
membranes based on a previous lysine mutagenesis study of kalata B1 (17). If these residues are 
close enough within in the length of the cross-linker (DSG spacer length 7.7 Å) they will be cross-
linked by the cross-linker.  
 
 
 
Figure 5-4: Mutants of kalata B1 ([T13K,P17K]kB1 and [T13K,R28K]kB1) and kalata B2 
([T13K,P17K]kB2 and [T13K,R28K]kB2) used for the chemical cross-linking experiments. 
Hydrophobic residues are shown in yellow and the residues mutated to lysine are labeled in red. 
 
5.3.2 Synthesis and characterisation of peptides by NMR  
The cyclic peptides were synthesised by Boc chemistry using thioester based cyclisation 
chemistry (18). Cyclisation and oxidation of the peptides were carried out using a range of different 
folding conditions to obtain correctly folded peptides. Mutants [T13K,R28K]kB1, 
[T13K,P17K]kB2 and [T13K,R28K]kB2 folded into a single isomer. The purity and mass of the 
folded peptides were determined using RP-HPLC equipped with an analytical column and ESI-MS 
for [T13K,R28K]kB1 (Figure 5-5), [T13K,P17K]kB2 (Figure 5-6) and [T13K,R28K]kB2 (Figure 
5-7). 
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Figure 5-5: RP-HPLC trace (top) and the ESI-MS spectra (bottom) for the cyclised and folded 
peptide [T13K,R28K]kB1. The mass spectra for [T13K,R28K]kB1 (Mw= 2891.38 Da) showing 
two major components corresponding to the M2+  (calc. 1446.7 Da) and M3+  (calc. 964.80 Da) of 
the cyclic peptide. The folded peptide eluted at retention time of 28 min on the HPLC profile with > 
95% purity as analysed through analytical RP-HPLC. 
 
Figure 5-6: RP-HPLC trace (top) and ESI-MS spectra (bottom) for the cyclised and folded 
peptide [T13K,P17K]kB2. Mass spectra of [T13K,P17K]kB2 (Mw= 3013.5 Da) showing two 
major component corresponding to the M2+  (calc. 1507.7 Da) and M3+  (calc. 1005.5 Da) of the 
cyclic peptide. The folded peptide eluted at retention time of 35 min with > 95% purity as analysed 
through analytical RP-HPLC. 
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.  
Figure 5-7: RP-HPLC trace (top) and ESI-MS spectra (bottom) for the cyclised and folded 
peptide [T13K,R28K]kB2. The mass spectra for [T13K,R28K]kB2 (Mw= 2954.4 Da) showing two 
major component corresponding to the M2+  (calc. 1478.2 Da) and M3+  (calc. 985.8 Da) of the 
cyclic peptide. The folded peptide eluted at retention time of 30.5 min with > 95% purity as 
analysed through analytical RP-HPLC. 
 
NMR spectroscopy was used to confirm the tertiary structure of the folded peptides. Figure 5-
8 shows the 1H NMR spectra of the synthesised kalata B1 and kalata B2 mutants. A comparison of 
αH chemical shifts for the mutants with that of native peptides showed that they have similar 
structures to the native peptides (Figure 5-9 and Figure 5-10). In contrast to other mutants, [T13K, 
P17K]kB1 did not get cyclised and oxidised in the folding conditions used and was not isolated 
during HPLC purification. Therefore this peptide was not tested in subsequent experiments. 
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Figure 5-8: 1H NMR spectra of kalata B1 and kalata B2 mutants. Representative NMR spectra 
of A) [T13K,P17K]kB1 B) [T13K,R28K]kB1 and C) [T13K,R28K]kB2 mutants. 
 
 
Figure 5-9: Comparison of αH chemical shifts of synthesised kalata B1 mutant compared to 
the native peptides. Chemical shifts of αH signals for kalata B1 and [T13K,R28K]kB1.  
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Figure 5-10: Comparison of αH chemical shifts of synthesised kalata B2 mutants compared to 
the native peptides. Chemical shifts of αH signals for kalata B2, [T13,P17K]kB2 and 
[T13,R28K]kB2.  
 
5.3.3 Cross-linking of synthesised mutants in liposomes 
To determine the oligomeric nature of cyclotides in membranes, chemical cross-linking 
experiments were performed. The lipids were selected based on previous experiments showing that 
kB1 binds weakly to POPC liposomes but strongly to POPE-containing liposomes (8). The mutants 
[T13K,R28K]kB1, [T13K,P17K]kB2 and [T13K,R28K]kB2 were cross-linked using DSG cross 
linker in the presence of POPC/POPE (4:1 molar ratio) and POPC liposomes. The cross-linked 
samples were analysed on SDS-PAGE gels by silver staining (Figure 5-11).  
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Figure 5-11: Chemical cross-linking of Mellitin and kalata B2 mutants in the presence of 
liposomes. A) Mellitin was used as a positive control and was cross-linked in the presence of 
POPE/POPG (1:1) liposomes. B) Cross-linking of [T13K,P17K]kB2 and [T13K,R28K]kB2 was 
examined in the presence of POPC/POPE (4:1) and POPC liposomes with the indicated peptide-to-
lipid ratio (P/L) and analysed on SDS-PAGE gel followed by silver staining. DSG was used as the 
cross-linker (CL). Controls without cross linker (-) were included. M indicates the molecular weight 
of the markers.  
 
Mellitin was used as a positive control in the chemical cross-linking experiments and was 
run on a separate gel to optimise the cross-linking protocol. Mellitin showed the formation of 
several bands in the presence of POPE/POPG (1:1) liposomes (Figure 5-11A). These bands 
corresponded to dimers (5.5 kDa), tetramers (11.0 kDa), pentamers (13.8 kDa) and higher 
molecular weight species. Such formation of oligomers is in agreement with a previous study in 
which bands of tetramers and octamers were identified (19). The molecular weight of the DSG 
cross-linker (0.13 kDa) linked to the peptide in cross-linked samples was considered along with the 
peptide molecular weight during the analysis of the bands observed on the gel. 
Chemical cross-linking of kalata B2 mutants was carried out in the presence of POPC/POPE 
and POPC liposomes (Figure 5-11B). Cross-linking of [T13K,P17K]kB2 with POPC liposomes did 
not show any bands in lane 1 (Figure 5-11B). This is expected because [T13K,P17K]kB2 does not 
bind to POPC. A single band was seen in lane 2 for [T13K,P17K]kB2 in POPC/POPE liposomes 
without cross-linker (Lane 2). This band should represent the monomeric form of 
[T13K,P17K]kB2; although the molecular weight of [T13K,P17K]kB2 is 3.0 kDa this band is 
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slightly above the marker band of 3.5 kDa in Figure 5-11B (labeled as ‘a’). The apparently higher 
molecular weight of [T13K,P17K]kB2 is probably the consequence of using molecular weight 
markers that are linear proteins, which can run faster on SDS-PAGE gel compared to cyclic 
peptides. We calculated the molecular weight of observed oligomers considering the difference in 
molecular weight of the marker and the mutant, which is approximately 1.0 kDa. Lane 3 shows 
several bands for [T13K,P17K]kB2 in the presence of POPC/POPE liposomes with the cross-linker. 
Bands are represented with arrows in Figure 5-11B with the estimated molecular weight of b) 7.5 
kDa, c) 10.6 kDa, d) 14.5 kDa, e) 16.6 f) 19.5 kDa g) 31 kDa and 38 kDa based on the linear 
marker molecular weight. As the linear marker runs faster than the cyclic peptide these molecular 
weight position suggests the presence of b) dimers (6.4 kDa), c) trimers (9.2 kDa), d) tetramers 
(13.3 kDa), e) pentamers (15.2 kDa), f) hexamers (18.9 kDa) and g) higher oligomers (between 31 
kDa and 38 kDa) formed for [T13K,P17K]kB2 mutant. Bands for heptamers (22.0 kDa) and 
octamers (25.2 kDa) were not obvious. These results show that [T13K,P17K]kB2 binds and forms 
oligomers in the presence of POPC/POPE liposomes. The mutant [T13K,R28K]kB2 in the presence 
of POPC/POPE without cross-linker (Lane 5) showed some bands in the upper part of the gel. A 
faint band was also observed in lane 6 for [T13K,R28K]kB2 in the presence of POPC/POPE 
liposomes with cross-linker. These bands could have occurred as a result of incomplete sample 
denaturation due to insufficient heating. No samples were run in lane 4 and 7. Cross-linking of 
[T13K,R28K]kB2 with POPC liposomes was done on a separate gel (data not shown) and did not 
show any bands.  
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Figure 5-12: Chemical cross-linking of kalata B1 mutant in the presence of liposomes. Cross-
linking of [T13K,R28K]kB1 was examined in the presence of POPC/POPE (4:1) and POPC 
liposomes with peptide-to-lipid ratios (P/L) as shown. Samples were analysed on SDS-PAGE gel 
followed by silver staining. DSG was used as cross-linker (CL). Controls samples without cross-
linker (-) were also included. M indicates the molecular weight of the markers.  
 
Chemical cross-linking of [T13K,R28K]kB1 was carried out in the presence of POPC/POPE 
and POPC liposomes (Figure 5-12). The mutant [T13K,R28K]kB1 in the presence of POPC/POPE 
liposomes without cross-linker (lane 3) showed multiple bands. A single band should have been 
observed. Formation of several bands in lane 3 could have been possibly due to similar sample 
problems as mentioned for [T13K,R28K]kB2. No bands were seen in lane 4 with [T13K,R28K]kB1 
cross-linked in the presence of POPC/POPE liposomes. It is possible that [T13K,R28K]kB1 does 
not bind to POPC/POPE liposomes so hence bands were not observed. No band was seen in lane 6 
for [T13K,R28K]kB1 cross-linked in presence of POPC liposomes. This is expected because 
[T13K,R28K]kB1 is not expected to bind to the POPC liposomes. No samples were run in lane 2 
and 5.  
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5.4 Discussion  
Cyclotides belonging to the Mobius and bracelet subfamilies are believed to interact with 
membranes through a mechanism that involves binding to PE-containing phospholipids and 
inserting into the hydrophobic region of the lipid bilayer, followed by membrane disruption through 
pore formation (2). Results obtained with electrophysiological experiments (5) suggested that 
oligomers might be involved in the pore formation. Oligomers were also observed in solution 
during analytical centrifugation studies for kalata B2 (13). However, whether oligomer formation 
occurs after initial insertion of cyclotides into the membrane is unknown and the possible structure 
of membrane bound oligomeric cyclotides is still to be investigated. Therefore the focus of this 
work was 1) to examine whether cyclotides oligomerise when bound to membranes and, if 
oligomerisation occurs, 2) to determine how these oligomers form.  
Kalata B1 and kalata B2 are prototypical cyclotides and numerous studies have been done to 
understand their structure and bioactivity. Kalata B1 and kalata B2 have shown evidence of self-
association in solution and therefore we chose these two peptides in this study. Different oligomeric 
forms (e.g. dimers, trimers, tetramers, octamers and higher oligomers) could be formed in the 
presence of a membrane environment. Based on an NMR study and previous cyclotide membrane 
binding studies, we proposed a tetramer model of cyclotides self-associating in membranes. Kalata 
B1 and kalata B2 mutants were designed to test the proposed model of cyclotide when bound to 
lipid membranes (Figure 5-3). Characterisation of the synthesised peptides with NMR spectroscopy 
showed that the native fold and overall structure of the cyclotide is retained. This is relevant, as the 
synthesised mutants should have the same residues exposed as the native cyclotides. 
Chemical cross-linking experiments showed the oligomeric nature of [T13K,P17K]kB2 
mutant bound to POPC/POPE lipid membranes. [T13K,P17K]kB2 existed as several oligomeric 
species in the presence of POPC/POPE liposomes. This suggests that the proposed model of the 
tetramer might be possible but other oligomer structures (such as dimers, trimers, pentamers, 
hexamers and higher oligomers) can also exist. Results obtained with mellitin, here used as a 
control to validate the cross-linking approach, are identical to results previously reported by others 
(19). [T13K,P17K]kB2 might be behaving similar to mellitin, which is known to aggregate on the 
membrane surface forming torodial pores and eventually leading to membrane disruption. Similar 
pore-formation mechanism has been proposed for cyclotides based on electrophysiological studies 
(5). In our study, formation of oligomeric species for [T13K,P17K]kB2 suggested that several 
oligomeric forms are possible along with the proposed tetramer. Some bands in the gel could be 
possibly due to the cross-linking occurring between the amino group of PE lipid head group and the 
lysine amino group of [T13K,P17K]kB2 mutant. To rule out this possibility, the cross-linked 
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samples can be subjected to mass spectroscopy and the mutants cross-linked to any PE head group 
can be identified. Membrane binding studies using SPR can be done to observe the binding of  
[T13K,P17K]kB2 mutant to POPC/POPE lipids systems.  
[T13K,R28K]kB2 did not show any band corresponding to a monomer as observed for the 
[T13K,P17K]kB2 mutant in POPC/POPE liposomes. It could be possible that [T13K,R28K]kB2 
does not have any binding to POPC/POPE lipid systems and to confirm this membrane binding 
studies can be performed using SPR. To prevent the occurrence of bands arising due to incomplete 
sample denaturation as a result of insufficient heating, new samples can be prepared and gels could 
be repeated. [T13K,R28K]kB1 also showed similar behavior to [T13K,R28K]kB2 in the presence 
and absence of the cross-linker which could be possible due to the lack of binding to POPC/POPE 
lipid systems since both the mutants had arginine residues replaced with lysine. It may be possible 
that arginine residue is important and might be playing a role during the oligomerisation process. 
Other possibility could be that mutation of this arginine residue can give rise to a different oligomer 
structure in the presence of a membrane environment.  
Optimisation of the various parameters involved in the chemical cross-linking experiments 
such as peptide concentration, incubation time and cross-linker concentration can also be 
considered. It could be possible the length of DSG linker was not long enough to cross-link 
[T13K,R28K]kB2 or [T13K,R28K]kB1 successfully. Therefore, different cross-linkers can be used 
for future cross-linking experiments e.g., bis[sulfosuccinimidyl] suberate (BS3) (11.4 Å), 
dithiobis[succinimidylpropionate] (DSP) (12.0 Å) and dissuccinimidyl tartrate (DST) (6.4 Å). The 
detection of the peptide bands on SDS-PAGE gel can be improved by optimising the steps used in 
the silver-staining protocol. 
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5.5 Conclusion  
The cross-linking studies suggest that the [T13K,P17K]kB2 mutant forms several oligomers 
when bound to lipid membranes. The proposed tetramer model seems to be possible along with 
several other oligomeric forms. On the other hand the behavior of the [T13K,R28K]kB2 and 
[T13K,R28K]kB1 mutants suggested that multimeric formation might depend on the specific 
cyclotides. Our study suggests that kalata B2 might also have the possibility to oligomerise in the 
presence of membranes and forms similar higher molecular structure species as observed for 
[T13K,P17K]kB2 mutant. Nevertheless more experiments have to be performed to confirm this 
hypothesis and to elucidate the orientation of the membrane-bound structure of kalata B2. One 
should first consider optimising the various parameters involved in cross-linking experiments as 
discussed earlier. Detailed conformational analysis of kalata B2 and its mutants in the presence of 
lipid membranes can be done using NMR techniques which have been used to study other peptides 
(20). This can provide structural insights at atomic resolution into the oligomeric states of 
cyclotides in lipid environment. The information obtained on the oligomerisation of cyclotides in 
membranes will give an understanding on the pore formation mechanism and further on their ability 
to exert various bioactivities. This can also be applicable in future for drug design studies where 
modification can be done in the cyclotide framework belonging to Möbius and bracelet cyclotides, 
which is important to modify and improve them as frameworks in pharmaceutical applications. 
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6.0 Overview  
In this thesis a range of disufide-rich cyclic peptides derived from plants, including kalata B1, 
kalata B2, MCoTI-II and SFTI-1 were studied with the aim of using them in pharmaceutical 
applications. In the past, extensive studies have been done on these peptides to explore their 
structures, mechanisms of action, bioactivities and biophysical properties. Because of their unique 
features, these peptides have great potential as templates in drug design (1). In particular, bioactive 
linear peptides have been grafted into disulfide-rich cyclic frameworks to improve their stability 
and bioactivity (2). In addition, the discovery of their cell-penetrating properties has promoted the 
use of disulfide-rich cyclic peptides to deliver bioactive sequences towards therapeutic targets 
inside cells (3,4). 
The overall goal of this thesis was to understand the mechanism of action associated with 
the membrane activity and the cell-penetrating attributes of disulfide-rich cyclic peptides. The first 
part of the thesis focused on examining the structural features that are relevant for the cell-
penetrating properties of two distinct disulfide-rich cyclic peptides i.e., MCoTI-II and SFTI-1. In 
the second part, a proof-of-concept study was carried out to show that MCoTI-II can be used as a 
vector to deliver bioactive sequences inside cells. The final part of this thesis investigated the 
membrane-bound structure of the cyclotides kalata B1 and kalata B2 from the Möbius subfamily 
and the importance of the self-association process, which might be related to the mechanism of 
action of cyclotides. 
In this Chapter, I summarise the main conclusions of this thesis in each of these areas and 
provide some suggestions for future work that could follow up on some aspects of the studies. 
Overall the thesis is a complete body of work that substantially achieved its original aims. 
 
6.1 Structural attributes governing the cell-penetrating properties of MCoTI-II and SFTI-1. 
In Chapter 3, the structural elements required for the cellular uptake of cyclic cell-penetrating 
peptides MCoTI-II and SFTI-1 were studied. Although both of these peptides occur in plants and 
are potent trypsin inhibitors they differ in their size and complexity. MCoTI-II belongs to the 
trypsin inhibitor subfamily of cyclotides and is expressed in the seeds of Momordica 
cochinchinensis (5,6). It contains three disulfide bonds whereas SFTI-1 is a small cyclic peptide 
isolated from sunflower seeds that contains only one disulfide bond (7). The cyclic backbone and 
internal disulfide bonds make both peptides more stable against proteolytic degradation than linear 
peptides. Due to their high stability, MCoTI-II and SFTI-1 have been used as scaffolds for drug 
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design, with a dozen examples now reported in the literature (1). Interestingly, both MCoTI-II and 
SFTI-1 have been reported to internalise into cells (3). MCoTI-II seems to internalise through 
endocytotic pathways and in particular by macropinocytosis (3,4). Positively charged residues 
exposed on the surface of MCoTI-II are essential for its internalisation into mammalian cells (3,4). 
SFTI-1 also internalises cells, but with an unknown mechanism (3).  
Positively charged residues (e.g. arginine and lysine) and hydrophobic aromatic residues (e.g.  
tryptophan and tyrosine) are common in CPPs and have been shown to play a role in their cellular 
uptake (8,9). The positively charged residues in Tat (10) and polyarginine (11) were shown to 
establish electrostatic interactions to anionic lipids (12) and glycosaminoglycan (13) present in the 
cell membranes. Arginines induce better cellular uptake than lysines even though both have the 
same net charge. The guanidine group of the arginine side chain has an affinity for the polar head 
group of phospholipids present on the cell membranes which leads to increased cellular uptake (14). 
Hydrophobic residues and an amphipathic character have been shown to be relevant in the 
internalisation of penetratin (15) and transportan (16), which are known CPPs that are believed to 
enter cells by a mechanism that involves insertion into lipid bilayers and direct membrane 
translocation. In particular, tryptophan an hydrophobic amino acid residue has been shown to 
increase the affinity for lipids present in the cell membrane (17).  
Chapter 3 focused on the features that are important for the internalisation of MCoTI-II and 
SFTI-1. A series of analogues was designed, synthesised and their cell-penetrating properties were 
compared. These studies are relevant, not only to provide insights into the internalisation 
mechanism, but also to guide the design of improved cyclic scaffolds for intracellular delivery. 
Lysine residues present in the native sequence of MCoTI-II and SFT1-1 were replaced with 
arginine, whereas tyrosine residues were replaced with tryptophan. To examine the importance of 
peptide folding, analogues that lacked the cyclic backbone and disulfide bonds were also 
synthesised. In addition, the all-D-enantiomer of SFTI-1, D-SFT1-1, was included to evaluate if the 
internalisation mechanism of SFTI-1 is dependent on a chiral receptor. 
Substitution of lysine with arginine and/or of tyrosine with tryptophan residues did not 
improve the cellular uptake of MCoTI-II. Interestingly, analogues with increased overall charge 
showed an increase in the internalisation rate, compared to native MCoTI-II. This is also observed 
for arginine rich CPPs such as YGR6G6 and YGR6E6, where an increase in the overall net charge 
has been shown to improve internalisation efficiency (18). The improved cellular uptake might be 
attributed to the increased electrostatic interaction of the peptide with negatively charged cell-
surface components such as phosphate, sulfate and carboxylate groups, which increases the peptide 
concentration in the cell vicinity, leading to its uptake through endocytic pathways. A backbone-
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acyclic analogue of MCoTI-II showed an increase in cellular uptake compared to the cyclic form, 
possibly due to the presence of NH2 and COOH termini in loop 6, which provides structural 
flexibility. The increase in the internalisation observed for MCoTI-II analogues did not correlate 
with an improvement in the ability to bind to neutral POPC and negatively charged POPC/POPS 
membranes studied here, suggesting that improvement in the internalisation rate is independent of 
the ability to insert into the lipid bilayer of the cell membrane. A mode of entry independent on 
peptide-lipid affinity was observed previously for native MCoTI-II (3). These results support the 
hypothesis that MCoTI-II gains access to the cell interior through a mechanism independent of an 
ability to insert into the lipid bilayer of cell membranes.  
In addition to a cyclic backbone and an ability to enter cells, MCoTI-II is not toxic against 
any of the cell lines tested so far, it has a large degree of flexibility within some of its loops (6,19), 
and as we have shown here, its internalisation efficiency can be further improved. Therefore, I 
propose that this peptide is a good option to develop as a delivery system for drug design. The 
results obtained here will be useful in the development of MCoTI-II as a framework for targeting 
important intracellular biological pathways associated in disease conditions such as cancer. MCoTI-
I, another cyclotide belonging to the trypsin inhibitor subfamily, is also a potential framework in 
drug design applications, and also has the ability to enter cells (20) that has already been 
successfully used to introduce bioactive peptide sequences inside the cell and was able to target 
intracellular protein-protein interactions (21). As a proof-of concept that MCoTI-II can also be used 
as a scaffold to direct bioactive sequences inside the cells inhibiting therapeutic protein and further 
inducing biological effect, I used it as a framework to develop peptides that target an intracellular 
protein with therapeutic potential (Chapter 4). 
Mutations in SFTI-1 did not affect its cellular uptake. An increase in the overall charge or 
incorporation of hydrophobic residues into SFTI-1 did not improve its internalisation efficiency. 
The all D-enantiomer, D-SFTI-1, internalised with an efficiency comparable to that observed with 
the native peptide, suggesting a receptor-independent mechanism. In fact, the cellular uptake of all 
of the SFT1-1 analogues was weak and comparable to that observed for Tat-G, a control used in 
this study to examine non-specific cellular uptake. This observation suggests that SFT1-1 enters by 
a non-specific endocytosis pathway. Overall, these results suggest that SFTI-1 is not the best 
scaffold to deliver cargoes inside cells and is better suited to target extracellular receptors as shown 
with KLK4 and integrin α9β1 studies that have resulted in potent molecules against prostate cancer 
(22,23) and angiogenesis (24). 
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6.2 Cyclotides as stable frameworks to direct therapeutic peptides intracellularly.  
Various loops of MCoTI-II have been grafted with several bioactive sequences to produce 
potent molecules with increased stability and affinity (2). The advantage of exceptional stability and 
cell-penetrating ability makes MCoTI-II a potential scaffold to deliver bioactive epitopes, which 
lack in vivo metabolic stability and low cell penetration. In Chapter 4, MCoTI-II was used to deliver 
peptidic sequences able to interact and inhibit SET, an intracellular protein overexpressed in CML 
cell lines. MCoTI-II was engineered to accommodate the linear peptide COG1410 into loop 6 to 
display the desired α-helical conformation of the epitope that is required for activity. Engineered 
MCoTI-II with COG1410 showed improved resistance against proteolytic degradation than the 
linear COG1410 peptide, demonstrating that stability of cyclic framework was maintained in the 
grafted peptide. In addition, the grafted MCoTI-II gained toxicity against cancer cells that 
overexpress SET and one of the grafted peptides showed an effect on the intracellular NF-κB 
pathway, which is dependent on activity of SET protein.  
Several grafting studies on MCoTI-II have been performed, producing a range of molecules 
with improved stability and affinity towards extracellular therapeutic proteins (2). Based on the 
results reported here, MCoTI-II can also be used to graft therapeutic peptides that are involved in 
regulation of a range of intracellular proteins in different human diseases. Overall, this chapter 
shows that internalisation and targeting benefits of MCoTI-II make it a promising scaffold for 
design of novel molecules that can access difficult intracellular drug targets.  
  
6.3 Insights into the oligomeric structure of cyclotides self-associating in the presence of 
membranes.  
 In Chapter 5 the oligomeric structures of cyclotides kalata B1 and kalata B2 in the presence 
of membranes were studied. Kalata B1 and kalata B2 are expressed in the leaves of Oldenlandia 
affinis and belong to the Möbius subfamily of cyclotides. They differ from each other in only five 
amino acid residues and have been extensively studied in terms of their structure and activity. 
Kalata B2 is more hydrophobic than kalata B1 and is more potent than kalata B1 in all of the 
bioactivities tested so far, including hemolytic (25), anti-HIV (25) and anthelminthic activities (26). 
Although cyclotides belonging to the Möbius and bracelet subfamilies have been shown to be toxic 
against a range of distinct targets, including insects (e.g., Helicoverpa armigera) (27), red blood 
cells (28) and cancer cells (29-32) all these activities appear to correlate with their ability to interact 
and disrupt cell membranes. A mechanism involving self-aggregation and formation of oligomeric 
pores in the cell membrane has been proposed (33). This pore formation mechanism is also 
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supported by the ability of kalata B1 to bind and disrupt the mid gut epithelial cells of cyclotide fed 
H. armigera (27).  
The formation of oligomers was observed for kalata B2 in sodium phosphate buffer (10 
mM, pH 7.4) at 1.6 mM concentration in analytical ultracentrifugation experiments. In that study, 
kalata B2 is present in a monomeric form (30%) but also oligomerises as a tetramer (42%) or 
octamer (25%) (34). Hence, due to the existence of such oligomers in solution it was proposed that 
they might play an important role in the mechanism of action and membrane binding of cyclotides. 
However a clear understanding on how cyclotides form pores and whether the membrane-bound 
oligomer structure is identical or distinct to that formed in solution is unknown.  
The main goal of Chapter 5 was to examine whether kalata B1 and kalata B2 oligomerise 
when bound to lipid membranes, and in case of oligomerisation how their quaternary structure is 
organised. Previously a NMR study showed that oligomerisation of kalata B2 in phosphate buffer 
involved the packing of hydrophobic residues exposed on the surface of kalata B2 molecule with 
another molecule of the oligomer (35). Based on that study and other membrane binding studies of 
cyclotides, a possible model that could explain the self-association of kalata B1 or kalata B2 in 
membranes was designed. Mutants were synthesised based on this model and cross-linked in the 
presence of lipid membranes to determine the nature of oligomeric species bound to membranes.  
Among the kalata B2 mutants, one showed a series of multimeric species, which 
corresponded to dimers, trimers, tetramers, pentamers, hexamers and higher oligomers. This 
suggested that different oligomeric structures are possible to exist along with the proposed tetramer 
model. The behavior of this mutant might be similar to mellitin, which is a membrane-acting 
peptide, and has been reported to form complex oligomers in POPE/POPG membranes as observed 
in cross-linking experiments (36). Mellitin is known to interact on the membrane surface, aggregate 
and form pores, which eventually leads to membrane disruption. A similar mechanism of pore 
formation resulting in membrane disruption has been proposed for cyclotides (33), suggesting that 
they might behave similar to mellitin. The various oligomeric species observed here for kalata B2 
mutant suggests that oligomerisation might be occurring on the membrane surface, which leads to 
pore formation and membrane disruption. It is possible that native kalata B2 might form complex 
oligomers with a specific and defined number when bound to the membrane surface. However, 
more experiments need to be carried out to confirm this hypothesis and explore the structure of 
cyclotide oligomers in membranes. Experiments to be carried out in the future are noted in detail in 
the discussion part of Chapter 5.  
Chapter 5 gave some information on the oligomerisation of cyclotides in a membrane 
environment, which relates to its pore formation mechanism and membrane binding activity. It is 
Chapter 6 Conclusion and Future Directions  
 
 124
very important to not change the inherent biophysical properties and maintain residues or interfaces 
that are believed to be involved during oligomerisation of kalata B1 and kalata B2 and features that 
can be relevant in the use of cyclotides as a scaffold in drug design (e.g. cyclic backbone, disulfide 
bonds) during grafting applications. Therefore, having more detail on the existence or otherwise of 
a defined oligomerisation state and its importance for the activity for cyclotides belonging to 
Möbius and bracelet subfamilies is very relevant to modify and improve their pharmaceutical 
application as framework in drug design.  
 
6.4 Conclusions  
Disulfide-rich cyclic peptides are an emerging class of peptide-based therapeutics deriving 
from their unique constrained archectiture, which provides them with chemical, thermal and 
enzymatic stability. They are widely used in grafting approaches to incorporate bioactive epitopes 
and this has resulted in novel molecules with increased stability and affinity towards a wide range 
of therapeutic targets. Exploration of the structure-transport properties of disulfide-rich cyclic 
peptides opens up avenues for their utilisation as vectors to deliver bioactive peptides compared to 
other unstable linear cell-penetrating peptides. Structural and physiochemical characteristics 
governing the cellular uptake of disulfide-rich cyclic peptides studied here suggests that their 
internalisation inside cells can be further improved. Knowledge of the structural attributes important 
for cell penetration will assist in the development and optimisation of novel peptides to address 
intracellular targets in disease conditions such as cancer, neurological diseases and inflammation. 
Other biophysical characteristics such as oligomerisation are also important features to be 
considered in drug design studies. Important residues involved in oligomerisation should be 
considered during the engineering of cyclotides from the Möbius subfamily.  
Overall the studies in this thesis have provided new knowledge of the biophysical features 
of cyclotides, including their oligomerisation and cell penetration, which is potentially significant 
for the development of disulfide-rich cyclic peptides as therapeutics. Although much remains to be 
done to fully realise the potential of cyclotides it is hoped that this thesis has made some 
contribution towards that potential. 
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1 INTRODUCTION
Cyclotides are a large family of plant-derived
mini-proteins. They are characterized by a head-to-
tail cyclic peptide backbone and a cystine knot
arrangement of their three conserved disulfide bonds.
They contain up to 37 amino acids (size ranges from
28 to 37 residues) but most are typically around
30 amino acids in size. They first came to notice
based on their presence as a bioactive component in
an indigenous medicine used to facilitate childbirth
in the Congo region of Africa in the 1960s (Gran,
1970). It was not until the mid-1990s, however,
that the cyclotide field started in earnest, with the
first determination of a cyclotide structure (Saether
et al., 1995) and later, the recognition that this pro-
totypic example might be part of a large family of
topologically unique proteins (Craik et al., 1999).
The first cyclotide discovered was kalata B1, so
named after a native medicine called kalata–kalata
from the plantOldenlandia affinis, which was used to
accelerate the process of childbirth. In 1970, the pep-
tide had been isolated and partially characterized by
a Norwegian physician, Lorents Gran, who discov-
ered that it comprised 29 amino acids but at that stage
had not determined any structural information (Gran,
1970). Some 20 years later the three-dimensional
structure of kalata B1 was determined (Saether et al.,
1995) and found to contain the cyclic cystine knot
(CCK)motif (Craik et al., 1999). The exceptional sta-
bility of kalata B1 was apparent early on, given its
isolation from the medicinal tea, which was prepared
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through boiling of the plant material. Typically, pep-
tides are susceptible to degradation at high temper-
atures and also in the milieu of proteolytic agents
encountered in the GI tract. However, the oral activ-
ity of kalata B1 suggests that it survives both of
these challenges. Later, work by Colgrave and Craik
(2004) demonstrated that the CCK motif structurally
defined by kalata B1 was responsible for its excep-
tional stability against thermal, chemical, and enzy-
matic proteolysis.
Cystine knots are present in a wide range of
plants and animals but in no other case is it com-
bined with a circular backbone and no other pro-
tein families have yet been discovered that adopt the
CCK motif. Cyclotides are of great interest because
of their unique structure and resultant exceptional
stability. Their unique structure and potential for
pharmacological activity mean that cyclotides have
attracted attention as scaffolds for drug design appli-
cations, the concept being that, for example, the
native kalata B1 scaffold can be chemically reengi-
neered with the insertion of biologically active epi-
topes into the peptide backbone to produce a desired
biological activity in a stable peptide framework
(Clark, Daly, and Craik, 2006; Gunasekera et al.,
2008; Garcia and Camarero, 2010). The target sites
for such grafting applications are typically one of
the six backbone loops between the six conserved
cysteine residues that form the core cystine knot
motif (Jagadish and Camarero, 2010; Chan et al.,
2011; Pinto et al., 2012a; Poth, Chan, and Craik,
2013).
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Figure 1 Isolation of cyclotides in O. affinis. (a) Schematic representation of the structure of kalata B1, showing the six loops and
the position of disulfide-bonded cysteines (represented using Roman numerals) forming the cyclic cystine knot motif represented in
all cyclotides. (b) Sequences of kalata B1–B17 extracted from O. affinis. Disulfide connectivity is shown using dotted lines. The
proto-N-terminal amino acid of the cyclotides, as encoded in the precursor protein is indicated by the black arrow as in panel (a). (c)
LC–MS trace for the crude extract of O. affinis aerial tissues. Peaks corresponding to kalata B1–17 are indicated (Plan et al., 2007).
Since the original discovery of kalata B1, more
than 250 other cyclotides have been reported and it
is estimated that there may be at least 50,000 mem-
bers of the family, which would make it one of
the largest known families of plant proteins (Gruber
et al., 2008). An individual plant typically contains
multiple cyclotides, as illustrated in Figure 1, which
shows a high performance liquid chromatography
(HPLC) trace of an extract from O. affinis, where 17
individual cyclotides have been identified and many
others are known to be present. As can be seen from
this HPLC trace, different cyclotides are expressed
to different extents in a given tissue, and it is also
known that the distribution of cyclotides from one tis-
sue to another also varies. For example, a comparison
of LC–MS (liquid chromatography–mass spectrome-
try) profiles of crude extracts obtained from different
plant tissues of Viola hederacea from the Violaceae
family demonstrated the diversity of constituent
cyclotides. Tissues examined included the leaves,
petioles, flowers, pedicels, aboveground runners,
belowground runners, bulbs, and roots (Trabi and
Craik, 2004).
Following the discovery of the uterotonic activ-
ity of kalata B1, a number of other natural product
screening studies were conducted in the mid-1990s,
including one in which researchers from the National
Cancer Institute discovered anti-HIV compounds cir-
culin A and circulin B (reported as macrocyclic
peptides) in a Tanzanian plant (Gustafson et al.,
1994), and another wherein a group at Merck discov-
ered a macrocyclic peptide with neurotensin antag-
onist activity in a South American plant (Psychotria
longipes) (Witherup et al., 1994). Since then a wide
range of other activities have been reported for natu-
ral cyclotides, including antimicrobial activity (Tam
et al. 1999), anti-fouling activity (Göransson et al.,
2004), cytotoxic activity (Lindholm et al., 2002),
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as well as a range of biological activities involving
pesticide functions, including insecticidal (Jennings
et al., 2001, 2005), nematocidal (Colgrave et al.,
2008, 2009), and anti-schistosomal activity (Malagón
et al., 2013). The latter series of activities has led to
the view that cyclotides are present in plants as natu-
ral defense agents, probably mainly directed against
insect pests (Gruber et al., 2007).
It is currently not known why one plant should
express a suite of upward of 100 cyclotides but it
might be to target multiple pests or a strategy to
avoid the development of resistance to an individual
defense agent. In any case, an individual plant tissue
can be regarded as containing a combinatorial library
of cyclotides, each having a different sequence and
bioactivity profile. This multiplicity presents some
challenges from a bioanalytical perspective, includ-
ing peak overlap during LC separations and large
variations in dynamic range (i.e., in the concentration
differences between most abundant and least abun-
dant cyclotides in a given tissue).
There have been a number of recent reviews on
cyclotides that have focused on various aspects of
their discovery (Daly, Rosengren, and Craik, 2009;
Gruber, 2010; Cemazar et al., 2012; Göransson
et al., 2012), characterization (Cascales and Craik,
2010; Ireland et al., 2010; Kaas and Craik, 2010),
biology (Bohlin et al., 2010; Franco, 2011; Pinto,
Fensterseifer, and Franco, 2012b), functions (Craik,
2009, 2012; Henriques and Craik, 2012; Mondal
and Gerlach, 2012), and applications (Daly and
Craik, 2009; Dörnenburg, 2009, 2010; Henriques and
Craik, 2010; Jagadish and Camarero, 2010; Smith,
Daly, and Craik, 2011; Craik et al., 2012a). The
first major review in the field was in 2004 when
we surveyed the distribution of cyclotides in plants
at a time when they had been found mainly in
the Rubiaceae and Violaceae families (Craik et al.,
2004). Since then, cyclotides have been reported in
a large number of plant species and their distri-
bution and evolution were recently reviewed (Koe-
hbach et al., 2013). Also, recently reviewed have
been their biosynthesis (Conlan et al., 2010; Aboye
and Camarero, 2012; Göransson et al., 2012), meth-
ods for their three-dimensional structure determina-
tion (Daly et al., 2010, 2011), and approaches to
their chemical (Gunasekera et al., 2006; Clark and
Craik, 2010; Conibear and Craik, 2011; Craik and
Conibear, 2011; Aboye and Camarero, 2012; Rein-
warth et al., 2012) and recombinant syntheses (Gould
et al., 2011). Several reviews have also reported on
the use of cyclotides as pharmaceutical templates
(Henriques and Craik, 2010; Smith, Daly, and Craik,
2011; Craik et al., 2012a). In keeping with the theme
of this Handbook, in this chapter, our focus is on
the bioanalysis of cyclotides. We first provide a
brief background on methods for their discovery and
characterization.
2 DISCOVERY
2.1 Currently Known Cyclotides among
Angiosperms
Cyclotides have been reported in five plant fami-
lies, namely Violaceae (violet), Rubiaceae (coffee),
Cucurbitaceae (cucurbit), Fabaceae (legume) (Poth
et al., 2011), and Solanaceae (nightshade) (Poth
et al., 2012). Also, tentative reports of cyclotide-like
peptides in Poaceae (grass) (Mulvenna et al., 2006)
and Apocynaceae (Gruber et al., 2008) families
have been made, with a recent report detailing
the characterization of acyclotides (homologous
sequences that lack backbone cyclization) in the
Poaceae family (Nguyen et al., 2013). Figure 2
illustrates the currently known cyclotide-containing
plant families. To date, more than 250 cyclotide
sequences have been characterized and documented
in Cybase (www.cybase.org.au), a database dedi-
cated to cyclotides and other naturally occurring
cyclic peptides (Kaas and Craik, 2010). Although the
full extent of cyclotide distribution is still unclear,
it is estimated that there could be at least 50,000
cyclotides yet to be discovered (Gruber et al., 2008),
making them one of the largest peptide families in the
plant kingdom. Cyclotides appear to be ubiquitous in
Violaceae (Simonsen et al., 2005; Ireland, Colgrave,
and Craik, 2006; Burman et al., 2009), having been
found in every species studied so far.
Cyclotides are expressed within ribosomally
synthesized precursor proteins, which harbor
one or more cyclotide domains. These can be
broadly separated into those encoded by dedicated
cyclotide genes and an intriguing example of where
a cyclotide-encoding domain has replaced an albu-
min subunit. Various types of precursor proteins
arise from dedicated cyclotide-encoding genes,
and for Violaceae and most Rubiaceae cyclotides
discovered to date, comprise an endoplasmic retic-
ulum (ER) signal sequence, a prodomain, and one
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Figure 2 Currently known cyclotide-containing families among angiosperms. The phylogenetic tree shows the relationship between the
plant orders and the families. The cyclotide- and cyclotide-like-containing families are indicated in light gray and the corresponding orders
to which they belong are shown in dark gray. The number of cyclotides sequenced in each family and the estimated number of species in each
family are also indicated. There are many cyclotides common to both the Rubiaceae and Violaceae families. Source: C.W. Gruber (2010).
Adapted from Wiley Periodicals, Inc.
or more cyclotide domains, each bracketed by an
N-terminal repeat region (NTR) and a C-terminal
region (CTR) (Kaas and Craik, 2010) as exempli-
fied by cycloviolacin O8 and kalata B2 as shown
in Figure 3a. Alternatively, they may be encoded
within precursor proteins lacking the NTR, where
the cyclotide domain directly follows the propeptide
[e.g., Phyb A in Solanaceae (Poth et al., 2012) and
some Rubiaceae cyclotides such as panitide L1
(Nguyen et al., 2012)]. Some precursors, including
Oak 4 and TIPTOP 1 contain multiple cyclotide
domains, which may code for different cyclotides
or repeats of the same cyclotide. The genes encod-
ing fabaceous cyclotides are different from the
previous examples in that the cyclotide domain
is situated within an otherwise intact albumin-1
gene, in place of the PA1b knottin described in all
other Fabaceae albumin-1 genes (Poth et al., 2011).
Trypsin-inhibitory cyclotides from Cucurbitaceae
are encoded within precursor proteins that encode
repeating cyclotide domains (up to seven) and uni-
formly also harbor an acyclotide-encoding subunit
at their C-termini. This is exemplified by TIPTOP1,
which encodes MCoTI-1 (Momordica cochinchinen-
sis trypsin inhibitor 1) and MCoTI-2 alongside the
linear MCoTI-5 (Mylne et al., 2012), as shown in
Figure 3a, b.
The presence of a proto-C-terminal asparagine or
aspartic acid residue has been demonstrated as inte-
gral for the cyclization of cyclotides (Jennings et al.,
2001; Saska et al., 2007; Gillon et al., 2008). The
excision and cyclization reactions in their biosyn-
thetic pathway are not yet fully understood; how-
ever, an asparaginyl endoproteinase (AEP) enzyme
has been implicated. AEP is an endoprotease found
in many plants that cleaves the C-terminus of the
peptide bonds to Asn and Asp residues. Through
this activity, it is considered crucial to the release
of the CTR of the mature cyclotide from its precur-
sor (Saska et al., 2007; Gillon et al., 2008), as well
as ligation to the N-terminus (which is presumed to
be liberated during an earlier cleavage event). The
presumed cyclization of cyclotides by AEP is in
keeping with similar findings on other cyclic plant
peptides such as SFTI-1, a 14-amino-acid trypsin
inhibitor isolated from sunflower seeds (Luckett
et al., 1999). Recently, it has been reported to
share the AEP-mediated maturation process (Mylne
et al., 2011), as has MCoTI-2 (Mylne et al., 2011,
2012).
2.2 Extraction of Cyclotides from Plant Tissues
Cyclotides are commonly extracted from plant tissue
using a combination of methanol and a hydrophobic
solvent such as dichloromethane (DCM) to remove
hydrophobic plant compounds such as lipids. The
protocol adopted in our laboratory for the extraction
of cyclotides from plant tissues is as follows:
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Figure 3 (a) Schematic comparison of representative cyclotide precursor proteins. Cyclotides are encoded within precursor proteins
typically comprising an endoplasmic reticulum signal sequence (ER signal, light green), an N-terminal propeptide region (gray). This is
followed by 1–3 copies of the mature peptide (red), each bracketed by the N-terminal repeat (NTR, blue) and a C-terminal repeat region
(yellow), with a short hydrophobic C-terminal tail at the end of the precursor (dark green). In the Fabaceae cyclotide gene, the cyclotide
domain is contiguous with the ER signal sequence and encodes an albumin-1 a-chain of 53 amino acids (black). Orange regions depict the
positions of knottin and acyclotide domains at the C-termini of TIPTOP1 and Panitide L1, respectively. Where multiple repeats of a cyclotide
are present, the region is identified by an arrow with n= 2, where n is the number of repeated domains. (b) Alignment of representative
cyclotides belonging to various plant families.
1. Harvest the plant material, and if required separate
the material into their different component tissues
(i.e., flowers, leaves, stems, and roots).
2. Using a mortar and pestle, grind the plant material
to powder after precooling with liquid nitrogen.
3. Pour the powdered material into a large beaker
and cover with methanol and an equal volume of
DCM. Stir the sample overnight at room temper-
ature.
4. Filter through awiremesh in order to remove plant
debris.
5. Transfer the filtrate to a separation flask, along
with a small amount of water (one quarter of
the filtrate volume) to aid in separation of the
two solvent layers. Collect and concentrate the
aqueous layer on a rotary evaporator.
6. Load the aqueous layer on a C18 flash column and
elute with solvent A (Milli-Q H2O with 0.05%
TFA) mixed with increasing concentrations of
solvent B [90% acetonitrile (ACN) in Milli-Q
H2Owith 0.05%TFA]. Concentrate the individual
fractions on rotary evaporator and lyophilize.
7. Dissolve dried samples in solvent A and analyze
using LC–MS with a C18 analytical HPLC col-
umn. The sample components elute during a lin-
ear gradient of 5–80% solvent B (v/v). The elu-
tion of cyclotides typically occurs at >30% ACN
(v/v).
8. Purify individual cyclotides using preparative
reversed-phase high performance liquid chro-
matography (RP-HPLC), dissolving the samples
in 100% solvent A. Subsequently, load the sam-
ples onto the C18 column and elute with a linear
gradient of 5–80% solvent B and collect indi-
vidual peaks. The collected fractions are ana-
lyzed by MS, and fractions containing masses
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characteristic of cyclotides (e.g., 2.5–4 kDa) are
retained.
9. Determine the sequences of the extracted
cyclotides using the methods described in
Section 2.3.
A recent report has detailed various extraction
processes, taking into account solvent, time, and
plant material (Yeshak et al., 2012).
2.3 Analysis of Cyclotides by Mass
Spectrometry
Our standard protocol for the discovery of cyclotides
(Gruber et al., 2008) first involves the identification
of late-eluting peaks in HPLC analyses of plant
extracts that have a mass of ∼3 kDa. The next step
is to narrow down a protein that contains six cysteine
residues, which is done by observing a mass shift
upon reduction and alkylation. Further tandem MS
can be used for sequencing of possible hits identified
using this protocol.
To reduce and alkylate a purified cyclotide or a
mixture of cyclotides, the following method is used:
1. Prepare a 1 mgmL−1 peptide solution in 30 μL of
100 mM ammonium bicarbonate (pH 8.0).
2. Add 3 μL of freshly prepared 100 mM dithiothre-
itol and incubate at 60 ∘C for 1 h.
3. Add 3 μL of freshly prepared 250 mM iodoac-
etamide and incubate at RT in the dark for 30 min.
4. Desalt the sample using a Ziptip (Millipore).
(i) Prepare a Ziptip by wetting with 70% ACN
(v/v) and 0.5% formic acid (v/v).
(ii) Wash the Ziptip with 0.5% formic acid (v/v).
(iii) Load the sample on the Ziptip.
(iv) Wash the Ziptip with 5% ACN (v/v) and
0.5% formic acid (v/v).
(v) Elute the desalted peptides with 10 μL of
80% ACN (v/v) and 0.5% formic acid (v/v).
5. Mix the desalted sample in a 1 : 1 ratio (v/v)
with matrix consisting of a saturated solution
of α-cyano-4-hydroxycinnamic acid in 50%
ACN (v/v) and 0.1% TFA with 5 mM ammo-
nium phosphate, and analyze by MALDI-MS
(matrix-assisted laser desorption/ionization mass
spectrometry) (this step is further detailed in the
following sections).
2.3.1 Sequencing of Cyclotides Following
Enzymatic Digestion
Cyclotides can be sequenced using a tandem mass
spectrometer equipped with either an ESI or MALDI
ionization source. These can also be used as com-
plementary techniques. Among the major differences
between ESI andMALDI-MS are themethod of sam-
ple introduction (solution compared with solid) and
the observed charged state of the analyte ions in
their resultant spectra (multiply charged and singly
charged compared with singly charged). The mul-
tiply charged precursor ions produced in ESI-MS
serve to enhance the yields of the fragment ions,
such that typically, precursors of a higher charge state
fragment more readily than those of a lower charge
state. This propensity can be used to advantage dur-
ing their sequence characterization. Multiply charged
precursor ions also allow for analysis of peptides with
higher molecular weights on spectrometers that have
a limited mass-to-charge range.
The use of MALDI-MS to characterize cyclotides
in plant extracts has been widely reported, and a gen-
eral approach to sample preparation for sequencing
is as follows:
1. Preparation of MALDI Matrix: A saturated solu-
tion of α-cyano-4-hydroxycinnamic acid (CHCA)
is prepared by dissolving the matrix in 50% ACN
and 0.1% TFA with 5 mM ammonium phos-
phate to give a final concentration of 5 mgmL−1.
The solution is vortexed and sonicated in a water
bath for several minutes and then centrifuged at
room temperature. The supernatant is then used in
the preparation of samples for MALDI-TOF MS
experiments.
2. Sample Preparation: An aliquot of isolated native
cyclotide solution (obtained by RP-HPLC) or
digests is diluted using 50% ACN and 0.1% TFA,
combined with the CHCA matrix solution in a
1 μL : 1 μL ratio, and mixed thoroughly. One
microliter of the sample/CHCA mixture is then
spotted onto the target plate and dried under a
gentle stream of nitrogen gas.
3. Sample Analysis (Example): MALDI-TOF MS
analysis is carried out in positive ion reflectron
mode on a TOF–TOF mass spectrometer. Multi-
ple positions on the MALDI spot are randomly
sampled with 100 shots for each position, and the
spectra accumulated over 2000 shots, in order to
provide representative spectra. The low mass gate
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is set to 500Da, and data are collected over a range
of 800–5000 Da, with focus mass of 3000 Da.
Spectra are externally calibrated as described by
Saska et al. (2008) by spotting CHCA matrix 1 : 1
with the ProteoMass MSCL1 peptide and pro-
tein MALDI-MS calibration kit calibration mix-
ture (Sigma) diluted to 1 : 400.
4. Analysis of Peptide Sequences: The linear peptide
fragments are analyzed using MALDI-TOF/TOF
and the spectra analyzed in order to determine the
peptide sequences.
Before the sequencing of cyclotides via MS/MS,
reduction of their disulfide bonds and cleavage of
their circular peptide backbone must first be per-
formed, as this information cannot be determined
while in their native folded state. The following pro-
tocol is used in our lab for the reduction, alkylation,
and digestion of cyclotides (Ireland, Colgrave, and
Craik, 2006; Plan et al., 2007; Wang et al., 2007):
1. Dissolve, reduce, and alkylate the peptide as
described in Section 2.3 (steps 1–3).
2. Aliquot 30 μL of the sample mixture and desalt
using a Ziptip. To confirm reduction and alky-
lation of cyclotides, compare the MALDI-MS
spectra of native versus reduced and alkylated
forms (confirm+ 348 Da mass shift).
3. Split sample to 3 × 10 μL aliquots.
4. To 10 μL, add 5 μL of endoGlu-C (40 ng μL−1)
and 5 μL of 100 mM ammonium bicarbonate,
and incubate at 37 ∘C for 3 h.
5. Separately, to 10 μL, add 5 μL of trypsin (40
ng μL−1) and 5 μL of 100 mM ammonium
bicarbonate, and incubate at 37 ∘C for 1 h.
6. Separately, perform both enzyme digests
together at 37 ∘C for 3 h, for example, 10
μL sample+ 5 μL endoGlu-C+ 5 μL trypsin.
7. Add an equal volume of 1% formic acid (v/v)
(e.g., 20 μL each) to quench the digestion, and
desalt each sample using Ziptip (Millipore). The
digested samples can be stored at 4 ∘C before
analysis.
8. Analyze the fragments resulting from the diges-
tions using MALDI-MS (confirm+ 18 Da mass
shift following linearization).
9. Acquire tandem mass spectra for each of the
peptide fragments and then analyze and assign
b- and y-ions using the protocol described
by Medzihradszky (2005) to determine the
sequence of the peptide analytes. In each case,
ensure that the entire sequence has been mapped.
An example of cyclotide analysis is shown in
Figure 4.
10. Use amino acid analysis to confirm peptide
composition. Different enzymes may be utilized
to help determine the sequence of the cyclotide.
For confident de novo sequencing of novel
cyclotides, it is vital that extensive sequence coverage
be attained by whichever ionization source has been
utilized to collect tandemMS data. In our laboratory,
typically, MALDI-TOF/TOF is used as an initial
check for peptide fragments resulting from enzy-
matic digestion of cyclotides. However, if the spectra
from MALDI-TOF/TOF experiments do not provide
sufficient sequence coverage, ESI can be used as a
complementary technique. In a sequence-dependent
manner, some cyclotides fragment more extensively
in MALDI-TOF/TOF experiments, whereas others
fragment and provide superior sequence coverage
in ESI. As stated, fragmentation is dependent on
the sequence features of each peptide analyte, and
therefore, we recommend using both ionization
techniques to provide the complementary and com-
prehensive information necessary for confident
assignments during de novo sequencing.
2.3.2 Case Study: Analyzing Cyclotide
Sequences in Mixtures Using MALDI TOF/TOF
The approach to characterization of novel cyclotide
sequences discussed in the previous section has
been adopted by many researchers investigating
cyclotides. Recently, Gruber’s laboratory described
the characterization of cyclotides from Viola igno-
bilis (Hashempour et al., 2013), a species of the vio-
let family from Iran, which was recently reported to
contain cyclotides (Hashempour et al., 2011). The
analysis involved the use of MALDI-TOF MS and
tandemMS with a selection of complementary enzy-
matic digests to attain full peptide sequence coverage
by assembling and aligning peptide sequences. They
refer to this approach in their report as sequence frag-
ment assembly, and it closely mirrors the approach
previously described in Section 2.3.1.
A frequently encountered problem using this
approach for characterizing cyclotides is the presence
of multiple peptides in the sample being analyzed
even after separation by RP-HPLC. Typically, this
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Figure 4 NanosprayMS sequencing analysis of cyclotide Cter H. On the left-hand side of the diagram, the digestion scheme and theoretical
masses of proteolytic fragments for Cter H is shown. (a) TOF-MS spectrum of combined trypsin and endoproteinase Glu-C digest products,
with cyclotide fragments indicated. The full-length linearized Cter H is represented by B3+. Peptides produced following dual enzymatic
cleavage of the cyclic precursor by trypsin and endoproteinase Glu-C are indicated by peaks labeled C2+ and D2+. (b) MS/MS spectrum
of precursor m/z 1051.23+ (3150.6 Da). (c) MS/MS spectrum of precursor m/z 880.52+ (1759.0 Da). (d) MS/MS spectrum of precursor m/z
706.32+ (1410.6 Da). The precursor peaks in panels B, C, and D are indicated with “P”.
multiplicity means that subsequent purification steps
are necessary before sequence characterization,
and this may be problematic as each purification
step results in sample loss. Gruber and colleagues
(Hashempour et al., 2013) sought to develop a
protocol to perform MALDI-TOF/TOF experiments
for characterization of cyclotide sequences using
semipure cyclotide fractions containing two or
more cyclotides. This protocol involved a combi-
nation of single or combined enzyme digestions
(to acquire fragments encompassing entire peptide
sequences) with tandemMS. Using this approach, 13
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sequences from V. ignobilis were characterized, and
the laborious isolation challenges were overcome.
2.4 Analysis of Cyclotides at the Nucleic Acid
Level
Analysis at the nucleic acid level is also a suit-
able approach for the discovery of novel cyclotides.
The screening methodology involves the isolation
of RNA for the preparation of cDNA that can be
used to characterize novel cyclotide sequences and
their respective precursor proteins. In our laboratory,
we use a simple method for RNA isolation, which
first involves the extraction of ground plant tissue
using phenol-chloroform and then precipitation of
RNA using lithium chloride. We have developed this
method for use at a 1.5 mL tube scale (Mylne et al.,
2006, 2010, 2011; Trabi et al., 2009; Qin et al., 2010).
The protocol for the 1.5 mL tube scale RNA
extraction in our laboratory is as follows:
1. Harvest the plant material and snap-freeze in
liquid nitrogen, storing at −80 ∘C. It is also
possible to store the whole plant material using
RNAlater (Ambion).
2. Grind the plant material to a fine powder in
a precooled mortar and pestle (liquid nitrogen)
or a 1.5 mL plastic tube using a micropestle if
there is only a small amount of material. Fine
glass beads (e.g., Sigma, catalog number G4649)
can be added to produce a fine tissue powder.
Tissue powder should not be thawed directly and
so liquid nitrogen should be used to pre-chill
any equipment (e.g., micropestles, spatulas, and
tubes) that comes in contact with the frozen
tissue powder.
3. Prepare a mixture of 0.25 mL of phenol and 0.5
mL of homogenization buffer (0.1 M Tris, pH
8.0, 5 mM EDTA, 0.1 M sodium chloride, 0.5%
SDS) in a 1.5mL tube for each sample and just
before use, add 5 μL of 2-mercaptoethanol. Heat
this mixture to 60 ∘C in a fume cupboard.
4. Add the aforementioned heated mixture to circa
0.3 mL of frozen tissue powder and shake well
for 15 min. Use of high quality 1.5mL tubes is
recommended to prevent leakage, and no more
than 0.3 mL of tissue powder should be added so
as to avoid overfilling the tube.
5. Add 0.25 mL of chloroform to the mixture and
shake for a further 15 min.
6. Centrifuge the mixture at top speed in a
bench-top centrifuge (14,000 × g) at room
temperature for 10 min. This step will generate a
large amount of insoluble interphase. Avoiding
this interphase, transfer the upper aqueous layer
to a new tube. Add an equal volume of 1 : 1
phenol : chloroform mixture to the tube.
7. Shake the tube for 10 min and then centrifuge
for 10 min, as described in the previous step.
The supernatant obtained here must then be
transferred to a new RNAse-free tube. To avoid
any RNAse contamination, particular care must
be taken during subsequent steps.
8. Add 0.1 vol of 3 M sodium acetate and 0.8 vol
of isopropanol to the supernatant (typically 0.5
mL) to precipitate all nucleic acids.
9. Incubate this at −80 ∘C for 15 min (may freeze
solid) and then centrifuge at top speed at 4 ∘C for
30 min.
10. Pour off the supernatant and invert the tube on a
tissue to dry for approximately 10 min and then
dissolve the DNA/RNApellet in 0.5mL of water.
11. To selectively precipitate the higher molecular
weight RNA, add 0.5 mL of 4M lithium chloride
(i.e., final concentration: 2 M) and incubate the
sample at 4 ∘C overnight.
12. Centrifuge the sample at top speed at 4 ∘C for
30 min and gently pipette off the supernatant.
The RNA pellet obtained at this stage is often
colorless and may not be visible.
13. To this RNA pellet, add 1mL of 80% ethanol and
spin the tube at top speed at 4 ∘C for 5 min. A
micropipette is generally used to gently remove
the wash, and the tube is inverted to drain the
pellet.
14. Allow the RNA pellet to dry before dissolving
it in 50 μL of water. There may still be some
insoluble material present after dissolution of the
pellet. Therefore, centrifuge for 5 min at room
temperature and transfer the RNA-containing
supernatant to a new tube.
15. Quantify the RNA using a UV (ultraviolet) spec-
trophotometer by its A260. The commonly used
measure of RNA sample quality is the A260/280
ratio, wherein 1.6–1.8 is the acceptable range
and 1.8–2.0 is preferred. To assess the integrity
of the RNA sample, we recommend running the
sample through electrophoresis. RNA of suitable
integrity for cloning experiments will show char-
acteristic bands (typically 4–7 dominant bands);
however, for root or seed RNA, which has less
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plastid RNA, only two bands may be observed.
If no bands are observed, this indicates that the
RNA has degraded.
16. To reverse transcribe RNA into cDNA, we typ-
ically use oligo(dT) primer in the Invitrogen
SuperScript kit and follow the manufacturer’s
instructions. Several kits are currently avail-
able, which can be selected at the user’s dis-
cretion. In case of 3′ rapid amplification of
cDNA ends (RACE), we have successfully used
JM38 (5′-GAG CAA CGT CAC GAA AGA
AGC GTT TTT TTT TTT TTT T-3′) (Mylne
et al., 2010). Contaminating genomic DNA can
be removed from the total RNA before this step
using DNAse. While not strictly necessary for
RACE PCR, it may be useful if a user has
encountered extra bands in downstream PCR
that are not the gene of interest. To amplify
full-length transcripts by 5′and 3′ RACE, we
have used the SMART RACE cDNA Amplifica-
tion kit (CLONTECH, catalog number 634923)
(Mylne et al., 2011).
3 CYCLOTIDE CHARACTERIZATION
Characterization of cyclotides can help provide an
understanding of not only their biosynthetic path-
way but also their structure and function. The pre-
vious section detailed the sequence characterization
(i.e., discovery) of cyclotides in both their nucleotide
and peptide forms. Here, we present methods for
their biophysical characterization. This includes a
description of how to use MALDI imaging tech-
niques to analyze cyclotide distribution, the ben-
efits of nuclear magnetic resonance (NMR) tech-
niques for structural analysis of cyclotides, and
using membranolytic assays to investigate cyclotide
function.
3.1 MALDI Imaging to Identify Novel
Cyclotides in the Solanaceae Family
In addition to its utilization for peptide identifica-
tion and sequence characterization, MALDI-MS
can be used to determine the spatial distribution
of peptide and small-molecule analytes. MALDI
mass spectrometric imaging (MSI) is a technique
in which mass spectra are collected in a raster
pattern across a section of tissue, generating an
average mass spectrum. The signal intensity map
can then be overlayed with an image of the sam-
ple to reveal the spatial distribution and relative
abundance of individual analytes present in the
sample section (Caprioli, Farmer, and Gile, 1997).
This technique has been used as an academic
research tool in the study of disease pathology
in animal and human tissues, as well as having
applications in medical diagnosis (Ljungdahl et al.,
2001; Castellino, Groseclose, and Wagner, 2011;
Gemoll, Roblick, and Habermann, 2011; Greer,
Sturm, and Li, 2011; Menger et al., 2011). In 2012,
Poth and colleagues described the characteriza-
tion of cyclotide expression and localization in
petunia using a combination of MALDI-MSI and
LC-ESI-MS analysis of leaf region extracts (Poth
et al., 2012).
Detection and sequencing of the cyclotides and
acyclotides from Petunia x hybrida was carried out
using the approach described in Section 2. This study
(Poth et al., 2012) was the first to report cyclotides
from the Solanaceae family. To analyze the distri-
bution of cyclotides in petunia leaves, a leaf tis-
sue section was analyzed using MALDI-MSI, and
a number of peptide masses that fell within the
diagnostic range for cyclotides were observed. One
of these signals corresponded to cyclotide Phyb A
(m/z 3069) and appeared to correlate to the vascu-
lar features observed on the prepared leaf section
(Figure 5). In addition, signals that did not correspond
to characterized cyclotides were detected during the
analysis. Signals at m/z 3110 and 3346 were abun-
dant in areas of the leaf section distinct from m/z
3069.
In an analyte-specific manner, either differential
or ubiquitous localization of peptide signals was
observed in the MALDI-MSI experiment. This
demonstrated that the intensities of nonlocalized
analytes were mostly uniform across regions com-
prising cells of varying sizes, as well as that other
analytes that did not locate to a specific region did not
cluster together. Altogether, the results demonstrated
the nonuniform distribution of the major cyclotide
mass, consistent with its colocation with the vas-
culature structures of the leaf. This work validated
MALDI-MSI as a suitable technique for providing
information on the spatial relative abundance of
peptide analytes ex planta.
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Figure 5 MALDI-MSI analysis of a petunia leaf, displaying localization of three distinct m/z signals, one of which corresponds to the
major cyclotide, Phyb A. (a) Dark field microscope image of a paradermal cryosection of P. x hybrida leaf, indicating vascular features. (b)
Localization of cyclotide Phyb A, with m/z 3069± 5 Da. (c) Localization of m/z 3110± 5 Da. (d) Localization of m/z 3346± 5 Da.
3.2 Structural Analysis of Cyclotides Using
NMR
NMR is a valuable tool for the characterization of
cyclotides and is able to provide information com-
plementary to that obtained from MS. NMR is a par-
ticularly useful technique for the structural analysis
of cyclotides, being the preferred method of analysis
owing to cyclotides’ small size, high solubility, and
characteristic well-defined structures (Daly, Rosen-
gren, and Craik, 2009). Of the 23 cyclotide struc-
tures deposited into the PDB, 22 have been solved
by NMR and 1 by X-ray crystallography. We have
previously noted that one difficulty associated with
the NMR analysis of cyclotides comes from the close
packing of the cystines in the cystine knot, which
may lead to mistaken conclusions if the disulfide
connectivity is inferred from only intercystine NOEs
(Nuclear Overhauser effect) (Skjeldal et al., 2002;
Craik et al., 2012b). Detailed approaches for defining
cyclotide disulfide connectivity, both chemical and
NMR have previously been described (Göransson
and Craik, 2003; Rosengren et al., 2003). Generally,
the procedures for NMR analysis of cyclotides are
comparable to those for other disulfide-rich peptides.
A detailed overview has recently been described in
Methods of Enzymology (Clark and Craik, 2012) and
so is not repeated here.
3.3 Membranolytic Assays of Cyclotides
Cyclotides have been shown to interact with model
membranes and to disturb lipid bilayers (Kamimori
et al., 2005; Shenkarev et al., 2006; Svangard et al.,
2007; Henriques et al., 2011). This was demonstrated
by the triggering of electrophysiological responses
in lipid bilayers and inducing leakage of lipid vesicle
contents (Huang et al., 2009). Membrane-binding
and membrane disruptive abilities of cyclotides are
dependent on membrane composition and correlate
with bioactivity (Henriques et al., 2011; Sando et al.,
2011; Henriques and Craik, 2012). For this reason,
membrane interaction studies are widely used to
characterize the mechanism of action of cyclotides.
This can be done in vitro using surface plasmon
resonance (SPR) and fluorescence methodologies.
We recently described these procedures (Craik et al.,
2012b).
4 QUANTIFICATION OF CYCLOTIDES
Various methods for the quantitation of cyclotides
have been developed, enabling their study in complex
matrices to answer questions about their ecological
roles in planta, as well as to assess their potential
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as biopharmaceutical scaffolds. In this section, we
review and compare published methods for their
quantification in plants via MALDI-TOF MS (Saska
et al., 2008) or a combination of MALDI-TOF
MS and LC-ESI-MS approaches (Ovesen et al.,
2011; Gründemann et al., 2012). The bioanalysis
and quantification of cyclotides in rat serum is also
discussed (Colgrave, Jones, and Craik, 2005).
4.1 Detection Methods in Plants
To gain a greater understanding of the biosynthe-
sis of cyclotides, an efficient and accurate means
of quantifying cyclotides in plant tissue is required.
The large dynamic range over which cyclotides exist
in nature (up to 14 mg g−1 dry plant weight per
cyclotide) (Ovesen et al., 2011), along with their sim-
ilar compact structures and multiplicity, means that
relatively low resolution protein analysis techniques
such as gel electrophoresis, immunoblotting, or stain-
ing are poor methods for cyclotide analysis and thus
quantification in plant extracts. Given their conve-
nient throughput and automated sample introduc-
tion, as well as high resolution and high sensitivity,
MALDI-TOF MS and LC-ESI-MS are the preferred
methods for quantification of cyclotides. Examples of
both approaches are discussed herein.
4.1.1 Quantification of Cyclotides in Plants
Using MALDI-TOF MS
Until recently, MALDI-TOF MS was not commonly
used for quantification of peptides in complex mix-
tures because of poor spot-to-spot reproducibility and
hence variation in signal ion intensities. However,
MALDI has been successfully applied in the quantifi-
cation of peptides (Saska et al., 2008), amino acids
(Zabet-Moghaddam, Heinzle, and Tholey, 2004),
oligonucleotides (Zhang and Gross, 2000), and nat-
ural products identified in food sources (Camafeita
et al., 1997; Wang, Sporns, and Low, 1999) and
is favored for its rapid, sensitive, and robust anal-
yses. To overcome the issue of reproducibility, the
cyclotide signal can be normalized to an internal stan-
dard (IS) peptide, which is introduced to the sample
beforeMS analysis (Saska et al., 2008). For example,
although kalata B2 has been shown to be a reliable
IS when quantifying kalata B1 in animal biofluids, it
cannot be used for quantification in plant extracts of
O. affinis because it occurs in natural high abundance
in this plant. Sample preparation and analysis for
quantification of kalata B1 in O. affinis extracts has
been reported (Saska et al., 2008) and is described
in the following sections, with particular attention
paid to the selection of an appropriate IS. Selec-
tion of an optimized matrix and application method
are critical aspects for the production of uniform
cocrystals, and together with data acquisition meth-
ods designed to overcome the difficulties surrounding
poor spot-to-spot reproducibility and signal degrada-
tion can contribute significantly to the robustness of
MALDI-TOF in quantification.
4.1.1.1 Sample Preparation
Calibration solutions of kalata B1 were prepared
from a stock solution of 0.5 mgmL−1 dissolved in
Milli-Q water and diluted further in 50% ACN and
0.1% TFA to give solutions with concentrations over
a range of 1–400 μgmL−1. Standard solutions were
produced through 10-fold dilution in solvent and
combined in a 1 : 1 ratio with the IS solution, consist-
ing of the Calibration Mixture 2 (Sequazyme peptide
Mass Standards Kit; Applied Biosystems), compris-
ing five peptides. The IS was prepared as a 1/200 or
1/400 dilution in 50% ACN and 0.1% TFA to give
a final concentration of 125 fmol μL−1 angiotensin
I, 125 fmol μL−1 ACTH(1–17), 93.75 fmol μL−1
ACTH(18–39), 187.5 fmol μL−1 ACTH(7–38), and
218.75 fmol μL−1 of bovine insulin. The MALDI
matrix and plant extract were prepared as described
in Section 2, with a 1 : 1 ratio of matrix to calibrated
solution or extract containing the IS and spotted onto
the MALDI plate.
4.1.1.2 Sample Analysis
MALDI-TOF MS was carried out in positive ion
reflector mode using a 200-Hz frequency-tripled
Nd:YAG (neodymium-doped yttrium aluminum gar-
net) laser at 355 nm. Fifty spectra at 30 ran-
domly selected positions were collated per spot over
1000–5000 Da and accumulated into a single spec-
trum. Calibration curves were produced by plotting
the area of the kalata B1 peaks relative to the area of
the IS signals, across the range of different cyclotide
concentrations. Relative area was determined using
the area of the first three peaks in the isotopic clusters
of the analyte and the IS protein.
A good correlation was observed between the rela-
tive area of the peptide signal and the concentration of
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the cyclotide as long as the mass difference between
kalata B1 and the IS did not exceed circa 1 kDa.
These results demonstrated that within a restricted
mass range, peptides structurally unrelated to the
peptide of interest can be successfully applied as ISs,
and that this should be considered when designing
quantification experiments for cyclotides.
To quantify cyclotide production in plant extracts,
it is necessary to confirm that the correlation between
cyclotide and the IS remains consistent in the extract
samples as observed in the calibration solutions. This
can be done by generation of a standard curve using
samples of known concentrations from plant extracts.
Once confirmed, the cyclotides can be quantified in
unknown samples. This is exemplified by Saska et al.
(2008), who were able to use this approach to quan-
tify transgenic kalata B1 production in Nicotiana
benthamiana.
Although cyclotides have been extensively studied
over the last two decades, key aspects of their biosyn-
thesis in plants remain undescribed. For example, the
subcellular location of the ligation and cyclization
reactions in cyclotide biosynthesis in plant cells was
until recently undetermined. To investigate the sub-
cellular location of cyclotide processing, an approach
to quantify cyclotides in plant cells is desirable.
An understanding of their biosynthetic pathway may
lead to improved yields of cyclotides in transgenic
plants.
Recently, subcellular targeting of cyclotides in
plant cells was reported by Anderson and colleagues
(Conlan et al., 2011). In this work, a combina-
tion of confocal microscopy and MALDI-TOF MS
techniques were used to examine the targeting of
green fluorescent protein (GFP)-tagged constructs
expressed transiently in N. benthamiana. Nine con-
structs were made to identify the regions from the
Oak1 precursor in O. affinis that are responsible
for the subcellular targeting of kalata B1. Through
this approach, they were able to demonstrate that
GFP-tagged cyclotide precursors accumulate in liv-
ing plant cell vacuoles (Conlan et al., 2011). This
suggests that excision and cyclization processes take
place in the vacuole where cyclotides are later stored.
Overall, these findings represent a significant step
toward understanding of the biosynthetic produc-
tion of cyclotides and also to the quantification of
cyclotides in living plant cells.
4.1.2 Quantification of Cyclotides in Plants
Using ESI-MS
In addition to being a method of choice for cyclotide
discovery and characterization, ESI-MS is also com-
monly used for peptide quantification. ESI-MS can
be coupled to liquid-based separation tools, allowing
for the analysis of complex mixtures with minimal
pretreatment of samples. Quantification of cyclotides
in plant material using RP-LC-ESI-MS has been
reported by Ovesen and coworkers (2011), who
sought to develop a simple and rapid method of anal-
ysis. This method was developed using kalata B1,
kalata B2, and cycloviolacin O2 as reference pep-
tides. These peptides span a range of net charges,
hydrophobicities and cyclotide subfamilies, and the
analyses described were conducted using an instru-
ment readily available in most research laborato-
ries. Following development of a robust quantifica-
tion method, it was applied in the quantification of
cyclotides in a collection of samples including crude
extracts ofO. affinis andViola odorata, as well as vio-
let tea and candied violets. The describedmethodwas
demonstrated as capable of quantifying cyclotides in
complex samples with a limit of detection (LOD) of
1.7–4.0 μg L−1 (Ovesen et al., 2011).
4.1.2.1 Sample Preparation
Stock solutions of the reference peptides (1
mgmL−1) were prepared in 25% methanol and
0.1% formic acid and standards were prepared by
dilution of stock aliquots using 25% methanol and
0.1% formic acid to give concentrations over the
range 0.05–10 μgmL−1. Cyclotides were quantified
in dried plants, tea extracts, and candied violet
extracts. Each sample was crushed into fine powder,
and 0.1 g was extracted with 70% methanol and
0.1% formic acid and sonicated for 1 h. Following
centrifugation of the samples, the supernatant was
collected. This extraction process was repeated an
additional time for each sample. Methanol phases
were combined, and before injection of the sample
on the LC–MS, the extract was diluted 1 : 2 (v/v)
with 0.1% formic acid to ensure that cyclotides
would be retained on the column at the beginning of
the run.
4.1.2.2 Determining Cyclotide Content
Six replicates for each concentration of the previ-
ously detailed reference peptides were analyzed in
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this ESI-MS study. Specifically, the peptide was
quantified by both method of standard addition
(MOSA) to plant material and using a calibration
curve independent of the samples. The responses
of the reference peptides were fitted by linear
regression and had r2 values >0.968. Using these
standard curves, the cyclotide content of the four
samples was determined. No significant differ-
ence was observed in cyclotide content between
using external calibration and using standard
addition.
4.2 Detection Methods in Biological Fluids
The stable framework afforded by cyclotides, and
thus their resistance to enzymatic degradation, has
made them exciting candidates for drug design and
development (Henriques and Craik, 2010). As a pre-
requisite to using this framework for medicinal appli-
cations, the pharmacokinetics of cyclotides must first
be understood. To achieve this, a sensitive, spe-
cific, and reliable method for detecting and quan-
tifying cyclotides in plasma is required. Colgrave
et al. (2005) have reported an approach to quan-
tify kalata B1 in rat plasma using MALDI-TOF
MS. In that study, rats were administered kalata B1
intravenously, and over a 3-h period, blood samples
were taken for analysis. Kalata B2 was selected as
an IS.
4.2.1 Dosing of Rats and Sample Preparation
Rats were fasted overnight with access to water
before administration of 3 mg kg−1 of kalata B1
over a 2-min period. Blood samples (ca. 300 μL)
were taken over 3 h from the tip of the tail. The
blood was collected into an Eppendorf tube contain-
ing 30 μL of 500 IUmL−1 of heparin. The sam-
ples were centrifuged and 100 μL of serum removed
for analysis. Calibration solutions and plasma sam-
ples were spiked with kalata B2 as the IS (final
concentration: 1 μgmL−1). A twofold excess of
ACN was added to precipitate large proteins out
of solution, and the samples were shaken and cen-
trifuged before removal of the supernatant for analy-
sis via MS.
4.2.2 Sample Analysis
Calibration curves were first constructed using
analyte peak areas from ESI LC–MS of plasma sam-
ples containing known concentrations of kalata B1.
The LOD in plasma using LC–MS was determined
to be 0.5 μgmL−1, which is not sufficiently sensitive
for in vitro pharmacokinetic studies. Therefore,
MALDI-TOF was used for quantification (samples
were prepared for MALDI analysis as described in
Section 2.3.1). Calibration curves were constructed
using summed peak area ratios of the analyte to the
IS versus the theoretical concentration, and each con-
centration was analyzed in triplicate. MALDI-TOF
MS displayed superior sensitivity to LC–MS with an
LOD for kalata B1 of 0.05 μgmL−1, which is suf-
ficient for cyclotide quantification in plasma for the
purposes of determining its pharmacokinetic profile.
However, at concentrations above 10 μgmL−1, the
detector was saturated, with analyte signal intensities
no longer displaying a linear correlation to concen-
tration. This problem can be overcome by dilution
of analyte plasma with a known volume of blank
plasma before bioanalysis. Calibration curves were
also derived using maximum signal intensity relative
to the known concentrations of kalata B1. Linear
regression analysis showed an r2 of 0.9995 when
using peak area and 0.9931 for signal intensity for
individual curves, and these values improved when
using the triplicate values. Unknown sample concen-
trations were extrapolated from the calibration curve
as illustrate in Figure 6.
4.3 Quantification of Cyclotides Expressed in
Plant Cell Cultures
The production of cyclotides in plant cell cultures
represents an attractive alternative method to their
chemical synthesis. Large-scale cultures can in prin-
ciple be used as biological factories to produce high
quality products in controlled conditions and offer
the advantage of controlled supply in addition to
being renewable and environmentally friendly (Dör-
nenburg, 2008). Over the last decade, efforts have
been made to express cyclotides in cell cultures with
the view of using them for drug development and in
pharmaceutical applications.
Dörnenburg and colleagues have reported on
cyclotide expression in plant cell cultures (Sey-
del et al., 2007; Dörnenburg, Frickinger, and Seydel,
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2008; Dörnenburg, 2010). The focus has been on
production of the cyclotide kalata B1 from O. affinis,
initiating cell lines from leaf, stem, and root explants
of axenic plants (Dörnenburg, 2009). Cell cultures
have also been initiated through germination of
decontaminated seeds in aseptic conditions on solid
agar-containing media (Seydel and Dörnenburg,
2006). Young shoot tips of the plantlets, which
contained higher levels of kalata B1, were then
used to generate cell cultures (Dörnenburg, 2010).
Research into irradiation and agitation, bioreactor
technology, and priming and elicitation strategies
have been investigated as strategies to improve
product yields (Dörnenburg, 2010). Productivity
of kalata B1 cultures vary greatly as the growth
conditions of the culture are altered (Dörnenburg,
2009), and process productivity of up to 0.5 mg of
kalata B1 L−1 day−1 has been reported (Seydel et al.,
2007). Using bioreactor technology to scale up the
synthesis, process productivity using a Medusa-type
bioreactor on a 25 L scale was estimated to be 21 mg
of kalata B1 per day (Dörnenburg, 2009). Although
this technology is not yet high yielding enough for
commercial applications, high yielding stable trans-
formed cell lines may provide a valuable means for
large-scale development, making this a promising
method for cyclotide production.
5 CONCLUSION
In this chapter, we described several methods com-
monly used to study cyclotides. Methods for the
discovery of cyclotides are well established and
involve a combination of chemical treatments (reduc-
tion/alkylation/enzyme digestion) with tandem MS
techniques. We found this to be a reliable approach
to identify the presence of cyclotides and to elucidate
Figure 6 MALDI-TOF spectra used in the analysis of stan-
dard solutions to produce a calibration curve for kalata B1. (a)
MALDI-TOF MS spectrum obtained from the analysis of the
1 μgmL−1 standard solution of kalata B1. (b) Plasma sample
“blank” spiked with the internal standard, kalata B2. (c) 0.05
μgmL−1 plasma standard solution with a signal-to-noise ratio
of >3 : 1. This is the lowest concentration detectable using this
method. (d) MALDI-TOF calibration curve for kalata B1 derived
using the relative sum of the peak areas of kalata B1 and inter-
nal standard (IS) kalata B2. Source: M.L. Colgrave, et al (2005).
Reproduced from Elsevier.
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their sequences. The presence of the CCK motif in
cyclotides requires that additional steps be taken in
their isolation and characterization compared to lin-
ear peptides. One of the main challenges associ-
ated with using MS for cyclotide characterization is
the absence of an N- or C-terminus and their sta-
ble cystine knotted structure, which together resist
fragmentation.
Although protocols for the discovery, character-
ization, and quantification of peptides from plant
tissue have been established, the development of
new methods, such as those that can be applied in
the characterization of molecular events in cyclotide
biosynthesis, will address pertinent questions in
the field of cyclotide biology. New methods for
the characterization of cyclotides are continually
being developed and will allow us to expand our
understanding of distribution, evolution, and the
biosynthetic pathway of cyclotides and how they
function. NMR has long been established as the
preferred technique for the structural analysis of
cyclotides, and the procedures used do not differ
greatly from those used for other disulfide-rich pep-
tides. Strong correlations between cyclotide bioactiv-
ity and membrane-binding activity have also led to a
focus on the development of membranolytic assays.
The continued development of accurate and efficient
methods for quantitation of cyclotides in plant tissues
and biofluids will also aid a greater understanding of
cyclotide pharmacokinetics, which will be important
for the application of cyclotides in drug design and
development.
6 RELATED ARTICLES
Extraction Methodologies: General Introduction;
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Proteomics and Its Research Techniques in Plants
ACKNOWLEDGMENTS
We thank David Wilson of James Cook University
who assisted in production of figures. Work in our
laboratory on cyclotides is supported by grants from
the Australian Research Council (DP0984390) and
the National Health and Medical Research Council
(APP1009267).
REFERENCES
Aboye, T. L., and Camarero, J. A. (2012) J. Biol. Chem., 287,
27026–27032.
Bohlin, L., Göransson, U., Alsmark, C., et al. (2010) Phytochem.
Rev., 9, 279–301.
Burman, R., Gruber, C. W., Rizzardi, K., et al. (2009) Phytochem-
istry, 71, 13–20.
Camafeita, E., Alfonso, P., Mothes, T., et al. (1997) J. Mass
Spectrom., 32, 940–947.
Caprioli, R. M., Farmer, T. B., and Gile, J. (1997) Anal. Chem., 69,
4751–4760.
Cascales, L., and Craik, D. J. (2010) Org. Biomol. Chem., 8,
5035–5047.
Castellino, S., Groseclose, M. R., and Wagner, D. (2011) Bioanal-
ysis, 3, 2427–2441.
Cemazar, M., Kwon, S., Mahatmanto, T., et al. (2012) Curr. Top.
Med. Chem., 12, 1534–1545.
Chan, L. Y., Gunasekera, S., Henriques, S. T., et al. (2011) Blood,
118, 6709–6717.
Clark, R. J., and Craik, D. J. (2010) Biopolymers, 94, 414–422.
Clark, R. J., andCraik, D. J. (2012)Methods Enzymol., 503, 57–74.
Clark, R. J., Daly, N. L., and Craik, D. J. (2006) Biochem. J., 394,
85–93.
Colgrave, M. L., and Craik, D. J. (2004) Biochemistry, 43,
5965–5975.
Colgrave, M. L., Jones, A., and Craik, D. J. (2005) J. Chromatogr.
A, 1091, 187–193.
Colgrave, M. L., Kotze, A. C., Huang, Y. H., et al. (2008)
Biochemistry, 47, 5581–5589.
Colgrave, M. L., Kotze, A. C., Kopp, S., et al. (2009) Acta Trop.,
109, 163–166.
Conibear, A. C., and Craik, D. J. (2011) Isr. J. Chem., 51, 908–916.
Conlan, B. F., Gillon, A. D., Craik, D. J., et al. (2010)Biopolymers,
94, 573–583.
Conlan, B. F., Gillon, A. D., Barbeta, B. L., et al. (2011) Am. J.
Bot., 98, 2018–2026.
Craik, D. J. (2009) Trends Plant Sci., 14, 328–335.
Craik, D. J. (2012) Toxins, 4, 139–156.
Craik, D. J., and Conibear, A. C. (2011) J. Org. Chem., 76,
4805–4817.
Craik, D. J., Daly, N. L., Bond, T., et al. (1999) J. Mol. Biol., 294,
1327–1336.
Craik, D. J., Daly, N. L., Mulvenna, J., et al. (2004) Curr. Protein
Pept. Sci., 5, 297–315.
Craik, D. J., Swedberg, J. E., Mylne, J. S., et al. (2012a) Expert
Opin. Drug Dis., 7, 179–194.
Craik, D. J., Henriques, S. T., Mylne, J. S., et al. (2012b)Methods
Enzymol., 516, 37–62.
Daly, N. L., and Craik, D. J. (2009) Fut. Med. Chem., 1,
1613–1622.
Daly, N. L., Rosengren, K. J., and Craik, D. J. (2009) Adv. Drug
Delivery Rev., 61, 918–930.
Daly, N. L., Chen, B., Nguyencong, P., et al. (2010)Aust. J. Chem.,
63, 771–778.
Daly, N., Rosengren, K. J., Troeira Henriques, S., et al. (2011) Eur.
Biophys. J., 40, 359–370.
Encyclopedia of Analytical Chemistry, Online ©2006–2014 John Wiley & Sons, Ltd.
This article is © 2014 John Wiley & Sons, Ltd.
This article was published in the Encyclopedia of Analytical Chemistry in 2014 by John Wiley & Sons, Ltd.
DOI: 10.1002/9780470027318.a9933
CYCLOTIDE ANALYSIS 17
Dörnenburg, H. (2008) Biotechnol. Lett., 30, 1311–1321.
Dörnenburg, H. (2009) Biotechnol. J., 4, 632–645.
Dörnenburg, H. (2010) Biopolymers, 94, 602–610.
Dörnenburg, H., Frickinger, P., and Seydel, P. (2008) J. Biotech-
nol., 135, 123–126.
Franco, O. L. (2011) FEBS Lett., 585, 995–1000.
Garcia, A. E., and Camarero, J. A. (2010) Curr. Mol. Pharmacol.,
3, 153–163.
Gemoll, T., Roblick, U. J., and Habermann, J. K. (2011)Mol. Med.
Rep., 4, 1045–1051.
Gillon, A. D., Saska, I., Jennings, C. V., et al. (2008) Plant J., 53,
505–515.
Göransson, U., and Craik, D. J. (2003) J. Biol. Chem., 278,
48188–48196.
Göransson, U., Sjogren, M., Svangard, E., et al. (2004) J. Nat.
Prod., 67, 1287–1290.
Göransson, U., Burman, R., Gunasekera, S., et al. (2012) J. Biol.
Chem., 287, 27001–27006.
Gould, A., Ji, Y., Aboye, T. L., et al. (2011) Curr. Pharm. Des., 17,
4294–4307.
Gran, L. (1970)Medd. Nor. Farm. Selsk., 32, 173–180.
Greer, T., Sturm, R., and Li, L. (2011) J. Proteomics, 74,
2617–2631.
Gruber, C. W. (2010) Biopolymers, 94, 565–572.
Gruber, C. W., Ma, Cˇ., Anderson, M. A., et al. (2007) Toxicon, 49,
561–575.
Gruber, C. W., Elliott, A. G., Ireland, D. C., et al. (2008) Plant
Cell, 20, 2471–2483.
Gründemann, C., Koehbach, J., Huber, R., et al. (2012) J. Nat.
Prod., 75, 167–174.
Gunasekera, S., Daly, N. L., Anderson,M. A., et al. (2006) IUBMB
Life, 58, 515–524.
Gunasekera, S., Foley, F. M., Clark, R. J., et al. (2008) J. Med.
Chem., 51, 7697–7704.
Gustafson, K. R., Sowder, R. C. I., Henderson, L. E., et al. (1994)
J. Am. Chem. Soc., 116, 9337–9338.
Hashempour, H., Ghassempour, A., Daly, N. L., et al. (2011)
Protein Pept. Lett., 18, 747–752.
Hashempour, H., Koehbach, J., Daly, N., et al. (2013) Amino
Acids, 44, 581–595.
Henriques, S. T., and Craik, D. J. (2010) Drug Discov. Today, 15,
57–64.
Henriques, S. T., and Craik, D. J. (2012) ACS Chem. Biol., 7,
626–636.
Henriques, S. T., Huang, Y. H., Rosengren, K. J., et al. (2011) J.
Biol. Chem., 286, 24231–24241.
Huang, Y. H., Colgrave, M. L., Daly, N. L., et al. (2009) J. Biol.
Chem., 284, 20699–20707.
Ireland, D. C., Colgrave, M. L., and Craik, D. J. (2006) Biochem.
J., 400, 1–12.
Ireland, D. C., Clark, R. J., Daly, N. L., et al. (2010) J. Nat. Prod.,
73, 1610–1622.
Jagadish, K., and Camarero, J. A. (2010) Biopolymers, 94,
611–616.
Jennings, C., West, J., Waine, C., et al. (2001) Proc. Natl. Acad.
Sci. U. S. A., 98, 10614–10619.
Jennings, C. V., Rosengren, K. J., Daly, N. L., et al. (2005)
Biochemistry, 44, 851–860.
Kaas, Q., and Craik, D. J. (2010) Biopolymers, 94, 584–591.
Kamimori, H., Hall, K., Craik, D. J., et al. (2005) Anal. Biochem.,
337, 149–153.
Koehbach, J., Attah, A. F., Berger, A., et al. (2013) Biopolymers,
100, 438–452.
Lindholm, P., Göransson, U., Johansson, S., et al. (2002) Mol.
Cancer Ther., 1, 365–369.
Ljungdahl, A., Hanrieder, J., Falth, M., et al. (2001) PLoS One, 6,
e25653.
Luckett, S., Garcia, R. S., Barker, J. J., et al. (1999) J. Mol. Biol.,
290, 525–533.
Malagón, D., Botterill, B., Gray, D., et al. (2013) Biopolymers,
100, 461–470.
Medzihradszky, K. F. (2005) Peptide sequence analysis, in Meth-
ods in Enzymology, ed. A. L. Burlingame, Academic Press,
Oxford, pp. 209–244.
Menger, R. F., Stutts, W. L., Anbukumar, D. S., et al. (2011) Anal.
Chem., 84, 1117–1125.
Mondal, D., and Gerlach, S. (2012)Chron. Young Sci., 3, 169–177.
Mulvenna, J. P., Mylne, J. S., Bharathi, R., et al. (2006) Plant Cell,
18, 2134–2144.
Mylne, J. S., Barrett, L., Tessadori, F., et al. (2006) Proc. Natl.
Acad. Sci. U. S. A., 103, 5012–5017.
Mylne, J. S., Wang, C. K., van der Weerden, N. L., et al. (2010)
Biopolymers, 94, 635–646.
Mylne, J. S., Colgrave, M. L., Daly, N. L., et al. (2011)Nat. Chem.
Biol., 7, 257–259.
Mylne, J. S., Chan, L. Y., Chanson, A. H., et al. (2012) Plant Cell,
24, 2765–2778.
Nguyen, G. K. T., Lim, W. H., Nguyen, P. Q. T., et al. (2012) J.
Biol. Chem., 287, 17598–17607.
Nguyen, G. K. T., Lian, Y., Pang, E. W. H., et al. (2013) J. Biol.
Chem., 288, 3370–3380.
Ovesen, R. G., Göransson, U., Hansen, S. H., et al. (2011) J.
Chromatogr. A, 1218, 7964–7970.
Pinto, M. F. S., Almeida, R. G., Porto, W. F., et al. (2012a) Evid.
Based Compl. Alt., 17, 40–53.
Pinto, M. S., Fensterseifer, I. M., and Franco, O. (2012b) Plant
cyclotides: an unusual protein family with multiple functions,
in Plant Defence: Biological Control, eds. J. M. Mérillon and
K. G. Ramawat, Springer, Netherlands, pp. 333–344.
Plan, M. R. R., Göransson, U., Clark, R. J., et al. (2007) Chem.
Bio. Chem., 8, 1001–1011.
Poth, A. G., Colgrave, M. L., Lyons, R. E., et al. (2011) Proc. Natl.
Acad. Sci. U. S. A., 108, 10127–10132.
Poth, A. G., Mylne, J. S., Grassl, J., et al. (2012) J. Biol. Chem.,
287, 27033–27046.
Poth, A. G., Chan, L. Y., and Craik, D. J. (2013) Biopolymers, 100,
480–491.
Qin, Q., McCallum, E. J., Kaas, Q., et al. (2010) BMC Genomics,
11, 111.
Reinwarth, M., Nasu, D., Kolmar, H., et al. (2012)Molecules, 17,
12533–12552.
Rosengren, K. J., Daly, N. L., Plan, M. R., et al. (2003) J. Biol.
Chem., 278, 8606–8616.
Saether, O., Craik, D. J., Campbell, I. D., et al. (1995) Biochem-
istry, 34, 4147–4158.
Sando, L., Henriques, S. T., Foley, F., et al. (2011) Chem. Bio.
Chem., 12, 2456–2462.
Encyclopedia of Analytical Chemistry, Online ©2006–2014 John Wiley & Sons, Ltd.
This article is © 2014 John Wiley & Sons, Ltd.
This article was published in the Encyclopedia of Analytical Chemistry in 2014 by John Wiley & Sons, Ltd.
DOI: 10.1002/9780470027318.a9933
18 STRATEGIES FOR SELECTIVE CLASSES OF COMPOUNDS
Saska, I., Gillon, A. D., Hatsugai, N., et al. (2007) J. Biol. Chem.,
282, 29721–29728.
Saska, I., Colgrave, M. L., Jones, A., et al. (2008) J. Chromatogr.
B, 872, 107–114.
Seydel, P., and Dörnenburg, H. (2006) Plant Cell Tissue Organ
Cult., 85, 247–255.
Seydel, P., Gruber, C., Craik, D., et al. (2007) Appl. Microbiol.
Biotechnol., 77, 275–284.
Shenkarev, Z. O., Nadezhdin, K. D., Sobol, V. A., et al. (2006)
FEBS J., 273, 2658–2672.
Simonsen, S. M., Sando, L., Ireland, D. C., et al. (2005) Plant Cell,
17, 3176–3189.
Skjeldal, L., Gran, L., Sletten, K., et al. (2002) Arch. Biochem.
Biophys., 399, 142–148.
Smith, A. B., Daly, N. L., and Craik, D. J. (2011) Expert Opin.
Ther. Pat., 21, 1657–1672.
Svangard, E., Burman, R., Gunasekera, S., et al. (2007) J. Nat.
Prod., 70, 643–647.
Tam, J. P., Lu, Y. A., Yang, J. L., et al. (1999) Proc. Natl. Acad.
Sci. U. S. A., 96, 8913–8918.
Trabi, M., and Craik, D. J. (2004) Plant Cell, 16, 2204–2216.
Trabi, M., Mylne, J. S., Sando, L., et al. (2009) Org. Biomol.
Chem., 7, 2378–2388.
Wang, J., Sporns, P., and Low, N. H. (1999) J. Agric. Food Chem.,
47, 1549–1557.
Wang, C. K. L., Colgrave, M. L., Gustafson, K. R., et al. (2007) J.
Nat. Prod., 71, 47–52.
Witherup, K. M., Bogusky, M. J., Anderson, P. S., et al. (1994) J.
Nat. Prod., 57, 1619–1625.
Yeshak, M. Y., Burman, R., Eriksson, C., et al. (2012) Phytochem.
Lett., 5, 776–781.
Zabet-Moghaddam, M., Heinzle, E., and Tholey, A. (2004) Rapid
Commun. Mass Spectrom., 18, 141–148.
Zhang, L.-K., and Gross, M. (2000) J. Am. Soc. Mass Spectrom.,
11, 854–865.
Encyclopedia of Analytical Chemistry, Online ©2006–2014 John Wiley & Sons, Ltd.
This article is © 2014 John Wiley & Sons, Ltd.
This article was published in the Encyclopedia of Analytical Chemistry in 2014 by John Wiley & Sons, Ltd.
DOI: 10.1002/9780470027318.a9933
